TARGETED CATALYTIC COMPLEMENT ACTIVATING MOLECULES AND METHODS OF USE THEREOF - Patent application

JP2024540844A5Active Publication Date: 2024-11-28OMEROS CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024520870
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-10-07
Filing Date
2022-10-06
Publication Date
2024-11-28
Estimated Expiration
2042-10-06

AI Technical Summary

Technical Problem

Pathogens and cancer cells have developed strategies to evade the host's complement system, necessitating targeted and intensified complement activation to effectively neutralize them.

Method used

Development of targeted complement activation molecules comprising a targeting domain and a serine protease effector domain, which can be derived from antibodies or other serine proteases, to specifically activate the complement system on pathogen or cancer cell surfaces.

Benefits of technology

These molecules induce complement-dependent cytotoxicity and phagocytosis, enhancing the immune response against pathogens and cancer cells, overcoming evasion strategies employed by these entities.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

In one aspect, the present disclosure provides targeted complement activating molecules comprising a target binding domain and a complement activating serine protease effector domain. In some embodiments, the target binding domain is derived from an antibody or an antigen-binding fragment thereof. Also provided are compositions and methods for treating cancer, autoimmune disease, or microbial infections, including bacterial, viral, fungal, or parasitic infections, with the targeted complement activating molecules. TIFF2024540844000064.tif82157
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] FIELD OF THEINVENTION The present invention relates to targeted complement activating molecules comprising a targeting domain and a serine protease domain for use in targeting complement activation, and related compositions and methods.

[0002] SEQUENCE LISTING STATEMENT The sequence listing associated with this application is provided in text format in lieu of a hard copy and is hereby incorporated by reference. The name of the .xml file in which the sequence listing is stored is MP_1_0303_US2_Sequence_Listing_20221003_ST26.xml. This file is 216KB, was created on October 3, 2022, and has been submitted through the Patent Center together with the submission of this specification. [Background technology]

[0003] background The complement system underpins innate host defense against pathogens and other acute insults (M.K. Liszewski and J.P. Atkinson, in Fundamental Immunology, ed. W.E. Paul, 3rd ed., Raven Press, Ltd., New York, 1993) and also plays a role in immune surveillance against cancer (P. Macor, et al., Front. Immunol., 9:2203, 2018). The complement system involves more than 30 fluid-phase and membrane-bound glycoproteins, cofactors, receptors, and regulatory proteins (S. Meyer, et al., mAbs, 6:1133, 2014), many of which are serine proteases, that form a cascade of highly regulated activation events. The complement system rapidly responds to molecular stress signals through a cascade of sequential proteolytic reactions initiated by the binding of pattern recognition receptors (PRRs) to unique structures on damaged cells, biomaterial surfaces, or microbial invaders (Reis et al., Nat. Rev. Immunol., 18:5, 2018). Activation of the complement cascade induces diverse immune effector functions, such as cell lysis, phagocytosis, chemotaxis, and immune activation (S. Meyer, et al., 2014). Furthermore, the complement system also acts as a bridge between the innate immune response and the subsequent activation of adaptive immunity. In addition to its anti-infective properties, the complement system is also involved in the clearance of immune complexes and apoptotic cells, tissue regeneration, mobilization of hematopoietic progenitor cells, and angiogenesis (TM Pierpont et al., Front. Oncol., 8:163, 2018).

[0004] The complement system can be activated by three distinct pathways: classical, alternative, and lectin. See Figure 1. Activation of the classical pathway is triggered by a conformational change in the classical pathway initiation complex C1, which is composed of a hexamer of trimeric chains, C1q, and a heterotetramer of C1q-related serine proteases C1r and C1s, as detailed below. Binding of C1q to a complex composed of host antibodies bound to foreign particles (i.e., antigens) initiates activation of the C1 complex. Activation of the classical pathway is largely dependent on a previous adaptive immune response by the host, and thus the classical pathway is an effector mechanism of the adaptive immune system. In contrast, both the lectin and alternative pathways are independent of adaptive immunity and are part of the innate immune system.

[0005] The classical pathway (CP) is primarily initiated by antibody-antigen complexes. Antibodies of subclasses IgM and IgG bind antigens on the surface of pathogens or target cells and recruit the C1 complex. The C1 complex is composed of the multimolecular recognition subcomponent C1q (composed of six heterotrimers of C1qA, B, and C chains) and the C1q-associated serine proteases C1r and C1s. Upon binding of C1q to the Fc region of either antigen-bound IgM or at least two IgGs bound to their respective antigens, the serine protease C1r is converted from its zymogen form to its enzymatically active form, which subsequently cleaves and activates its substrate C1s. Once activated, C1s cleaves C4 into its fragments C4a and C4b. C4b binds to complement component C2. This complex, C4bC2, is cleaved by C1s in a second cleavage step to release C2b, forming the complement C3 convertase complex, C4bC2a, the so-called C3 convertase, which cleaves the abundant plasma complement component C3 into C3a and C3b.

[0006] The lectin pathway is triggered by the binding of pattern recognition molecules, such as mannose-binding lectin (MBL), ficolins, or collectin-11 and collectin-10, to pathogen-associated molecular patterns (PAMPs) or apoptotic or distressed host cells. The recognition molecules form complexes with the MBL-associated serine proteases MASP-1 and MASP-2, activating them upon binding, which leads to the cleavage of C2 and C4 and the formation of the C3 convertase (C4bC2a).

[0007] The alternative pathway (AP) is initiated by spontaneous hydrolysis ("tickover") of C3 to C3(HO), which binds to factor B (fB). The resulting conversion of the C3(HO)fB complex requires the enzymatic activity of another highly specific serine protease, called factor D. The availability of enzymatically active factor D is thought to be the limiting factor in the alternative pathway amplification loop, and its availability requires the action of another enzyme, MASP-3, which is required for the conversion of pro-factor D (proCFD) to its active form, mature factor D (matCFD) (Dobo et al., 2016). Another serine protease, matCFD, cleaves fB bound to C3(HO) into Ba and Bb. Bb is also a serine protease and is involved in the formation of the alternative C3 convertase C3(H2O)Bb, which cleaves C3 into C3a and C3b. By this mechanism, the alternative pathway is constitutively active at a low level. An AP amplification loop is formed when newly generated C3b, either formed by C3(H2O)Bb or by the classical and lectin pathway C3 convertases C4bC2a, binds to the target surface and sequesters fB to form the C3bfB complex, which is cleaved by matCFD to generate another C3 convertase complex, C3bBb. This convertase can be further stabilized by properdin, which prevents the disruption of this complex and the conversion of C3b by factors H and I. C3bBb is the functional convertase of the alternative pathway.

[0008] These three pathways converge after the formation of the C3 convertases C4bC2a and C3bBb. The C3 cleavage fragment C3a is an anaphylatoxin that promotes inflammation. C3b acts as an opsonin by covalently binding to the surface of target cells via a thioester bond, marking them for circulating complement receptor (CR)-displaying effector cells, such as NK cells and macrophages, which contribute to complement-dependent cellular cytotoxicity (CDCC) and complement-dependent cellular phagocytosis (CDCP), respectively. C3b also binds to the C3 convertases (either C4bC2a or C3bBb) to form the C5 convertases (C4bC2a(C3b)n or C3bBb(C3b)n, respectively), which lead to MAC formation and subsequent CDC. Furthermore, the cell-associated cleavage fragments of C3b, iC3b and C3dg, can promote adaptive immune responses through complement receptor-mediated cytotoxicity (CDCC and CDCP) and B cell activation (MC Carroll, Nat. Immunol., 5:981, 2004).

[0009] Formation of C5 convertase leads to cleavage of C5 into C5a and C5b. C5a is another anaphylatoxin. C5b recruits C6-9 to form the membrane attack complex (MAC or C5b-9 complex). MAC triggers pore formation leading to membrane destruction and cytolysis of target cells (so-called complement-dependent cytotoxicity, CDC). Direct cytolysis by MAC formation has traditionally been recognized as the terminal effector mechanism of the complement system, but C3b-mediated opsonization and proinflammatory signaling, as well as the anaphylatoxin function of C3a, are thought to play important roles in mediating complement-dependent inflammatory pathology.

[0010] Complement regulatory proteins (CRPs) prevent unnecessary complement activation and consumption of complement components. These proteins are present in most cells and play a crucial role in protecting host cells from complement-mediated damage through tight regulation. CRPs can be soluble proteins (sCRP) or membrane-bound complement regulatory proteins (mCRP) (PF Zipfel and C. Skerka, Nat. Rev. Immunol. 9:729, 2009). One of the most abundant protease inhibitors in the circulation is C1 inhibitor (C1inh), with a mean plasma concentration of 0.25 g / L (H. Gregorek, Comp. and Inflamm. 8:310, 1991). C1inh binds to and inactivates C1r, C1s, and two of the MBL-associated serine proteases, MASP-1 and MASP-2. It is therefore the major inhibitor for the classical and lectin pathways. Other sCRPs include C4-binding protein (C4BP) and factors H and I (PF Zipfel and C. Skerka, 2009).

[0011] In contrast to sCRP, mCRP controls the complement pathways by targeting both C3 and C4 (PF Zipfel and C. Skerka, 2009). For example, CD46 (membrane cofactor protein; MCP) is a cofactor of factor I, which mediates the cleavage of C3b and C4b into their respective inactive breakdown products, iC3b and iC4b, respectively, thereby leading to the inhibition of all three complement pathways. CD55 (decay-accelerating factor; DAF) promotes the decay of C3 and C5 convertases, which inhibits all three complement pathways. CD59 (protectin) prevents the assembly of the MAC by inhibiting the polymerization of C9 and its subsequent binding to C5b-8, thus inhibiting all three pathways.

[0012] For most microorganisms, this first line of defense provided by complement is sufficient to prevent infection and preserve the integrity of the host organism. Pathogens are microorganisms that have acquired a way to subvert the host's immune system, breach the barriers that protect the host from microbial invasion, and establish an infection. Pathogens have developed various methods to subvert the host's immune defenses. For example, the bacterium Neisseria meningitidis has a surface protein called factor H binding protein that sequesteres and binds the host's negative complement control component factor H (fH) to the bacterial surface. This in turn protects the bacterium from complement activation because the surface-bound factor H disrupts and inactivates complement C3 and C5 convertases that are formed on the pathogen surface, thereby preventing the host's complement system from neutralizing, killing, or opsonizing the pathogen. Other strategies that pathogens have evolved to evade complement attack include sequestration of host C4-binding proteins by bacterial surface proteins such as PspA and PspC of Streptococcus pneumoniae to prevent the formation of C3 and C5 convertases of the classical and lectin pathways, C4bC2a and C4bC2a(C3b)n, respectively, on the bacterial surface (Haleem KS, et al. Infect Immun. 2018 Dec 19;87(1):e00742-18), and the release of complement-activating bacterial toxins that consume complement and direct it away from vulnerable pathogen surfaces.

[0013] The complement system also plays a role in cancer suppression. Neoplastic transformation leads to several genetic and epigenetic modifications that alter the morphology and composition of cell membranes. During this transformation process, normal cells express tumor-specific markers and produce proinflammatory signals that are recognized by the cancer immune surveillance network. Complement is considered to be part of the cancer immune surveillance network (Pio et al., 2014). It has been demonstrated that all three complement pathways are activated in malignant tumors (Macor, Capolla and Tedesco, 2018). Complement protein C3 degradation products and complement activation products (i.e., C5a, C3a, and C5b-9) have been detected in several types of cancer (Afshar-Kharghan, 2017). Besides complement components, CRP has also been found in cancer. In fact, mCRP and sCRP are overexpressed on cancer cells among various cancer types (Meyer, Leusen and Boross, 2014). Thus, the complement system is a host mechanism to combat cancer, and cancer cells can resist complement attack by overexpressing CRP.

[0014] The central role of complement in multiple physiological processes requires that complement activation be tightly controlled. However, pathogens (PF Zipfel and C. Skerka, 2009) and cancer cells (A. Geller and J. Yan, Front. Immunol. 10:1, 2019) have been shown to use evasion strategies, including the expression of negative complement regulatory proteins, to block complement activity. Thus, there is a need for therapies that enhance complement activity against pathogens or dysfunctional autologous cells (e.g., cancer cells or autoimmune cells), for example, by directing complement activation to the pathogen or dysfunctional cell or to tissues in which the pathogen or dysfunctional cell resides. Summary of the Invention

[0015] overview This Summary is provided to introduce a selection of concepts in a simplified form that are further described below in the Detailed Description. This Summary is not intended to identify key features of the claimed subject matter, nor is it intended to be used as an aid in determining the scope of the claimed subject matter.

[0016] In one aspect, the present disclosure provides a targeted complement activation molecule, comprising a targeting domain or target binding domain and a complement activation serine protease effector domain. In some embodiments, the target binding domain is derived from an antibody. In some embodiments, the target binding domain comprises an antigen-binding fragment of an antibody. In some embodiments, the complement activation serine protease effector domain is catalytically active, while in other embodiments, the complement activation serine protease effector domain is in the form of a zymogen. In some embodiments, the target binding domain binds to an antigen present on a cell, such as CD20, CD38, or CD52. In other embodiments, the target binding domain binds to an antigen present on a microbial pathogen, such as on a bacterial pathogen, on a viral pathogen, on a fungal pathogen, or on a parasitic pathogen.

[0017] In some embodiments, the targeted complement activating molecule comprises a fusion protein comprising the N-terminus of a serine protease effector domain fused to the C-terminus of an antibody heavy chain or fragment thereof or fused to the C-terminus of an antibody light chain or fragment thereof. In another embodiment, the fusion protein comprises the C-terminus of a serine protease effector domain fused to the N-terminus of an antibody heavy chain or fragment thereof or fused to the N-terminus of an antibody light chain or fragment thereof. In some embodiments, the targeted complement activating molecule comprises a fusion protein as described above and a second antibody chain that is a light chain or fragment thereof when the fusion protein comprises a heavy chain or fragment thereof, and a second antibody chain that is a heavy chain or fragment thereof when the fusion protein comprises a light chain or fragment thereof. In some embodiments, the targeted complement activating molecule comprises a fusion protein comprising the N-terminus of a serine protease effector domain fused to the C-terminus of a single chain antibody or fragment thereof, or a fusion protein comprising the C-terminus of a serine protease effector domain fused to the N-terminus of a single chain antibody or fragment thereof.

[0018] In some embodiments, the serine protease effector domain comprises complement factor D or a fragment thereof, C1r or a fragment thereof, C1s or a fragment thereof, MASP-2 or a fragment thereof, MASP-3 or a fragment thereof, MASP-1 or a fragment thereof, C2a or a fragment thereof, or Bb or a fragment thereof.

[0019] Also provided herein are polynucleotides encoding the targeted complement activating molecules or portions thereof, and cloning vectors or expression cassettes comprising such polynucleotides.

[0020] Further provided herein are host cells expressing targeted complement activating molecules and methods of producing targeted complement activating molecules comprising culturing said host cells under conditions allowing expression of said molecules and isolating said molecules.

[0021] Also provided herein is a method of activating at least one complement pathway in a mammalian subject using the targeted complement activation molecule.In some embodiments, the targeted complement activation molecule can be used to induce complement-dependent cytotoxicity (CDC), complement-dependent cellular cytotoxicity (CDCC), or complement-dependent cytophagocytosis (CDCP) in target cells.In some embodiments, the targeted complement activation molecule can be used to treat cancer, autoimmune disease, or microbial infection, such as bacterial infection, viral infection, fungal infection, or parasitic infection. [Brief description of the drawings]

[0022] The foregoing aspects and many of the attendant advantages of the present invention will become more readily appreciated as they become better understood by reference to the following detailed description, when taken in conjunction with the accompanying drawings as hereinafter described. [Figure 1] FIG. 1 is a diagram illustrating the classical, lectin and alternative complement pathways. [Diagram 2] Graphical illustration of surface levels of CD20, CD55 and CD59 on CD20+ cancer cell lines Ramos, Kasumi-2 and SU-DHL-8. Cells were stained with primary antibodies targeting CD20 (RTX), CD55 (CBL511, Millipore) and CD59 (MAB1759, Millipore) and a secondary antibody, a fluorophore-conjugated anti-human IgG Fc Ab (Biolegend). Controls are shown as light grey lines. Expression levels are shown as dark grey lines. Fluorescence was measured by FACS. [Diagram 3]This is a diagram illustrating a particular format for the targeted complement activating molecule described herein. Such molecules may include a targeting domain derived from an antibody and a serine protease effector domain fused to either the heavy or light chain of the antibody. Shown are an unmodified antibody (leftmost) and a targeted complement activating molecule that includes a protease effector domain fused to the C-terminus of the heavy chain (second from the left), the N-terminus of the heavy chain (center), the C-terminus of the light chain (second from the right), or the N-terminus of the light chain (rightmost). [Figure 4] Figure 1 shows the results of SDS-PAGE analysis of certain targeted complement activating molecules containing serine protease effector domains from MASP-1, MASP-2 or MASP-3 as described herein. Subunits of each fusion were separated using 4-12% gradient polyacrylamide gels (NuPAGE Bis-Tris gels, Invitrogen) and polypeptide sizes were estimated using molecular weight markers (SeeBlue Plus 2, Invitrogen). Abbreviations of the different molecules analyzed are listed in Table 1. Rituximab (RTX) was used as a control. [Diagram 5] Figure 1 shows the results of SDS-PAGE analysis of certain targeted complement activation molecules containing serine protease effector domains from C1r, C1s, C2a, Bb or complement factor D (CFD) as described herein. Subunits of each fusion were separated using 4-12% gradient polyacrylamide gels (NuPAGE Bis-Tris gels, Invitrogen) and polypeptide sizes were estimated using molecular weight markers (SeeBlue Plus 2, Invitrogen). Abbreviations of the various molecules analyzed are listed in Table 1. Rituximab (RTX) was used as a control. [Figure 6]1 shows SDS-PAGE analysis of the activation of a specific targeted complement activation molecule containing a serine protease effector domain from MASP-3, as described herein. Zymogen RTX(H)ΔK-M3 (2 μM) was diluted in 10 mM HEPES, pH 7.4, 140 mM NaCl, 0.1 mM EDTA buffer and incubated at 37° C. alone (negative control) or with the addition of MASP-2 (CCP1 / 2SP) (91 nM) at various time points (0, 10, 20, 40, 60, 90, 120, 150 and 190 min). Samples were removed at each time point and placed at −20° C. to stop the reaction. To verify the cleavage of MASP-3 fusion protein, SDS-PAGE analysis was performed under reducing conditions. Bands corresponding to zymogen and active forms of RTX-MASP-3 are shown. [Figure 7] Figure 1 shows SDS-PAGE analysis of potential degradation-resistant variants of certain targeted complement activation molecules described herein. Subunits of each fusion were separated using 4-12% gradient polyacrylamide gels (NuPAGE Bis-Tris gels, Invitrogen) and polypeptide sizes were estimated using molecular weight markers (SeeBlue Plus 2, Invitrogen). Abbreviations of the different molecules analyzed are listed in Table 1. Rituximab (RTX) was used as a control. [Figure 8]SDS-PAGE analysis of additional potential degradation-resistant variants of certain targeted complement-activating molecules containing serine protease effector domains from C1r or C1s described herein is shown. Subunits of each fusion were separated using 4-12% gradient polyacrylamide gels (NuPAGE Bis-Tris gels, Invitrogen) and polypeptide sizes were estimated using molecular weight markers (SeeBlue Plus 2, Invitrogen). Abbreviations of the various molecules analyzed are listed in Table 1. Targeted complement-activating molecules shown in lanes 6 and 8 (RTX(H)N297G,ΔK-C1sD456W and RTX(H)N297G,ΔK-C1sP458W, respectively) were incubated with C1r for 1 or 3 h to convert the serine protease effector domains to their active forms and then subjected to SDS-PAGE analysis to check for degradation (right panel). [Figure 9] 1 shows the binding of certain targeted complement activation molecules described herein to target cells. B cell line Ramos cells (ATCC) (0.5×106 cells) were stained with rituximab as the primary antibody or one of 12 targeted complement activation molecules that contain a targeting domain derived from rituximab. Fluorophore-conjugated anti-human IgG Fc Ab (BioLegend) was used as the secondary antibody. Unstained cells and cells stained with secondary Ab only were included as controls. Fluorescence was measured by FACS. Controls are shown as light gray lines. Rituximab binding is shown as a dark gray line. Targeted complement activation molecule binding is shown as a filled dark gray area. [Figure 10]Figure 1 shows the kinetics of binding to CD20 as measured by Biolayer Interferometry (BLI) for certain targeted complement activating molecules described herein. Binding assays were performed on an AHC biosensor. 69 nM of targeted complement activating molecules diluted in kinetic buffer (PBS, 0.02% Tween 20, 1% BSA, 0.05% DDM, 0.01% CHS) were loaded (loading phase) and antigen CD20 diluted in kinetic buffer was added in a 2-fold series starting from 0, 6.25, 12.5, 25, 50, 100 and 200 nM (association phase). Assays were performed on an Octet RED96 system (ForteBio Inc.) and analyzed with Octet CFR software (ForteBio Inc.). The noisy and smooth lines are the difference between the measured data and the global fit. Data for the anti-CD20 antibodies rituximab (RTX) and obinutuzumab (OBZ) are shown for comparison. [Figure 11A] Figures 11A and 11B show the results of a serine protease activity assay for certain targeted complement activation molecules described herein. Substrates C4 (Figure 11A) or C3 (Figure 11B) were diluted in PBS (1x), pH 7.4, and incubated at 37°C either alone ("none") or with the indicated targeted complement activation molecules at an enzyme / substrate ratio of 1:20. Samples were removed after 3 hours to stop the reaction. SDS-PAGE analysis under reducing conditions was performed to verify cleavage of C4 or C3. The cleavage products C4b and C3b are indicated by arrows. [Figure 11B] See legend to Figure 11A. [Figure 12A]Figures 12A and 12B show the results of a C4 deposition assay for certain targeted complement activation molecules described herein. ELISA plates were coated with 100 μl of mannan (50 μg / mL) and either 215 nM (Figure 12A) or 69 nM (Figure 12B) of rituximab or the indicated targeted complement activation molecules suspended in coating buffer. The plates were incubated overnight at 4°C. Remaining protein binding sites were then blocked by adding 250 μl of 1% BSA in PBS buffer to each well and incubating at room temperature for 2 hours. The plates were washed three times with PBS containing 0.05% Tween 20. Hirudin plasma from MASP-2 knockout (KO) mice (left panel of Figure 12A) or wild-type (WT) mice (right panel of Figure 12A) was diluted with PBS (calcium-free, magnesium-free) to a final concentration of 10%. Normal human serum (NHS) (Figure 12B) was diluted in PBS (calcium-free, magnesium-free) to a final concentration of 1%. Plates were incubated with plasma for 15 min at 4°C. C4 (0.2 μg / mL) antibody diluted in wash buffer was added to the plate and incubated for 30 min at 37°C and 200 rpm. Secondary antibody (0.043 μg / mL) diluted in wash buffer was added to the plate and incubated for 30 min at room temperature. Absorbance was measured at 450 nm after addition of the colorimetric substrate TMB. [Figure 12B] See legend to Figure 12A. [Figure 13]Figure 1 shows the results of a C3 deposition assay for certain targeted complement activation molecules described herein. ELISA plates were coated with 215 nM rituximab or the indicated targeted complement activation molecules suspended in coating buffer. Plates were incubated overnight at 4°C. Remaining protein binding sites were then blocked by adding 250 μl of 1% BSA in PBS buffer to each well and incubating at room temperature for 2 hours. Plates were washed three times with PBS containing 0.05% Tween 20. Hirudin plasma from MASP-1 / 3 knockout (KO) mice (left panel) or wild-type (WT) mice (second panel from the left) was diluted in MgEGTA buffer (10 mM EGTA, 5 mM MgCl2, 5 mM barbital, 145 mM NaCl [pH 7.4]) to a final concentration of 10%. Normal human serum (NHS) was diluted in MgEGTA to a final concentration of 3% (third panel from the left) or 10% (right panel). Plates were incubated with plasma for 20 min (mouse plasma and 3% NHS) or 25 min (10% NHS) at 37°C. C3 antibody (2.4 μg / mL) diluted in wash buffer was added to the plate and incubated for 30 min at 37°C and 200 rpm. Secondary antibody (0.043 μg / mL) diluted in wash buffer was added to the plate and incubated for 30 min at room temperature. Absorbance at 450 nm was measured after addition of the colorimetric substrate TMB. [Figure 14A]Figures 14A and 14B show detection of complement factors C3b (Figure 14A) or MAC (Figure 14B) deposited on Kasumi-2 target cells after treatment with certain targeted complement activating molecules described herein. Rituximab or the indicated targeted complement activating molecules were diluted in assay buffer to a concentration of 12.5 nM. Normal human serum (NHS) was diluted in assay buffer to a final concentration of 15%. Kasumi-2 cells were resuspended in assay buffer to a final concentration of 300,000 cells / ml and transferred to a 6-well assay plate. Diluted protein and NHS were added to the wells. Plates were incubated at 37°C in a humidified incubator for 2 hours. Cells were then resuspended in FACS buffer, blocked to prevent non-specific binding, and stained with primary antibodies (rabbit anti-human C3c or monoclonal mouse anti-human C5b-9). After 20 min incubation on ice, cells were washed twice and resuspended in FACS buffer containing secondary antibody (APC anti-rabbit IgG or PE anti-mouse IgG). Cells were incubated for an additional 20 min on ice, then washed three times and resuspended in FACS buffer. Samples of stained cells were analyzed by FACS (FACSCalibur). [Figure 14B] See legend to Figure 14A. [Figure 15]Detection of CD52 or CD38 using anti-CD52 or CD38 antibodies or certain targeted complement activation molecules described herein (columns marked "CD52" and "CD38"), and detection of complement factor C3b deposited on HT target cells after treatment with certain targeted complement activation molecules described herein (column marked "C3b"). To detect CD52 or CD38, about 500,000 cells of human B-cell lymphoma line HT (ATCC) were harvested and resuspended in FACS buffer. To prevent non-specific binding, 5 μl of blocking solution was added to 100 μl of cell suspension, which was then incubated at room temperature for 15 minutes. Antibodies alemtuzumab (targeting CD52) and daratumumab (targeting CD38) or the indicated targeted complement activation molecules were added to the cell suspension and incubated on ice for 20 minutes. Cells were then washed twice and resuspended in FACS buffer containing secondary antibody (mouse anti-human IgG1 conjugated with Alexa Fluor 647). Cells were incubated on ice for 20 min, then washed three times and resuspended in FACS buffer. Samples of stained cells were analyzed by FACS (FACSCalibur). To detect C3b, alemtuzumab, daratumumab, or the indicated targeted complement activating molecule was diluted in assay buffer to a concentration of 12.5 nM. Normal human serum (NHS) was diluted in assay buffer to a final concentration of 15%. HT cells were resuspended in assay buffer to a final concentration of 300,000 cells / ml and transferred to a 6-well assay plate. Diluted protein and NHS were added to the wells. Plates were incubated for 2 h at 37°C in a humidified incubator. Cells were then resuspended in FACS buffer, blocked to prevent non-specific binding, and stained with primary antibody (rabbit anti-human C3c). After 20 min incubation on ice, cells were washed twice and resuspended in FACS buffer containing secondary antibody (APC anti-rabbit IgG). Cells were incubated for an additional 20 min on ice, then washed three times and resuspended in FACS buffer. Samples of stained cells were analyzed by FACS (FACSCalibur). [Figure 16]Figure 1 shows the results of a complement-dependent cytotoxicity (CDC) assay using rituximab or certain targeted complement activating molecules as described herein. Ramos cells (ATCC) were resuspended in assay buffer to a final concentration of 10,000 cells per well and transferred to a 96-well plate. To each well was added 15% NHS and 12.5 nM rituximab or the indicated targeted complement activating molecule. Controls with no antibody or targeted complement activating molecule and no cells were included. Plates were incubated at 37°C for 2 hours before adding CytoTox-Glo (Promega). After a further 15 minutes of incubation at room temperature, luminescence was measured using a Luminoskan plate reader. [Figure 17] Figure 1 shows the results of a complement-dependent cytotoxicity (CDC) assay using rituximab or certain targeted complement activating molecules described herein. Ramos cells (ATCC) were resuspended in assay buffer to a final concentration of 10,000 cells per well and transferred to a 96-well plate. Each well received 15% NHS and either 12.5 nM rituximab or the indicated targeted complement activating molecule (left panel) or the concentrations of rituximab or targeted complement activating molecule shown on the x-axis (right panel). Controls with no antibody or targeted complement activating molecule and no cells were included. Plates were incubated at 37°C for 2 hours before adding CytoTox-Glo (Promega). After a further 15 minutes of incubation at room temperature, luminescence was measured using a Luminoskan plate reader. [Figure 18]Figure 1 shows the results of a complement-dependent cytotoxicity (CDC) assay using rituximab or certain targeted complement activating molecules as described herein. Ramos cells (ATCC) were resuspended in assay buffer to a final concentration of 10,000 cells per well and transferred to a 96-well plate. To each well was added 15% NHS and 37.5 nM rituximab or the indicated targeted complement activating molecule. Controls with no antibody or targeted complement activating molecule and no cells were included. Plates were incubated at 37°C for 2 hours (left panel) or 3 hours (right panel) before adding CytoTox-Glo (Promega). After a further 15 minutes of incubation at room temperature, luminescence was measured using a Luminoskan plate reader. [Figure 19A]Figures 19A and 19B show the results of a complement-dependent cytotoxicity (CDC) assay using rituximab or certain targeted complement-activating molecules described herein. Three different concentrations of rituximab or the indicated targeted complement-activating molecules, 112.5 nM, 37.5 nM, and 12.5 nM, were prepared in assay buffer (Opti-MEM cell culture medium). Normal human serum (NHS) was diluted in assay buffer to a final concentration of 10%. Ramos cells were washed with PBS, resuspended in assay buffer to a final concentration of 150,000 cells per well, and transferred to a 96-well assay plate. The diluted proteins and human serum were added to the wells. The plate was incubated for 2 hours at 37°C in a humidified incubator. Propidium iodide (5 μl) was added, and stained cells were immediately analyzed by flow cytometry (FACSCalibur). Cells treated with NHS only and unstained cells were included as controls. The dotted line indicates the NHS only control, the solid line indicates a concentration of 12.5 nM, the light grey area indicates a concentration of 37.5 nM, and the dark grey area indicates a concentration of 112.5 nM. Figure 19A shows the results of an assay using rituximab (left panel) or MatCFD-RTX (right panel) at several different concentrations. Figure 19B shows a comparison of the assay results using rituximab or MATCFD-RTX at 112.5 nM. [Figure 19B] See legend to Figure 19A. [Figure 20]Figure 1 shows the results of a complement-dependent cytotoxicity (CDC) assay using rituximab or certain targeted complement activating molecules in the presence of antibodies against either or both of the complement regulatory proteins (CRPs) CD55 (clone BRIC 216, Sigma-Aldrich) and CD59 (clone BRIC 229, IBGRL). The monoclonal antibody rituximab (RTX) and a modified version of rituximab (RTXN297G) were tested, as were targeted complement activating molecules containing mature factor D (MatCFD) and either RTX or RTXN297G. The RTX antibody, RTXN297G antibody, or targeted complement activating molecule were prepared to a final concentration of 337.5 nM in assay buffer (RPMI 1640 medium [-] L-glutamine, 5% FBS (heat inactivated), 100x GlutaMax, and 25 mM HEPES). Anti-CD55 antibodies were prepared in assay buffer to a final concentration of 10 μg / mL. Anti-CD59 antibodies were prepared in assay buffer to a final concentration of 2 μg / mL. Normal human serum (NHS) was diluted in assay buffer to a final concentration of 15%. Ramos cells were resuspended in assay buffer to a final concentration of 300,000 cells per well and transferred to a 96-well assay plate. Diluted protein and NHS were added to the wells. Plates were incubated for 2 hours at 37°C in a humidified incubator. Propidium iodide (5 μL, Invitrogen) was added and stained cells were immediately analyzed by flow cytometry (FACSCalibur). Cells treated with NHS and RTX antibody, RTXN297G antibody or targeted complement activation molecules in the absence of anti-CD55 and anti-CD59 (no inhibitors) were included as controls. [Figure 21] Figure 1 shows the binding of three different mouse monoclonal antibodies to the factor H binding protein (fHbP) of N. meningitidis. The left panel shows the binding of each of the three antibodies to recombinant fHbP on the surface of an ELISA plate. The right panel shows the binding of each of the three antibodies to N. meningitidis on the surface of an ELISA plate. [Figure 22] Shown is the binding of mouse-human chimeric versions of three mouse monoclonal antibodies to N. meningitidis on the surface of an ELISA plate. [Diagram 23] 1 shows the binding of certain targeted complement activating molecules described herein to Neisseria meningitidis on the surface of an ELISA plate. The targeted complement activating molecules tested were clone 19-C1r, which contains a binding domain from a chimeric mouse monoclonal antibody against Neisseria meningitidis fHbP and a serine protease effector domain from C1r, and clone 19-C1s, which contains a binding domain from a chimeric mouse monoclonal antibody against Neisseria meningitidis fHbP and a serine protease effector domain from C1s. Binding of the chimeric antibody clone 19 is shown for comparison. [Figure 24] Figure 1 shows the evaluation of antibody titers against Neisseria meningitidis serogroup B (MC58) in various human sera. ELISA plates were coated with Neisseria meningitidis and incubated with different serum dilutions from 12 different human sera. Antibodies against Neisseria meningitidis were detected using a horseradish peroxidase (HRP)-conjugated anti-human IgG antibody. [Diagram 25] Illustrates detection of complement factor C5b-9 (also known as MAC) deposited on meningococcal cells after treatment with certain complement activating molecules described herein. Mixtures containing 10 μg / mL of targeted complement activating molecules in 5% normal human serum (NHS) previously confirmed to have low titers of anti-Neisseria antibodies were incubated for the times indicated on the x-axis. Controls included NHS alone or NHS with clone 19 anti-fHbP antibody. Detection was performed with a monoclonal antibody against MAC. [Figure 26A]Figures 26A and 26B show the results of a meningococcal serum bactericidal assay using serum samples from four different individuals. Bacteria were incubated with buffer solution only (BBS), or with 2.5% normal human serum (NHS), or in the presence of 10 μg / mL of anti-fHbp antibody clone 19 or targeted complement activating molecules clone 19-C1r or clone 19-C1s. Samples were taken at the indicated time points and plated overnight at 37° C. and 5% CO2 on blood agar plates. The bactericidal activity of the serum was calculated by measuring the reduction in the viable bacterial count recovered compared to the original bacterial count at time zero and with heat-inactivated serum. Results are shown as colony forming units (cfu) / ml. Each row shows the results for a different serum sample. For each serum sample, the chart on the left shows the results after 30 minutes and the chart on the right shows the results after 60 minutes. [Figure 26B] See legend to Figure 26A. [Figure 27A] Figures 27A-C show the results of complement component deposition assays using serum from four different individuals. Complement component deposition was assayed as described for Figures 26A and 26B, but at various serum concentrations. Figure 27A shows C3b deposition, Figure 27B shows C4b deposition, and Figure 27C shows C5b deposition. [Figure 27B] See legend to Figure 27A. [Figure 27C] See legend to Figure 27A. [Figure 28]Figure 1 shows the results of a complement C3b deposition assay using anti-fHbp antibody clone 19 and targeted complement activation molecules including chimeric antibody clone 19 and one of C1r, C1s, MASP-2, MASP-3 and factor D. Maxisorp polystyrene microtiter ELISA plates were coated overnight at 4°C with meningococcal antigen MC58. The next day, remaining binding sites were blocked with 5% nonfat milk. Wild-type mouse serum (5%) was added to the plates at various time points at room temperature along with 150 nM of clone 19 antibody, targeted complement activation molecules, or isotype control antibody. After incubation, the ELISA plates were washed and complement C3b deposition was detected using rabbit anti-C3b antibody followed by goat anti-rabbit HRP-conjugated antibody. [Figure 29] Figure 1 shows the results of an assay for binding of monoclonal antibodies against the pneumococcal antigen PspA to S. pneumoniae. Anti-PspA antibodies 5C6.1 and RX1MI005 were tested. S. pneumoniae strain D39 was incubated with either 5C6.1 or RX1MI005 at a concentration of 10 μg / mL for 30 minutes at room temperature, then washed and incubated with Alexa Fluor goat anti-human IgG for 30 minutes. Binding was measured by FACS analysis. [Diagram 30] Figure 1 shows the results of an assay for binding of chimeric anti-PspA antibody RX1MI005 and targeted complement activating molecules, including RX1MI005 and either C1r or C1s, to S. pneumoniae. ELISA plates were coated with S. pneumoniae strain D39 in coating buffer and blocked with 5% nonfat milk. Serial dilutions of antibody or targeted complement activating molecule were added to the plate and incubated for 30 min at room temperature before washing. Bound antibody and targeted complement activating molecule were detected using HRP-conjugated anti-human IgG. An irrelevant isotype antibody was included as a control. [Diagram 31]Figure 1 shows the results of an assay for complement C3b deposition using the PspA antibody RX1MI005, targeted complement activating molecules including RX1MI005 and either C1r or C1s, and an isotype control antibody. S. pneumoniae cells were washed twice with TBS buffer and resuspended in BBS++ buffer (4 mM barbital, 145 mM NaCl, 2 mM CaCl2, 1 mM MgCl2, pH 7.4) to a final concentration of 106 cfu per 100 mL. Bacterial suspensions (100 μL) were opsonized with antibodies or targeted complement activating molecules using 1% (vol / vol) NHS for 15 min at room temperature. Nonopsonized bacteria served as a negative control. After opsonization, bacterial samples were washed twice with TBS buffer and bound C3b was detected using FITC-conjugated rabbit anti-human C3c (Dako). Fluorescence intensity was measured with a FACSCalibur cell analyzer (BD Biosciences). [Diagram 32] Assay results of antibody and targeted complement activating molecule binding to Candida albicans are shown. Antibody 1A2, which binds to a fungal mannan epitope present on C. albicans, was used along with antibody 1A2 and targeted complement activating molecules including C1r. An irrelevant isotype antibody was used as a control. ELISA plates were coated with Candida albicans in coating buffer and blocked with 5% nonfat milk. Serial dilutions of antibody 1A2 and targeted complement activating molecules were added to the plates and incubated for 30 minutes at room temperature before washing. Bound antibody was detected using HRP-conjugated anti-human IgG. [Diagram 33]Assay results of antibody and targeted complement activation molecule binding to Candida albicans are shown. Fungal cells were incubated with targeted complement activation molecules including antibody 1A2 or antibody 1A2 and C1r for 30 min at room temperature, then washed and incubated with Alexa Fluor goat anti-human IgG for 30 min. Binding was measured by FACS analysis. An irrelevant isotype antibody was used as a control. [Diagram 34]The results of an assay measuring C3b deposition triggered by certain antibodies and targeted complement activation molecules on the surface of Candida albicans are shown. The left panel shows the evaluation of antibody titers against Candida albicans in various human sera. ELISA plates were coated with Candida albicans and incubated with sera from five different individuals. Antibodies against Candida albicans were detected using horseradish peroxidase (HRP)-conjugated anti-human IgG antibodies. The serum with the lowest titer of Candida albicans antibodies measured (indicated as "GC") was used for the C3b deposition assay, and the results are shown in the right panel. For the C3b deposition assay, Maxisorp polystyrene microtiter ELISA plates were coated with formalin-fixed Candida albicans in carbonate buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6). The next day, wells were blocked with 5% nonfat milk in TBS buffer (10 mM Tris-HCl, 140 mM NaCl, pH 7.4) for 2 h and then washed with TBS buffer containing 0.05% (v / v) Tween 20 and 5 mM CaCl2. 1% NHS serum "GC" containing 150 nM of antibody or targeted complement activating molecule diluted in BBS++ buffer (4 mM barbital, 145 mM NaCl, 2 mM CaCl2, 1 mM MgCl2, pH 7.4) was added to the plates and incubated for 5, 10, 15, 20 and 25 min at room temperature before washing. C3b deposition was detected using rabbit anti-C3c (Dako) followed by peroxidase-conjugated goat anti-rabbit IgG. After 1 hour, the wells were washed, then 100 μL of 1-Step Ultra TMB solution (Thermo Fisher Scientific) was added to each well and incubated at room temperature for 5 minutes. The reaction was stopped by adding 2M H2SO4, and the optical density at 450 nm was immediately measured. [Diagram 35]Figure 1 shows the results of an assay measuring the binding of 11 different anti-Fnbp antibodies to Staphylococcus aureus. Antibodies were generated by injecting mice with the S. aureus antigen fibronectin binding protein (Fnbp). Hybridomas were formed and supernatant samples were taken and screened by ELISA. This resulted in 11 candidate antibodies. ELISA plates were coated with S. aureus and remaining binding sites were blocked using 5% nonfat milk. S. aureus Fc receptors were blocked with Fc blocking agent. A range of concentrations of purified monoclonal antibodies were incubated with the ELISA plates for 1 hour at room temperature. Antibody binding was detected using a rabbit anti-mouse HRP conjugated antibody. Clone G was identified as showing the best binding to S. aureus. [Diagram 36] Figure 1 shows the results of an assay measuring the binding of anti-FnbpB antibody clone G to S. aureus MSSA strains. S. aureus MSSA bacteria were washed twice with TBS buffer and resuspended in BBS++ buffer (4 mM barbital, 145 mM NaCl, 2 mM CaCl2, 1 mM MgCl2, pH 7.4) to a final concentration of 107 cfu / mL. S. aureus Fc receptors were blocked with Fc blocking agent. Bacterial suspensions (100 μL) were incubated with 150 nM mouse monospecific antibodies for 30 min at room temperature. Bacteria opsonized with isotype control antibodies were used as negative controls. After incubation, bacterial samples were washed twice with TBS buffer and bound antibodies were detected using FITC-conjugated rabbit anti-mouse IgG. Fluorescence intensity was measured on a FACSCalibur cell analyzer (BD Biosciences). [Figure 37]Figure 1 shows the results of an assay measuring the binding of anti-Fnbp antibody clone G to three different S. aureus MRSA isolates. S. aureus MRSA cells from each of the three different isolates were washed twice with TBS buffer and resuspended in BBS++ buffer (4 mM barbital, 145 mM NaCl, 2 mM CaCl2, 1 mM MgCl2, pH 7.4) to a final concentration of 107 cfu / mL. S. aureus Fc receptors were blocked with Fc blocking agent. Bacterial suspensions (100 μL) were incubated with 150 nM of antibody for 30 min at room temperature. Bacteria opsonized with isotype control antibody were used as negative control. After incubation, bacterial samples were washed twice with TBS buffer and bound antibody was detected using FITC-conjugated rabbit anti-mouse IgG. Fluorescence intensity was measured on a FACSCalibur cell analyzer (BD Biosciences). [Figure 38A] Figures 38A and 38B show the results of an assay measuring the binding of antibodies and targeted complement activation molecules to S. aureus. Chimeric monoclonal anti-FnbpB antibody clone G was tested with targeted complement activation molecules including clone G and C1r or C1s. ELISA plates were coated with either recombinant FnbpB (Figure 38A) or S. aureus (MRSA strain) (Figure 38B), and then the remaining binding sites were blocked using 5% nonfat milk. The Fc receptors of S. aureus were blocked with Fc blocking agents. A series of concentrations of purified monoclonal antibody clone G and targeted complement activation molecules including clone G and C1r or C1s were incubated with the ELISA plates for 1 hour at room temperature. Binding of antibodies and targeted complement activation molecules was detected using an HRP-conjugated rabbit anti-human IgG antibody. The targeted complement-activating molecules showed good binding to both recombinant FnbpB (FIG. 38A) and S. aureus (an MRSA strain) (FIG. 38B). [Figure 38B] See legend to Figure 38A. [Figure 39]Figure 1 shows the results of an assay measuring binding of certain antibodies and targeted complement activating molecules to an antigen from Plasmodium falciparum. The antigen used was P. falciparum reticulocyte binding protein homolog 5 (PfRH5). Anti-PfRH5 antibodies R5.004 and R5.016 were tested, as were targeted complement activating molecules including R5.004 with C1r, R5.004 with C1s, R5.016 with C1r, or R5.016 with C1s. The monoclonal antibody rituximab was used as a negative control. Maxisorp polystyrene microtiter ELISA plates were coated with 50 μL per well of cell supernatant from cells transfected with PfRH5. The next day, wells were blocked with 1% BSA in PBS (1x) for 2 hours and then washed with PBS buffer containing 0.05% (v / v) Tween 20. Two-fold serial dilutions of antibodies and targeted complement activating molecules were prepared in buffer containing 0.1% BSA in PBS (1x) with a maximum concentration of 13.9 nM. 100 μL of each sample was transferred to an ELISA plate and incubated at room temperature. After 1 hour, the plate was washed and 100 μL of goat HRP-conjugated anti-human IgG detection antibody was added to the plate, followed by incubation at room temperature for 30 minutes. The plate was washed and 100 μL of 1-step Ultra TMB solution (Thermo Fisher Scientific) was added to each well and incubated at room temperature for 2 minutes. The reaction was stopped by the addition of 2M H2SO4 and the optical density at 450 nm was immediately measured. [Diagram 40]Figure 1 shows the results of an assay measuring complement C3b deposition triggered by certain antibodies and targeted complement activation molecules on the surface of PfRH5-coated wells. Anti-PfRH5 antibodies R5.004 and R5.016 were tested, as were targeted complement activation molecules including R5.004 with C1r, R5.004 with C1s, R5.016 with C1r, or R5.016 with C1s. Monoclonal antibody rituximab was used as a negative control. Maxisorp polystyrene microtiter ELISA plates were coated with 50 μL per well of cell supernatant from PfRH5-transfected cells. The next day, wells were blocked with 1% BSA in PBS (1x) for 2 h and then washed with PBS buffer containing 0.05% (v / v) Tween 20. Normal human serum (NHS) containing 13.9 nM of antibody or targeted complement activating molecule was diluted to a concentration of 3% in BBS++ buffer (4 mM barbital, 145 mM NaCl, 2 mM CaCl2, 1 mM MgCl2, pH 7.4) and added to the wells. Plates were incubated at room temperature for either 5, 10, 15, 20 or 25 min and then washed three times. C3b deposition was detected using rabbit anti-human C3c (Dako) followed by peroxidase-conjugated goat anti-rabbit IgG (Southern Biotech). After 1 h, plates were washed three times and 100 μL of 1-Step Ultra TMB solution (Thermo Fisher Scientific) was added to each well and incubated for 2 min at room temperature. The reaction was stopped by the addition of 2M H2SO4 and the optical density at 450 nm was immediately measured. [Diagram 41]Figure 1 shows the bacterial load in blood samples from mice infected with Neisseria meningitidis. Twelve-week-old female C57BL / 6 wild-type mice (Charles River Laboratory) were used in this study. Twelve hours prior to infection, mice were injected intraperitoneally (ip) with iron dextran (400 mg / kg, Sigma-Aldrich). The following day, mice were injected ip with 100 μL of a subcultured Neisseria meningitidis B-MC58 suspension containing 5 × 106 cfu in PBS and iron dextran (400 mg / kg). Monoclonal antibody clone 19 or targeted complement activating molecules including clone 19 and C1r or C1s were injected ip 18 hours prior to infection. Mice treated with isotype control antibody served as controls. Inoculum dose was confirmed by viable counts after plating on 5% (vol / vol) blood agar. Blood samples were obtained at predetermined time points, serially diluted in PBS, and spread onto blood agar plates, after which viable counts were calculated. Mice treated with targeted complement activation molecules including clone 19 and C1r showed significantly lower blood bacterial loads compared to mice receiving clone 19 antibody. Results are mean ± SEM. *P<0.05 and **P<0.01 by Student's t-test. [Diagram 42] Figure 4 shows survival rates of mice treated with antibody clone 19, targeted complement activating molecules including clone 19 and C1r or C1s, and isotype control antibody prior to infection with Neisseria meningitidis. Mice were treated and infected as described in Figure 43. Mice were monitored for progression of clinical signs and were euthanized when they became lethargic. A significantly longer survival time was observed in mice treated with targeted complement activating molecules including clone 19 and C1r compared to mice treated with clone 19 antibody. Mantel-Cox log-rank test; n=12 mice / group; *P<0.05. [Diagram 43]Figure 1 shows the results of an assay measuring the binding of antibodies and certain targeted complement activation molecules to the HIV-1 envelope glycoprotein GP120. Antibody PGT121 was used together with targeted complement activation molecules including PGT121 and C1r or C1s. An irrelevant isotype antibody was used as a control. Maxisorp polystyrene microtiter ELISA plates were coated with recombinant GP120 at 2 μg / mL in coating buffer. The next day, wells were blocked with 5% nonfat milk in PBS for 2 hours and then washed with TBS buffer containing 0.05% (v / v) Tween 20. Two-fold serial dilutions of antibodies and targeted complement activation molecules were prepared in TBS buffer starting at 15 μg / mL. 100 μL of samples were transferred to the ELISA plate and incubated at room temperature. After 1 hour, the plate was washed and 100 μL of HRP-conjugated goat anti-human IgG detection antibody was added to the plate and incubated at room temperature for 30 minutes. The plate was washed and 100 μL of 1-Step Ultra TMB solution (Thermo Fisher Scientific) was added to each well and incubated at room temperature for 2 minutes. The reaction was stopped by adding 2M H2SO4 and the optical density at 450 nm was immediately measured. [Diagram 44]Figure 1 shows the results of an assay measuring C3b deposition triggered by antibody PGT121 and targeted complement activating molecules, including PGT121 and C1r or C1s, on the surface of GP120-coated ELISA wells. Maxisorp polystyrene microtiter ELISA plates were coated with 2 μg / mL recombinant GP120 in coating buffer. The next day, wells were blocked with 5% nonfat milk in PBS for 2 h and then washed with TBS buffer containing 0.05% (v / v) Tween 20. 7.5 μg of antibody or targeted complement activating molecule-containing NHS was diluted to a concentration of 2.5% in BBS++ buffer (4 mM barbital, 145 mM NaCl, 2 mM CaCl2, 1 mM MgCl2, pH 7.4), added to the plate and incubated at room temperature for 5, 10, 15, 20 and 25 min, then washed three times. C3b deposition was detected by using rabbit anti-human C3c (Dako) followed by peroxidase-conjugated goat anti-rabbit IgG (Southern Biotech). After 1 h, plates were washed three times and 100 μL of 1-Step Ultra TMB solution (Thermo Fisher Scientific) was added to each well at room temperature. The reaction was stopped by the addition of 2M H2SO4 and the optical density at 450 nm was immediately measured. [Diagram 45]Figure 1 shows the results of an assay measuring binding of anti-FnbpB antibody clone G and targeted complement activation molecules, including clone G with C1r or C1s, to Fnbp-coated ELISA plates. Maxisorp polystyrene microtiter ELISA plates were coated with recombinant S. aureus FnbpB at 2 μg / mL in coating buffer. The next day, wells were blocked with 5% nonfat milk in PBS for 2 h and then washed with TBS buffer containing 0.05% (v / v) Tween 20. Two-fold serial dilutions of antibodies and targeted complement activation molecules were prepared in TBS buffer, starting at 15 μg / mL. 100 μL of samples were transferred to the ELISA plate and incubated at room temperature. After 1 h, the plate was washed and 100 μL of HRP-conjugated goat anti-human IgG detection antibody was added to the plate, followed by incubation at room temperature for 30 min. The plate was washed and 100 μL of 1-Step Ultra TMB solution (Thermo Fisher Scientific) was added to each well and incubated at room temperature for 2 minutes. The reaction was stopped by adding 2M H2SO4 and the optical density at 450 nm was immediately measured. [Figure 46]Figure 1 shows the results of an assay measuring C3b deposition triggered by anti-FnbpB antibody clone G and targeted complement activating molecules including clone G with C1r or C1s on the surface of FnbpB-coated ELISA wells. Maxisorp polystyrene microtiter ELISA plates were coated with 2 μg / mL recombinant FnbpB in coating buffer. The next day, wells were blocked with 5% nonfat milk in PBS for 2 h and then washed with TBS buffer containing 0.05% (v / v) Tween 20. 7.5 μg of antibody or targeted complement activating molecule containing NHS was diluted to a concentration of 2.5% in BBS++ buffer (4 mM barbital, 145 mM NaCl, 2 mM CaCl2, 1 mM MgCl2, pH 7.4) and added to the plate and incubated at room temperature for 5, 10, 15, 20 and 25 min and then washed three times. C3b deposition was detected by using rabbit anti-human C3c (Dako) followed by peroxidase-conjugated goat anti-rabbit IgG (Southern Biotech). After 1 h, plates were washed three times and 100 μL of 1-Step Ultra TMB solution (Thermo Fisher Scientific) was added to each well at room temperature. The reaction was stopped by the addition of 2M H2SO4 and the optical density at 450 nm was immediately measured. [Figure 47]Figure 1 shows the results of an assay measuring binding of the anti-S protein antibody bebuterovimab and targeted complement activating molecules, including bebuterovimab and C1r or C1s, to SARS-CoV-2 S protein. Maxisorp polystyrene microtiter ELISA plates were coated with recombinant SARS-CoV-2 S protein at 2 μg / mL in coating buffer. The next day, wells were blocked with 5% nonfat milk in PBS for 2 h and then washed with TBS buffer containing 0.05% (v / v) Tween 20. Two-fold serial dilutions of antibodies or targeted complement activating molecules were prepared in TBS buffer, starting at 15 μg / mL. 100 μL of samples were transferred to the ELISA plate and incubated at room temperature. After 1 h, the plate was washed and 100 μL of goat anti-human HRP detection antibody was added to the plate, followed by incubation at room temperature for 30 min. The plate was washed and 100 μL of 1-Step Ultra TMB solution (Thermo Fisher Scientific) was added to each well and incubated at room temperature for 2 minutes. The reaction was stopped by adding 2M H2SO4 and the optical density at 450 nm was immediately measured. [Figure 48]Figure 1 shows the results of an assay measuring C3b deposition triggered by bebuterobimab or targeted complement activating molecules including bebuterobimab and C1r or C1s on the surface of S protein-coated ELISA plates. Maxisorp polystyrene microtiter ELISA plates were coated with 2 μg / mL recombinant S protein in coating buffer. The next day, wells were blocked with 5% nonfat milk in PBS for 2 h and then washed with TBS buffer containing 0.05% (v / v) Tween 20. 7.5 μg of antibody or targeted complement activating molecule in 2.5% NHS was diluted in BBS++ buffer (4 mM barbital, 145 mM NaCl, 2 mM CaCl2, 1 mM MgCl2, pH 7.4), added to the plate and incubated at room temperature for 5, 10, 15, 20 and 25 min, then washed three times. C3b deposition was detected by using rabbit anti-human C3c (Dako) followed by peroxidase-conjugated goat anti-rabbit IgG (Southern Biotech). After 1 h, plates were washed three times and 100 μL of 1-Step Ultra TMB solution (Thermo Fisher Scientific) was added to each well at room temperature. The reaction was stopped by the addition of 2M H2SO4 and the optical density at 450 nm was immediately measured. [Figure 49]Figure 1 shows the results of an assay measuring binding of targeted complement activation molecules including anti-M protein antibodies RB572 and RB574, and either BR572 or RB574 with one of C1r and C1s. Maxisorp polystyrene microtiter ELISA plates were coated with 2 μg / mL SARS-CoV-2 M protein in PBS (1×). The next day, wells were blocked with 1% BSA in PBS (1×) for 2 h and then washed with PBS buffer containing 0.05% (v / v) Tween 20. Two-fold serial dilutions of antibodies and targeted complement activation molecules were prepared in buffer containing 0.1% BSA in PBS (1×) with a top concentration of 400 nM. 100 μL of samples were transferred to the ELISA plate and incubated at room temperature. After 1 hour, the plate was washed and 100 μL of HRP-conjugated goat anti-human IgG detection antibody (American Qualex Antibodies, A130PD) was added to the plate followed by incubation at room temperature for 30 minutes. The plate was washed and 100 μL of 1-Step Ultra TMB solution (Thermo Fisher Scientific) was added to each well and incubated at room temperature for 2 minutes. The reaction was stopped by the addition of 2M H2SO4 and the optical density at 450 nm was immediately measured. An irrelevant antibody, RTX, was used as a control. [Figure 50]Figure 1 shows the results of an assay measuring C3b deposition triggered by anti-M protein antibody RB574 or targeted complement activating molecules including RB574 and C1r. Maxisorp polystyrene microtiter ELISA plates were coated with 2ug / mL of SARS-CoV-2 M protein. The next day, wells were blocked with 1% BSA in PBS (1x) for 2 hours and then washed with PBS buffer containing 0.05% (v / v) Tween 20. 200nM of antibody or targeted complement activating molecule in 3% NHS was diluted in BBS++ buffer (4mM barbital, 145mM NaCl, 2mM CaCl2, 1mM MgCl2, pH 7.4) and added to the plate and incubated for 5, 10, 15, 20, 25, and 30 minutes at room temperature and then washed three times. C3b deposition was detected by using rabbit anti-human C3c (Dako) followed by HRP-conjugated goat anti-rabbit IgG (Southern Biotech). After 1 h, plates were washed three times and 100 μL of 1-Step Ultra TMB solution (Thermo Fisher Scientific) was added to each well and incubated for 2 min at room temperature. The reaction was stopped by the addition of 2M H2SO4 and the optical density at 450 nm was immediately measured. An irrelevant antibody, RTX, was used as a control. [Figure 51]Figure 1 shows the results of an assay measuring binding of targeted complement activating molecules, including the anti-Aspergillus antibody hJF5 or hJF5 with C1r or C1s, to Aspergillus fumigatus. Maxisorp polystyrene microtiter ELISA plates were coated with Aspergillus fumigatus in coating buffer. The next day, wells were blocked with 5% nonfat milk in PBS for 2 h and then washed with TBS buffer containing 0.05% (v / v) Tween 20. Two-fold serial dilutions of antibodies and targeted complement activating molecules were prepared in TBS buffer starting at 15 μg / mL. 100 μL of samples were transferred to the ELISA plate and incubated at room temperature. After 1 h, the plate was washed and 100 μL of goat anti-human HRP detection antibody was added to the plate, followed by a 30-min incubation at room temperature. The plate was washed and 100 μL of 1-Step Ultra TMB solution (Thermo Fisher Scientific) was added to each well and incubated at room temperature for 2 minutes. The reaction was stopped by adding 2M H2SO4 and the optical density at 450 nm was immediately measured. [Figure 52]Figure 1 shows the results of an assay measuring C3b deposition triggered by anti-Aspergillus antibody hJF5 or targeted complement activating molecules including hJF5 and C1r or C1s on the surface of Aspergillus fumigatus. Maxisorp polystyrene microtiter ELISA plates were coated with Aspergillus fumigatus in coating buffer. The next day, wells were blocked with 5% nonfat milk in PBS for 2 h and then washed with TBS buffer containing 0.05% (v / v) Tween 20. 7.5 μg of antibody or targeted complement activating molecule in 2.5% NHS was diluted in BBS++ buffer (4 mM barbiturate, 145 mM NaCl, 2 mM CaCl2, 1 mM MgCl2, pH 7.4), added to the plates and incubated at room temperature for 5, 10, 15, 20 and 25 min before being washed three times. C3b deposition was detected by using rabbit anti-human C3c (Dako) followed by peroxidase-conjugated goat anti-rabbit IgG (Southern Biotech). After 1 h, plates were washed three times and 100 μL of 1-Step Ultra TMB solution (Thermo Fisher Scientific) was added to each well at room temperature. The reaction was stopped by the addition of 2M H2SO4 and the optical density at 450 nm was immediately measured. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0023] Detailed Description I. Definition Unless specifically defined herein, all terms used herein have the same meaning as would be understood by a person skilled in the art of the present invention. The following definitions are provided to clarify the terms used in the specification and claims to describe the present invention. Additional definitions are set forth throughout this disclosure.

[0024] Any concentration range, percentage range, ratio range, or integer range is understood herein to include any integer value within the stated range, and fractions thereof, as appropriate, unless otherwise indicated or otherwise clear from the context. Any numerical ranges recited herein for any physical characteristic, such as polymer subunits, size, or thickness, are understood to include any integer within the stated range, and fractions thereof, as appropriate, unless otherwise indicated or otherwise clear from the context. As used herein, the term "about" is intended to indicate that the range or value given may vary by ±10% of the stated range or value, unless otherwise indicated.

[0025] As used herein, the terms "a," "an," and "the" should be understood to refer to one or more of the referred components. The use of alternatives (e.g., "or") should be understood to mean either one or both of the alternatives, or any combination thereof. As used herein, the terms "include," "have," and "comprise" are used synonymously, and these terms and variations thereof are intended to be non-limiting.

[0026] "Optional" or "optionally" means that the subsequently described element, component, event or circumstance may be present or occur, or may not be present or occur, and that the description encompasses the presence or occurrence of the element, component, event or circumstance as well as its absence or not occurring.

[0027] It should be understood that each individual construct or group of constructs derived from the various combinations of structures and subunits described herein is disclosed by this application to the same extent as if each construct or group of constructs was described individually, and thus selection of a particular structure or particular subunit is within the scope of this disclosure.

[0028] The term "consisting essentially of" is not equivalent to "comprising" and refers to materials or steps specified in a claim or that do not materially affect the essential characteristics of the claimed subject matter. For example, a domain, region or module of a protein (e.g. a binding domain) or protein "consists essentially of" a particular amino acid sequence if the amino acid sequence of the domain, region, module or protein contains extensions, deletions, mutations or combinations thereof (e.g. amino- or carboxy-terminal amino acids or amino acids between domains) which extensions, deletions, mutations or combinations thereof, taken together, account for at most 20% (e.g. at most 15%, 10%, 8%, 6%, 5%, 4%, 3%, 2% or 1%) of the length of the domain, region, module or protein and do not substantially affect (i.e. do not reduce activity by more than 50%, e.g. by not more than 40%, 30%, 25%, 20%, 15%, 10%, 5%, or 1%) of the activity of the domain, region, module or protein.

[0029] As used herein, the terms "treat", "treatment" or "ameliorate" refer to the medical management of a disease, disorder or condition of interest. In general, an appropriate dose or treatment regimen comprising the targeted complement activating molecule or composition of the present disclosure is administered in an amount sufficient to elicit a therapeutic or preventive benefit. Therapeutic or preventive / preventive benefits include improved clinical outcomes, relief or alleviation of symptoms associated with disease, reduced symptom occurrence, improved quality of life, prolonged disease-free state, reduced disease extent, stabilization of disease state, delayed or prevented disease progression, remission, survival, prolonged survival, or any combination thereof.

[0030] A "therapeutically effective amount" or "effective amount" of a targeted complement activating molecule, polynucleotide, vector, host cell, or composition of the present disclosure refers to an amount of a composition or molecule sufficient to provide a statistically significant therapeutic benefit, including improved clinical outcome, reduction or alleviation of symptoms associated with a disease, reduction in the occurrence of symptoms, improved quality of life, prolonged disease-free state, reduction in the extent of disease, stabilization of a disease state, delayed disease progression, remission, survival, or prolonged survival. When referring to an individual active ingredient administered alone, a therapeutically effective amount refers to the effect of that ingredient or cells expressing that ingredient alone. When referring to a combination, a therapeutically effective amount refers to the combined amount of active ingredients or complementary active ingredients combined with cells expressing the active ingredients that provides a therapeutic effect, whether administered sequentially, sequentially, or simultaneously.

[0031] A "subject" as used herein includes any mammal, including, but not limited to, humans, non-human primates, dogs, cats, horses, sheep, goats, cows, rabbits, pigs, and rodents. Subjects may be male or female, and subjects may be of any suitable age, including infants, juveniles, adolescents, adults, or geriatric subjects.

[0032] As used herein, "amino acid" refers to natural and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function similarly to natural amino acids. Natural amino acids are those encoded by the genetic code, as well as those that are later modified, such as hydroxyproline, γ-carboxyglutamic acid, and O-phosphoserine. Amino acid analogs refer to compounds that have the same basic chemical structure as natural amino acids, i.e., an α-carbon bonded to a hydrogen, a carboxyl group, an amino group, and an R group, such as homoserine, norleucine, methionine sulfoxide, and methionine methylsulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as natural amino acids. "Amino acid mimetics" refer to chemical compounds that have a structure that is different from the general chemical structure of amino acids, but function similarly to naturally occurring amino acids.

[0033] "Mutation" as used herein refers to a change in the sequence of a nucleic acid molecule or polypeptide molecule when compared to a reference or wild-type nucleic acid molecule or polypeptide molecule, respectively. Mutations can result in several different types of changes in the sequence, including nucleotide or amino acid substitutions, insertions or deletions.

[0034] In the broadest sense, the natural amino acids can be divided into groups based on the chemical characteristics of the side chain of each amino acid. By "hydrophobic" amino acid we mean any of the following: Ile, Leu, Met, Phe, Trp, Tyr, Val, Ala, Cys, or Pro. By "hydrophilic" amino acid we mean any of the following: Gly, Asn, Gln, Ser, Thr, Asp, Glu, Lys, Arg, or His.

[0035] "Conservative substitutions" refer to amino acid substitutions that do not significantly affect or alter the binding characteristics of a particular protein. Generally, conservative substitutions are those in which the substituted amino acid residue is replaced with an amino acid residue having a similar side chain. Conservative substitutions include those found in one of the following groups: Group 1: alanine (Ala or A), glycine (Gly or G), serine (Ser or S), threonine (Thr or T); Group 2: aspartic acid (Asp or D), glutamic acid (Glu or Z); Group 3: asparagine (Asn or N), glutamine (Gln or Q); Group 4: arginine (Arg or R), lysine (Lys or K), histidine (His or H); Group 5: isoleucine (Ile or I), leucine (Leu or L), methionine (Met or M), valine (Val or V); and Group 6: phenylalanine (Phe or F), tyrosine (Tyr or Y), tryptophan (Trp or W). Additionally or alternatively, amino acids can be grouped into conservative substitution groups according to similar function, chemical structure, or composition (e.g., acidic, basic, aliphatic, aromatic, or sulfur-containing). For example, where substitution is of interest, the aliphatic group can include Gly, Ala, Val, Leu, and Ile. Other conservative substitution groups include sulfur-containing: Met and cysteine ​​(Cys or C); acidic: Asp, Glu, Asn, and Gln; small aliphatic, non-polar or weakly polar residues: Ala, Ser, Thr, Pro, and Gly; polar, negatively charged residues and their amides: Asp, Asn, Glu, and Gln; polar, positively charged residues: His, Arg, and Lys; large aliphatic, non-polar residues: Met, Leu, Ile, Val, and Cys; and large aromatic residues: Phe, Tyr, and Trp. Further information can be found in Creighton (1984) Proteins, WH Freeman and Company.

[0036] "Protein" or "peptide" or "polypeptide" as used herein refers to a polymer of amino acid residues. Protein applies to both natural amino acid polymers and to amino acid polymers in which one or more amino acid residues are artificial chemical mimetics of corresponding natural amino acids, as well as to non-natural amino acid polymers. Variants of the proteins, peptides and polypeptides of the present disclosure are also envisioned. In certain embodiments, variant proteins, peptides and polypeptides comprise or consist of an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.9% identical to the amino acid sequence of a given or reference amino acid sequence described herein.

[0037] "Nucleic acid molecule" or "oligonucleotide" or "polynucleotide" or "polynucleic acid" refers to an oligomeric or polymeric compound comprising covalently linked nucleotides that may be composed of natural subunits (e.g., purine or pyrimidine bases) or non-natural subunits (e.g., morpholine rings). Purine bases include adenine, guanine, hypoxanthine and xanthine, while pyrimidine bases include uracil, thymine and cytosine. Nucleic acid molecules include polyribonucleic acid (RNA), including, for example, mRNA, microRNA, siRNA, viral genomic RNA, and synthetic RNA, and polydeoxyribonucleic acid (DNA), including, for example, cDNA, genomic DNA, and synthetic DNA. Both RNA and DNA can be single-stranded or double-stranded. If single-stranded, the nucleic acid molecule can be the coding strand or the non-coding strand (antisense strand). A nucleic acid molecule that codes for an amino acid sequence includes all nucleotide sequences that code for the same amino acid sequence. Some versions of the nucleotide sequence may also include introns, provided that the introns can be removed by co-transcriptional or post-transcriptional mechanisms. In other words, different nucleotide sequences may code for the same amino acid sequence as a result of redundancy or degeneracy in the genetic code, or due to splicing.

[0038] Variants of the nucleic acid molecules of the present disclosure are also contemplated. A variant nucleic acid molecule is at least 70%, 75%, 80%, 85%, 90%, and preferably 95%, 96%, 97%, 98%, 99%, or 99.9% identical to a nucleic acid molecule of a given or reference polynucleotide described herein, or hybridizes to the polynucleotide under stringent hybridization conditions of 0.015 M sodium chloride, 0.0015 M sodium citrate at about 65-68° C., or 0.015 M sodium chloride, 0.0015 M sodium citrate, and 50% formamide at about 42° C. A variant nucleic acid molecule retains the ability to encode a binding domain thereof that has a functionality described herein, such as binding a target molecule.

[0039] "Percent sequence identity" refers to the relationship between two or more sequences, determined by comparing sequences. A preferred method for determining sequence identity is designed to give the best match between the sequences being compared. For example, sequences are aligned for optimal comparison (e.g., gaps can be introduced in one or both of the first and second amino acid or nucleic acid sequences for optimal alignment). In addition, non-homologous sequences can be ignored for comparison. Percent sequence identity referred to herein is calculated over the entire length of the reference sequence, unless otherwise indicated. Methods for determining sequence identity and sequence similarity can be found in publicly available computer programs. Sequence alignment and percent identity calculations can be performed using BLAST programs (e.g., BLAST2.0, BLASTP, BLASTN, or BLASTX), or Megalign (DNASTAR) software. The mathematical algorithm used in the BLAST program can be found in Altschul et al., Nucleic Acids Res. 25:3389-3402, 1997. Appropriate parameters for measuring alignment can be determined by known methods, including any algorithms needed to achieve maximal alignment over the full-length of the sequences being compared.

[0040] The term "isolated" means that the material is removed from its original environment (e.g., the natural environment if it occurs in nature). For example, a naturally occurring nucleic acid or naturally occurring polypeptide present in a living animal is not isolated, but the nucleic acid or polypeptide separated from some or all of the coexisting materials in a natural system is isolated. Such a nucleic acid may be part of a vector and / or such a nucleic acid or polypeptide may be part of a composition (e.g., a cell lysate), but is still isolated in that such a vector or composition is not part of the natural environment for the nucleic acid or polypeptide. "Isolated" can also describe, in some embodiments, an antibody, antigen-binding fragment, polynucleotide, vector, host cell, or composition that is outside the human body.

[0041] The term "gene" means a segment of DNA or RNA involved in producing a polypeptide chain, and the term, in certain contexts, encompasses the regions preceding and following the coding region (e.g., the 5' untranslated region (UTR) and the 3' UTR) as well as the intervening sequences (introns) between individual coding segments (exons).

[0042] "Functional variant" refers to a polypeptide or polynucleotide that is structurally similar or substantially structurally similar to a parent or reference compound of the present disclosure, but differs slightly in composition (e.g., one or more bases, atoms or functional groups are different or added or removed) such that the polypeptide or encoded polypeptide is capable of performing at least one function of the parent polypeptide with at least 50% efficiency, preferably at least 55%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.9%, 100% activity level of the parent polypeptide or at an activity level higher than the activity level of the parent polypeptide. In other words, a functional variant of a polypeptide of the disclosure or the encoded polypeptide has "similar binding," "similar affinity," or "similar activity" if the functional variant exhibits improved performance or has no more than a 50% reduction in performance compared to a parent or reference polypeptide in a chosen assay, such as an assay for measuring enzymatic activity or binding affinity.

[0043] A "functional portion" or "functional fragment" as used herein refers to a polypeptide or polynucleotide that comprises only a domain, portion or fragment of a parent or reference compound, where the polypeptide or encoded polypeptide retains at least 50% of the activity associated with the domain, portion or fragment of the parent or reference compound, preferably at least 55%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.9%, 100% or greater than the activity level of the parent polypeptide, or confers a biological benefit (e.g., an effector function). A "functional portion" or "functional fragment" of a polypeptide or encoded polypeptide of the present disclosure has "similar binding" or "similar activity" if the functional portion or fragment exhibits improved performance or has no more than a 50% reduction in performance compared to a parent or reference polypeptide in a chosen assay (for affinity, the reduction is preferably no more than 20% or 10%, or no more than a 1 log difference compared to the parent or reference).

[0044] As used herein, the terms "engineered," "recombinant," or "non-natural" refer to an organism, microorganism, cell, protein, polypeptide, nucleic acid molecule, or vector that contains at least one genetic modification or has been modified by the introduction of an exogenous or heterologous nucleic acid molecule, where such modification or modification is introduced by genetic engineering (i.e., human intervention). Genetic modifications include, for example, modifications that introduce expressible nucleic acid molecules that code for functional RNA, proteins, fusion proteins, or enzymes, or modifications that introduce additions, deletions, substitutions, or other functional disruptions of the genetic material of a cell. Further modifications include, for example, non-coding control regions, where modifications alter the expression of a polynucleotide, gene, or operon.

[0045] "Heterologous" or "non-endogenous" or "exogenous" as used herein refers to any gene, protein, compound, nucleic acid molecule, or activity that is not native to a host cell or subject, or any gene, protein, compound, nucleic acid molecule, or activity that is native to a host cell or subject that has been modified. Heterologous, non-endogenous, or exogenous includes genes, proteins, compounds, or nucleic acid molecules that have been mutated or otherwise modified such that the structure, activity, or both differ between the native gene, protein, compound, or nucleic acid molecule and the modified gene, protein, compound, or nucleic acid molecule. In certain embodiments, a heterologous, non-endogenous, or exogenous gene, protein, or nucleic acid molecule (e.g., receptor, ligand, etc.) is not endogenous to a host cell or subject, and a nucleic acid encoding such a gene, protein, or nucleic acid molecule may be added to the host cell by conjugation, transformation, transfection, electroporation, etc., where the added nucleic acid molecule may be integrated into the host cell genome or may exist as extrachromosomal genetic material (e.g., as a plasmid or other self-replicating vector). "Homologous" or "homolog" refers to a gene, protein, compound, nucleic acid molecule, or activity found in or derived from a given host cell, species, or strain. For example, a heterologous or exogenous polynucleotide or gene encoding a polypeptide may be homologous to a native polynucleotide or gene and may encode a homologous polypeptide or activity, but the polynucleotide or polypeptide may have an altered structure, sequence, expression level, or any combination thereof. The non-endogenous polynucleotide or gene, and the encoded polypeptide or activity, can be from the same species, different species, or a combination thereof.

[0046] In certain embodiments, a nucleic acid molecule or a portion thereof native to a host cell will be considered heterologous to the host cell if it has been modified or mutated. Alternatively, a nucleic acid molecule native to a host cell may be considered heterologous if it has been modified with a heterologous expression control sequence or modified with an endogenous expression control sequence that is not normally associated with the nucleic acid molecule native to the host cell. In addition, the term "heterologous" may refer to a biological activity that is different, modified, or not endogenous to the host cell. As described herein, two or more heterologous nucleic acid molecules can be introduced into a host cell as separate nucleic acid molecules, as multiple genes that are individually controlled, as polycistronic nucleic acid molecules, as a single nucleic acid molecule encoding an antibody or antigen-binding fragment (or other polypeptide), or any combination thereof.

[0047] As used herein, the term "endogenous" or "native" refers to a polynucleotide, gene, protein, compound, molecule, or activity that is normally present in a host cell or subject.

[0048] The term "expression" as used herein refers to the process by which a polypeptide is produced based on a coding sequence of a nucleic acid molecule, e.g., a gene. This process can include transcription, post-transcriptional control, post-transcriptional modification, translation, post-translational control, post-translational modification, or any combination thereof. The nucleic acid molecule to be expressed is typically operably linked to an expression control sequence (e.g., a promoter).

[0049] The term "operably linked" refers to the association of two or more nucleic acid molecules on a single nucleic acid fragment such that the function of one is affected by the other. For example, a promoter is operably linked to a coding sequence if it can affect the expression of that coding sequence (i.e., the coding sequence is under the transcriptional control of the promoter). "Unlinked" means that the associated genetic elements are not closely related to each other so that the function of one does not affect the other.

[0050] As described herein, two or more heterologous nucleic acid molecules can be introduced into a host cell as separate nucleic acid molecules, as multiple individually regulated genes, as polycistronic nucleic acid molecules, as a single nucleic acid molecule encoding a protein (e.g., the heavy chain of an antibody), or any combination thereof. When two or more heterologous nucleic acid molecules are introduced into a host cell, it is understood that the two or more heterologous nucleic acid molecules can be introduced as a single nucleic acid molecule (e.g., on a single vector), on separate vectors, integrated into a single site or multiple sites on a host chromosome, or any combination thereof. The number of heterologous nucleic acid molecules or protein activities referred to refers to the number of different encoding nucleic acid molecules or the number of different protein activities, and not the number of separate nucleic acid molecules introduced into the host cell.

[0051] The term "construct" refers to any polynucleotide (or, if the context makes clear, a fusion protein of the present disclosure) that contains a recombinant nucleic acid molecule. The (polynucleotide) construct may be present in a vector (e.g., bacterial vector, viral vector) or integrated into a genome. A "vector" is a nucleic acid molecule capable of transporting another nucleic acid molecule. A vector may be, for example, a plasmid, a cosmid, a virus, an RNA vector, or a linear or circular DNA or RNA molecule, which may include chromosomal, non-chromosomal, semisynthetic, or synthetic nucleic acid molecules. Vectors of the present disclosure also include transposon systems (e.g., Sleeping Beauty, see, e.g., Geurts et al., Mol. Ther. 8:108, 2003; Mates et al., Nat. Genet. 41:753, 2009). Exemplary vectors are those capable of autonomous replication (episomal vectors), those capable of delivering polynucleotides to a cellular genome (e.g., viral vectors), or those capable of expressing the nucleic acid molecule to which they are linked (expression vectors).

[0052] As used herein, "expression vector" or "vector" refers to a DNA construct containing a nucleic acid molecule operably linked to suitable control sequences capable of achieving expression of the nucleic acid molecule in a suitable host. Such control sequences typically include a promoter to achieve transcription, an optional operator sequence to control such transcription, a sequence encoding a suitable mRNA ribosomal binding site, and sequences that control the termination of transcription and translation. A vector can be a plasmid, a phage particle, a virus, or simply a potential genomic insert. Once transformed into a suitable host, the vector can replicate and function independently of the host genome, or in some cases, can integrate into the genome itself or deliver a polynucleotide contained in the vector to the genome without vector sequences. In this specification, "plasmid", "expression plasmid", "virus" and "vector" are often used interchangeably.

[0053] The term "introduced" in the context of inserting a nucleic acid molecule into a cell means "transfection," "transformation," or "transduction," and includes reference to the incorporation of a nucleic acid molecule into a eukaryotic or prokaryotic cell, where the nucleic acid molecule may be integrated into the genome of the cell (e.g., chromosome, plasmid, plastid, or mitochondrial DNA), converted into an autonomous replicon, or expressed transiently (e.g., transfected mRNA).

[0054] In certain embodiments, the polynucleotide of the present disclosure may be operably linked to certain elements of the vector. For example, polynucleotide sequences required to affect the expression and processing of the ligated coding sequence may be operably linked. Expression control sequences may include appropriate transcription initiation, termination, promoter, and enhancer sequences, efficient RNA processing signals, such as polyadenylation signals, sequences that stabilize cytoplasmic mRNA, sequences that increase translation efficiency (i.e., Kozak consensus sequences), sequences that increase protein stability, and sequences that enhance protein secretion in some cases. Expression control sequences may be operably linked if they are contiguous with the gene of interest. Expression control sequences that act in trans or at a distance to control the gene of interest may also be considered to be operably linked.

[0055] In certain embodiments, the vector comprises a plasmid vector or a viral vector (e.g., lentivirus vector or gamma-retrovirus vector). Viral vectors include retroviruses, adenoviruses, parvoviruses (e.g., adeno-associated viruses), coronaviruses, negative-stranded RNA viruses, such as orthomyxoviruses (e.g., influenza viruses), rhabdoviruses (e.g., rabies and vesicular stomatitis viruses), paramyxoviruses (e.g., measles and Sendai), positive-stranded RNA viruses, such as picornaviruses and alphaviruses, and double-stranded DNA viruses, such as adenoviruses, herpesviruses (e.g., herpes simplex virus types 1 and 2, Epstein-Barr virus, cytomegalovirus), and poxviruses (e.g., vaccinia, fowlpox, and canarypox). Other viruses include, for example, Norwalk virus, togaviruses, flaviviruses, reoviruses, papovaviruses, hepadnaviruses, and hepatitis viruses. Examples of retroviruses include avian leukosis sarcoma, mammalian type C, B, D viruses, the HTLV-BLV complex, lentiviruses, and spumaviruses (Coffin, JM, Retroviridae: The viruses and their replication, in Fundamental Virology, 3rd ed., BN Fields et al., ed., Lippincott-Raven Publishers, Philadelphia, 1996).Methods of using retroviral and lentiviral viral vectors and packaging cells to transduce mammalian host cells with viral particles containing transgenes are known in the art and have been previously described, for example, in U.S. Patent No. 8,119,772; Walchli et al., PLoS One 6:327930, 2011; Zhao et al., J.Immunol.174:4415, 2005; Engels et al., Hum.Gene Ther.14:1155, 2003; Frecha et al., Mol.Ther.18:1748, 2010; and Verhoeyen et al., Methods Mol.Biol.506:97, 2009. Retroviral and lentiviral vector constructs and expression systems are also commercially available. Other viral vectors, including DNA viral vectors, such as adenovirus-based vectors and adeno-associated virus (AAV)-based vectors, herpes simplex virus (HSV)-derived vectors, such as amplicon vectors, replication-deficient HSV and attenuated HSV, can also be used for polynucleotide delivery (Krisky et al., Gene Ther. 5:1517, 1998).

[0056] Other vectors that can be used in the compositions and methods of the present disclosure include those derived from baculoviruses and alphaviruses (Jolly, D J. 1999. "Emerging Viral Vectors," in "The Development of Human Gene Therapy," ed. Friedmann T., New York: Cold Spring Harbor Lab, pp. 209-40), or plasmid vectors (e.g., Sleeping Beauty or other transposon vectors).

[0057] When the viral vector genome contains multiple polynucleotides to be expressed as separate transcripts in a host cell, the viral vector may also contain additional sequences between the two (or more) transcripts that allow bicistronic or polycistronic expression. Examples of such sequences used in viral vectors include an internal ribosome entry site (IRES), a furin cleavage site, a viral 2A peptide, or any combination thereof.

[0058] Plasmid vectors are also known in the art, including DNA-based plasmid vectors for expressing one or more proteins in vitro or for direct administration to a subject.Such vectors may contain bacterial origin of replication, viral origin of replication, genes encoding components required for plasmid replication, and / or one or more selection markers.Such vectors may also contain additional sequences that allow bicistronic or polycistronic expression.

[0059] As used herein, the term "host" refers to a cell or microorganism that is the target of genetic modification with a heterologous nucleic acid molecule to produce a polypeptide of interest (e.g., an antibody of the present disclosure).

[0060] A host cell may include any individual cell or cell culture that can incorporate a vector or nucleic acid or express a protein. The term also includes the progeny of the host cell, whether genetically or phenotypically the same or different. Suitable host cells depend on the vector, and may include mammalian cells, animal cells, human cells, monkey cells, insect cells, yeast cells, and bacterial cells. These cells may be induced to incorporate vectors or other materials by transformation using viral vectors, calcium phosphate precipitation, DEAE-dextran, electroporation, microinjection, or other methods. See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual 2d ed. (Cold Spring Harbor Laboratory, 1989).

[0061] As used herein, the term "complement activation" refers to a molecule that can participate in one or more complement pathways in a manner that leads to the deposition of complement components on the target cell surface and, optionally, to target cell death. The exact sequence of events resulting from complement activation depends on the complement pathway (i.e., classical, lectin, or alternative) that is activated and the role of the specific complement activation molecule within that pathway. As mentioned above, each complement pathway involves the sequential activation of a series of serine proteases. Thus, the serine proteases of the complement pathway, such as mannan-binding lectin-associated serine proteases (MASPs) MASP-1, MASP-2, and MASP-3, C1r, C1s, C2a, complement factor D (CFD), and complement factor Bb, are examples of complement activation molecules.

[0062] "Antigen" as used herein refers to an immunogenic molecule that elicits an immune response. This immune response may involve antibody production, activation of specific immune-competent cells, activation of complement, antibody-dependent cellular cytotoxicity, or any combination thereof. Antigens (immunogenic molecules) may be, for example, peptides, glycopeptides, polypeptides, glycopolypeptides, polynucleotides, polysaccharides, lipids, etc. It is clear that antigens may be synthesized, recombinantly produced, or derived from biological samples. Exemplary biological samples that may contain one or more antigens include tissue samples, fecal samples, cells, biological fluids, or combinations thereof. Antigens may be expressed by cells that have been modified or genetically engineered to express the antigen. Antigens may also be present in or on infectious agents, e.g., present in virions, or expressed or presented on the surface of cells infected with an infectious agent.

[0063] The term "epitope" or "antigenic epitope" includes any molecule, structure, amino acid sequence, protein determinant that is recognized and specifically bound by a cognate binding molecule, such as an immunoglobulin, or other binding molecule, domain, or protein. Epitope determinants generally contain chemically active surface groups of molecules, such as amino acids or sugar side chains, and can have specific three-dimensional structural characteristics and specific charge characteristics. When the antigen is or comprises a peptide or protein, the epitope can be composed of consecutive amino acids (e.g., linear epitopes), or non-contiguous amino acids that are derived from different parts or regions of the protein and are adjacent due to protein folding (e.g., discontinuous or conformational epitopes), or that are adjacent regardless of protein folding.

[0064] The term "antibody" refers to an immunoglobulin molecule consisting of one or more polypeptides that specifically bind to an antigen through at least one epitope recognition site. For example, the term "antibody" includes intact antibodies, including at least two heavy chains and two light chains connected by disulfide bonds, as well as any antigen-binding portion or fragment of an intact antibody, such as an scFv, Fab, or Fab'2 fragment, that has or retains the ability to bind to the antigen target molecule recognized by the intact antibody. The term also includes full-length or fragments of antibodies of any class or subclass, including IgG and its subclasses (e.g., IgG1, IgG2, IgG3, and IgG4), IgM, IgE, IgA, and IgD.

[0065] The term "antibody" is used herein in the broadest sense and includes antibodies and antibody fragments thereof derived from any antibody-producing mammal (e.g., mouse, rat, rabbit, and primate, including human) or obtained by hybridoma, phage selection, recombinant expression, or transgenic animals (or other methods of producing antibodies or antibody fragments). The term "antibody" is not intended to be limited as to the source of the antibody or the manner in which it is made (e.g., by hybridoma, phage selection, recombinant expression, transgenic animals, peptide synthesis, etc.). Exemplary antibodies include polyclonal, monoclonal and recombinant antibodies, multispecific antibodies (e.g., bispecific antibodies), humanized antibodies, fully human antibodies, murine antibodies, chimeric mouse-human, mouse-primate, primate-human monoclonal antibodies, and anti-idiotypic antibodies, and exemplary antibodies can be any intact molecule or fragment thereof. As used herein, the term "antibody" includes not only intact polyclonal or monoclonal antibodies, but also fragments thereof (e.g., dAb, Fab, Fab', F(ab')2, Fv), single chains (e.g., ScFv), synthetic variants thereof, naturally occurring variants, fusion proteins comprising an antibody portion with an antigen-binding fragment of the required specificity, humanized antibodies, chimeric antibodies, and any other modified configuration of immunoglobulin molecule containing an antigen-binding site or fragment (epitope recognition site) of the required specificity. The term also includes engineered and / or otherwise modified forms of immunoglobulins containing antigen-binding fragments thereof, such as intrabodies, peptibodies, diabodies, triabodies, tetrabodies, tandem di-scFv, tandem tri-scFv, etc.

[0066] The terms "VH" and "VL" refer to the variable binding regions from antibody heavy and light chains, respectively. VL can be a kappa class chain or a lambda class chain. The variable binding region comprises discrete, clearly defined subregions known as complementarity determining regions (CDRs) and framework regions (FRs). CDRs are located within the hypervariable regions (HVRs) of an antibody and generally refer to the sequences of amino acids within the antibody variable region that, taken as a whole, confer the antigen specificity and / or binding affinity of the antibody. Consecutive CDRs (i.e., CDR1 and CDR2 and CDR2 and CDR3) are separated from each other in the primary structure by framework regions.

[0067] A "chimeric antibody" as used herein is a recombinant protein that contains variable domains and complementarity determining regions derived from a non-human species (e.g., rodent), while the remainder of the antibody molecule is derived from a human antibody. In some embodiments, a chimeric antibody is composed of the antigen-binding domain of one antibody operatively linked or otherwise fused to a heterologous constant region of a different antibody. For example, a mouse-human chimeric antibody may contain the antigen-binding domain of a mouse antibody fused to a constant region derived from a human antibody. In some embodiments, the heterologous constant region may be derived from a different Ig class than the parent antibody, such as IgA (including subclasses IgA1 and IgA2), IgD, IgE, IgG (including subclasses IgG1, IgG2, IgG3, and IgG4), and IgM.

[0068] A "humanized antibody" as used herein is a molecule, typically prepared using recombinant techniques, that has an antigen-binding site derived from an immunoglobulin of a non-human species, with the remainder of the immunoglobulin structure of the molecule based on the structure and / or sequence of a human immunoglobulin. Humanized antibodies differ from chimeric antibodies in that typically only the CDRs from the non-human species are used, which are grafted onto the appropriate framework regions in the human variable domain. The antigen-binding site may be wild-type or modified by one or more amino acid substitutions. In some embodiments, a humanized antibody retains all CDR sequences (e.g., a humanized mouse antibody that contains all six CDRs from a mouse antibody). In another embodiment, a humanized antibody has one or more CDRs (one, two, three, four, five, six) that are modified compared to the original antibody, also referred to as one or more CDRs "derived from" one or more CDRs from the original antibody.

[0069] As used herein, the term "antibody fragment" refers to a portion derived from or related to a full-length antibody, generally including the antigen-binding or variable region thereof. Specific examples of antibody fragments include Fab, Fab', F(ab)2, F(ab')2 and Fv fragments, scFv fragments, diabodies, linear antibodies, single-chain antibody molecules, and multispecific antibodies formed from antibody fragments.

[0070] As used herein, the term "antigen-binding fragment" refers to a polypeptide fragment containing at least one CDR of an immunoglobulin heavy and / or light chain that specifically binds to the antigen against which the antibody was raised. An antigen-binding fragment may contain one, two, three, four, five, or all six CDRs of the VH and VL sequences from an antibody.

[0071] "Fab" (fragment antigen binding) is the portion of an antibody that binds an antigen and comprises the variable region and the CH1 of a heavy chain linked to a light chain by an interchain disulfide bond. Each Fab fragment is monovalent with respect to antigen binding; that is, each Fab fragment has a single antigen-binding site. Pepsin treatment of an antibody yields one large F(ab')2 fragment, which roughly corresponds to two disulfide-linked Fab fragments with divalent antigen-binding activity and still has the ability to cross-link antigen. Both Fab and F(ab')2 are examples of "antigen-binding fragments". Fab' fragments differ from Fab fragments in that they have several additional residues at the carboxy terminus of the CH1 domain, including one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine ​​residues of the constant domains bear free thiol groups. F(ab')2 antibody fragments are often produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.

[0072] Fab fragments may be joined, for example, by a peptide linker, to form a single chain Fab, also referred to herein as "scFab." In these embodiments, the interchain disulfide bonds present in native Fab may not be present, and the linker serves to link or connect, in whole or in part, the Fab fragments into a single polypeptide chain. A Fab fragment from a heavy chain (e.g., comprising, consisting of, or consisting essentially of VH+CH1, i.e., "Fd") and a Fab fragment from a light chain (e.g., comprising, consisting of, or consisting essentially of VL+CL) may be linked in any configuration to form an scFab. For example, scFabs may be arranged from N-terminus to C-terminus as follows: (heavy chain Fab fragment-linker-light chain Fab fragment) or (light chain Fab fragment-linker-heavy chain Fab fragment).

[0073] "Fv" is a small antibody fragment that contains a complete antigen recognition and binding site. This fragment generally consists of a dimer of one heavy chain variable region domain and one light chain variable region domain in tight non-covalent association. However, even a single variable domain (i.e., half of an Fv containing only the three CDRs specific for an antigen) has the ability to recognize and bind to an antigen, although typically with a lower affinity than the entire binding site.

[0074] A "single-chain Fv", also abbreviated as "sFv" or "scFv", is an antibody fragment that contains a VH antibody domain and a VL antibody domain connected into a single polypeptide chain. The scFv polypeptide may include a polypeptide linker disposed between the VH and VL domains to link them and enable the scFv to maintain or form the desired structure for antigen binding. However, a linker is not required. Such a peptide linker can be incorporated into the fusion polypeptide using standard techniques known in the art. Additionally or alternatively, the Fv can have a disulfide bond formed between the VH and VL to stabilize the VH and VL. For a description of scFvs, see the review by Pluckthun (1994) in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore, eds., Springer-Verlag, New York, pp. 269-315. In certain embodiments, the antibody or antigen-binding fragment comprises an scFv comprising a VH domain, a VL domain, and a peptide linker linking the VH domain to the VL domain. In particular embodiments, the scFv comprises a VH domain linked to the VL domain by a peptide linker, which can be in a VH-linker-VL or VL-linker-VH orientation. Any scFv of the disclosure can be engineered such that the C-terminus of the VL domain is linked to the N-terminus of the VH domain by a short peptide sequence, or vice versa (i.e., (N)VL(C)-linker-(N)VH(C) or (N)VH(C)-linker-(N)VL(C). Alternatively, in some embodiments, a linker can be linked to the N-terminal portion or N-terminus of the VH domain, VL domain, or both.

[0075] A peptide linker sequence for use in an scFv or other fusion protein, such as a targeted complement activating molecule described herein, can be selected, for example, based on the following criteria: (1) it can adopt an extended and flexible conformation; (2) it cannot or lacks the ability to adopt a secondary structure that can interact with a functional epitope on the first and second polypeptides and / or the target molecule; and / or (3) it lacks or is relatively low in hydrophobic or charged residues that may react with the polypeptide and / or the target molecule. Other considerations for linker design (e.g., length) can include the conformation or range of conformations in which VH and VL can form a functional antigen binding site. In certain embodiments, the peptide linker sequence contains, for example, Gly, Asn, and Ser residues. Other nearly neutral amino acids, such as Thr and Ala, can also be included in the linker sequence. Other amino acid sequences that may be usefully employed as linkers include those disclosed in Maratea et al., Gene 40:39 46 (1985); Murphy et al., Proc. Natl. Acad. Sci. USA 83:8258 8262 (1986); U.S. Pat. No. 4,935,233 and U.S. Pat. No. 4,751,180. Other illustrative, non-limiting examples of linkers may include, for example, the pentamer Gly-Gly-Gly-Gly-Ser (SEQ ID NO:99), which may be repeated once or may be repeated 1-5 or more times, and may begin or end in the middle of a repeat. See, for example, SEQ ID NO:100.Any suitable linker may be used, and a suitable linker can generally be less than about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 15 23, 24, 25, 26, 27, 28, 29, 30, 40, 50, 60, 70, 80, 90, 100 amino acids in length, or about 200 amino acids in length, preferably comprises a flexible structure (which can provide flexibility and room for conformational movement between the two regions, domains, motifs, fragments or modules connected by the linker), and is preferably biologically inert and / or has a low risk of immunogenicity in humans.

[0076] Antibodies can be monospecific (e.g., bind to a single epitope) or multispecific (e.g., bind to multiple epitopes and / or target molecules). Bispecific or multispecific antibodies or antigen-binding fragments, in some embodiments, can comprise one, two, or more antigen-binding domains (e.g., a VH and a VL). There can be two or more binding domains that bind to the same epitope or different epitopes, and bispecific or multispecific antibodies or antigen-binding fragments provided herein, in some embodiments, can comprise two or more binding domains that collectively bind to different antigens or pathogens.

[0077] Antibodies and antigen-binding fragments can be constructed in a variety of formats. Exemplary antibody formats are disclosed in Spiess et al., Mol. Immunol. 67(2):95 (2015) and Brinkmann and Kontermann, mAbs 9(2):182-212 (2017).These formats and methods for making them are incorporated herein by reference and include, for example, Bispecific T cell Engager (BiTE), DART, Knobs-Into-Holes (KIH) assembly, scFv-CH3-KIH assembly, KIH common light chain antibody, TandAb, Triple Body, TriBi minibody, Fab-scFv, scFv-CH-CL-scFv, F(ab')2-scFv2, tetravalent HCab, intrabody, CrossMab, Dual Action Fab (DAF) (two-in-one or four-in-one), DutaMab, DT-IgG, Charge Pair, Fab-arm exchange, Fab-arm fusion ... Exchange), SEEDbody, Triomab, LUZ-Y assembly, Fcab, κλ body, orthogonal Fab, DVD-Ig (e.g., U.S. Pat. No. 8,258,268, which formats are incorporated herein by reference in their entirety), IgG(H)-scFv, scFv-(H)IgG, IgG(L)-scFv, scFv-(L)IgG, IgG(L,H)-Fv, IgG(H)-V,V(H)-IgG, IgG(L)-V,V(L)-IgG, KIH IgG-scFab, 2scFv-IgG, IgG-2scFv, scFv4-Ig, Zybody, and DVI-IgG (four-in-one), as well as the so-called FIT-Ig (e.g., PCT Publication No. WO 2013 / 023361, which are incorporated herein by reference in their entirety). 2015 / 103072, which formats are incorporated herein by reference in their entireties), the so-called WuxiBody format (e.g., PCT Publication No. WO 2019 / 057122, which formats are incorporated herein by reference in their entireties), and the so-called In-Elbow-Insert Ig format (IEI-Ig, e.g., PCT Publication Nos. WO 2019 / 024979 and WO 2019 / 025391, which formats are incorporated herein by reference in their entireties).

[0078] An antibody or antigen-binding fragment may comprise two or more VH domains, two or more VL domains, or both (i.e., two or more VH domains and two or more VL domains). In certain embodiments, an antigen-binding fragment comprises the format (from N-terminal to C-terminal) VH-linker-VL-linker-VH-linker-VL, where the two VH sequences may be the same or different, and the two VL sequences may be the same or different. Such linked scFvs may comprise any combination of VH and VL domains arranged to bind a given target. In formats comprising two or more VH and / or two or more VL, one, two or more different epitopes or antigens may be bound. It will be understood that formats incorporating multiple antigen-binding domains may comprise VH and / or VL sequences in any combination or orientation. For example, an antigen-binding fragment can comprise the formats VL-linker-VH-linker-VL-linker-VH, VH-linker-VL-linker-VL-linker-VH, or VL-linker-VH-linker-VH-linker-VH-linker-VL.

[0079] As used herein, the modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and no limitation is intended as to the source of the antibody or the manner in which it is made (e.g., by hybridoma, phage selection, recombinant expression, transgenic animals, etc.). The term "monoclonal antibody" encompasses intact and full-length monoclonal antibodies, as well as fragments thereof (e.g., Fab, Fab', F(ab')2, Fv), single chain variants thereof, fusion proteins containing an antigen-binding portion, humanized monoclonal antibodies, chimeric monoclonal antibodies, and immunoglobulin molecules of any other modified configuration containing an antigen-binding fragment (epitope recognition site) with the requisite specificity and binding ability for the epitope. Monoclonal antibodies may be obtained using any technique which provides for the production of antibody molecules by continuous cell lines in culture, such as the hybridoma method described in Kohler, G., et al., Nature 256:495, 1975, or may be made by recombinant DNA methods (e.g., U.S. Patent No. 4,816,567 to Cabilly). Monoclonal antibodies may also be isolated from phage antibody libraries using the techniques described in Clackson T. et al., Nature, 352:624-628, 1991 and Marks JD, et al., J. Mol. Biol., 222:581-597, 1991. Such antibodies may belong to any immunoglobulin class, including IgG, IgM, IgE, IgA, IgD, and any subclass thereof.

[0080] Recognized immunoglobulin polypeptides include kappa and lambda light chains, and alpha, gamma (IgG1, IgG2, IgG3, IgG4), delta, epsilon, and mu heavy chains, or equivalents in other species. A full-length immunoglobulin "light chain" (about 25 kDa or about 214 amino acids) contains a variable region of about 110 amino acids at the NH2-terminus and a kappa or lambda constant region at the COOH-terminus. A full-length immunoglobulin "heavy chain" (about 50 kDa or about 446 amino acids) similarly contains a variable region (about 116 amino acids) and one of the heavy chain constant regions mentioned above, e.g., gamma (about 330 amino acids).

[0081] The basic four-chain antibody unit is a heterotetrameric glycoprotein composed of two identical light (L) chains and two identical heavy (H) chains. IgM antibodies differ from the above arrangement in that they consist of five basic heterotetrameric units with an additional polypeptide called the J chain, and therefore have 10 antigen-binding sites. Secretory IgA antibodies also differ from the basic structure in that they polymerize to form multivalent assemblies containing two to five basic four-chain units with the J chain. Each L chain is linked to the H chain by one covalent disulfide bond, while the two H chains are linked to each other by one or more disulfide bonds depending on the H chain isotype. Each H chain and each L chain also has regularly spaced intrachain disulfide bridges. The pairing of a VH and a VL together forms a single antigen-binding site.

[0082] Each H chain has a variable domain (VH) at the N-terminus followed by three constant domains (CH1, CH2, CH3) in the α, γ, and δ chains and four CH domains (CH1, CH2, CH3, CH4) in the μ and ε chains.

[0083] Each L chain has a variable domain (VL) at the N-terminus followed by a constant domain (CL) at the other end. When an L chain and an H chain pair, the VL aligns with the VH and the CL aligns with the first constant domain (CH1) of the heavy chain. The L chains of any vertebrate species can be assigned to one of two types, called kappa (κ) and lambda (λ), based on the amino acid sequence of their constant domains (CL).

[0084] Immunoglobulins can be assigned to different classes or isotypes depending on the amino acid sequence of the constant domain (CH) of their heavy chains. There are five classes of immunoglobulins, IgA, IgD, IgE, IgG, and IgM, which have heavy chains designated alpha (α), delta (δ), epsilon (ε), gamma (γ), and mu (μ), respectively. The γ and α classes are subdivided into subclasses based on subtle differences in CH sequence and function; for example, humans express the following subclasses: IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2.

[0085] For the structure and properties of these various classes of antibodies, see, e.g., page 71 and chapter 6 of Basic and Clinical Immunology, 8th Edition (Daniel P. Stites, Abba I. Terr and Tristram G. Parslow (eds.), Appleton and Lange, Norwalk, Conn., 1994).

[0086] The term "variable" refers to the fact that the sequence of certain segments of the V domains varies widely among antibodies. The V domains mediate antigen binding and define the specificity of a particular antibody for its particular antigen. However, the variability is not evenly distributed throughout the 110 amino acid span of the variable domains. Rather, the V regions consist of relatively invariant stretches of 15-30 amino acids called framework regions (FRs), separated by shorter, extremely variable regions called "hypervariable regions" each 9-12 amino acids long. Native heavy and light chain variable domains each contain four FRs that are largely in a beta-sheet configuration, connected by three hypervariable regions that form loops that connect and sometimes form part of the n-sheet structure. The hypervariable regions in each chain are held in close proximity by the FRs, and the hypervariable regions from the other chain contribute to the formation of the antigen-binding site of antibodies (see Kabat, et al., "Sequences of Proteins of Immunological Interest," 5th ed., Public Health Service, National Institutes of Health, Bethesda, Md. (1991)). The constant domains are not directly involved in binding of antibodies to antigens, but exhibit various effector functions.

[0087] "Effector function" as used herein refers to the biological activity attributable to the Fc region of an antibody. Examples of antibody effector functions include antibody-dependent cellular cytotoxicity (ADCC), C1q binding and complement-dependent cytotoxicity, Fc receptor binding, phagocytosis, downregulation of cell surface receptors, and participation in B cell activation. Modifications such as amino acid substitutions can be made to the Fc domain to modify (e.g., enhance or reduce) one or more functions of an Fc-containing polypeptide. Such functions include, for example, Fc receptor binding, regulation of antibody half-life, ADCC function, protein A binding, protein G binding, and complement binding. Amino acid modifications that modify Fc function include, for example, T250Q / M428L, M252Y / S254T / T256E, H433K / N434F, M428L / N434S, E233P / L234V / L235A / G236Δ / A327G / A330S / P331S, E333A, S239D / A330L / I332E, P257I / Q311, K326W / E333S, S239D / I332E / G236A, N297Q, K322A, S228P, L235E / E318A / K320A / K322A, L234A / L235A, and L234A / L235A / P329G mutations. Other Fc modifications and their effects on Fc function are known in the art.

[0088] As used herein, the term "hypervariable region" refers to the amino acid residues of an antibody that are responsible for antigen binding. The hypervariable region contains several "complementarity determining regions" (CDRs). The heavy chain contains three CDR sequences (CDRH1, CDRH2 and CDRH3) and the light chain contains three CDR sequences (CDRL1, CDRL2 and CDRL3). There are various systems for identifying and numbering the amino acids that make up the CDRs. For example, the hypervariable region generally comprises CDRs at approximately residues 24-34 (L1), 50-56 (L2), and 89-97 (L3) in the light chain variable domain and at approximately residues 31-35 (H1), 50-65 (H2), and 95-102 (H3) in the heavy chain variable domain, as numbered according to the Kabat numbering system described in Kabat, et al., "Sequences of Proteins of Immunological Interest," 5th ed., Public Health Service, National Institutes of Health, Bethesda, Md. (1991), and / or at approximately residues 24-34 (L1), 50-56 (L2), and 89-97 (L3) in the light chain variable domain and at approximately residues 31-35 (H1), 50-65 (H2), and 95-102 (H3) in the heavy chain variable domain, as numbered according to the Kabat numbering system described in Chothia and and / or comprising CDRs at about residues 24-34 (L1), 50-56 (L2), and 89-97 (L3) in the light chain variable domain and 26-32 (H1), 52-56 (H2), and 95-102 (H3) in the heavy chain variable domain, when numbered according to the Chothia numbering system described in Lefranc, JP, et al., Nucleic Acids Res 27:209-212; Ruiz, M., et al., Nucleic Acids Res When numbered according to the IMGT numbering system described in, e.g., J. Med. 28:219-221 (2000), the CDRs are contained at approximately residues 27-38 (L1), 56-65 (L2), and 105-117 (L3) in VL, and 27-38 (H1), 56-65 (H2), and 105-117 (H3) in VH.Equivalent residue positions can be annotated and compared for different molecules using the Antigen Receptor Numbering And Receptor Classification (ANARCI) software tool (2016, Bioinformatics 15:298-300). Thus, the identification of the CDRs of an exemplary variable domain (VH or VL) provided herein according to one numbering scheme does not exclude antibodies that contain the CDRs of the same variable domain determined using a different numbering scheme.

[0089] As used herein, "specifically binds" refers to an antibody or antigen-binding fragment that binds to an antigen with a particular affinity, but does not significantly associate or associate with any other molecules or components in the sample. Affinity is measured using the k on / k off The equilibrium association constant (K a ) or k with units M off / k on The equilibrium dissociation constant K is calculated as the ratio of d It can be defined as:

[0090] In some contexts, antibodies and antigen-binding fragments may be described in terms of their affinity and / or avidity for the antigen. Unless otherwise indicated, avidity refers to the overall binding strength of an antibody or antigen-binding fragment to an antigen, which reflects the binding affinity of the antibody or antigen-binding fragment, the binding valency (e.g., whether the antibody or antigen-binding fragment contains 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more binding sites), and other agents that can affect binding, for example, (e.g., whether noncompetitive inhibitors of the antibody or antigen-binding fragment are present).

[0091] Each embodiment herein applies mutatis mutandis to every other embodiment, unless expressly stated otherwise. It is contemplated that any embodiment discussed in this specification can be implemented with respect to any method, kit, reagent, or composition of the invention, and vice versa. Furthermore, the compositions of the invention can be used to achieve the methods of the invention.

[0092] II. Overview The present disclosure provides compositions and methods for targeted activation of the complement pathway. Traditionally, therapeutic antibodies have been explored as a treatment for cancer, since it is well known that cell-mediated immunity plays a crucial role in tumor suppression through the action of natural killer cells and cytotoxic T lymphocytes. However, recent studies have shown that the complement system also has an important role in immune surveillance against cancer. In some human tumors, deposition of activated complement components has been reported along with overexpression of complement regulatory proteins (CRPs) (Macor et al, Front. Immunol. 9:2203 (2018)). The effector mechanisms that lead to cytotoxic activity against cancer cells are primarily Fc-mediated, and these include antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), complement-dependent cell-mediated cytotoxicity (CDCC), and complement-dependent cytophagocytosis (CDCP).

[0093] Several strategies have been developed to target complement activation to the tumor cell surface using monoclonal antibodies (mAbs), but many of these mAbs have shown suboptimal activity in driving classical pathway complement activation.Factors that influence cytotoxicity include hexamerization of the antibody Fc region, which is required for more efficient C1 binding, epitope density on the target cell, and expression of complement regulatory proteins (CRPs).

[0094] For an antibody / antigen complex (i.e., immune complex) to initiate classical pathway activation in response to pathogen infection or the presence of a non-self antigen, an antibody of the IgM subclass must bind to the antigen, or at least two IgG subclass antibodies must bind to the antigen in such a way that at least two of the six C-terminal immunoglobulin Fc region-binding "globular head" domains of C1q are able to bind to the IgG immune complex. This requires a stoichiometrically appropriate distribution of antigen-binding immune complexes on the target cell surface. Immune complexes cannot activate the classical pathway if their binding positions are too far from each other, because they cannot form a pattern that allows the C1q recognition component to bind to at least two IgG immune complexes in close proximity to each other. The distribution of immune complexes on the activating surface depends on the distribution of antibody ligands, which therefore determines whether an IgG complex can trigger classical pathway activation. This is why many monoclonal antibodies of the IgG immunoglobulin class cannot activate complement.

[0095] The present disclosure provides a novel and broadly applicable mAb platform, termed "targeted complement activation therapy" (T-CAT), that fully exploits the potential of complement to maximize the activity of therapeutic mAbs. This platform is not only suitable for targeting cancer cells, but can also be used to direct complement activity to any cell expressing an antigen for which an antibody can be generated. Thus, the T-CAT platform can be used for a wide variety of applications, such as the treatment of cancer, autoimmune disorders, and pathogen infections, including bacterial, viral, fungal, and parasitic infections. Targeted complement activation molecules, including fusion proteins with both an antibody-derived targeting domain and a serine protease effector domain capable of activating one or more complement pathways, deliver targeted complement activation activity to the location of the antigen targeted by the antibody. The targeted cell or tissue depends on the antigen-binding domain selected for use in the fusion protein.

[0096] The T-CAT platform supports the host's innate immune defense by combining the specificity of host immunoglobulins for microbial surface components with the ability to initiate complement activation directly on microbial target surfaces without relying on complex, tightly regulated, pattern recognition-dependent activation pathways that can be subverted by pathogen evasion mechanisms. Similarly, the T-CAT platform supports the immune system's attack on malignant cells by activating complement even though they overexpress negative regulatory complement components on their surface.

[0097] The T-CAT technology overcomes the steric requirement of antibodies to drive complement activation because neither the classical nor lectin pathway pattern recognition molecules are required to initiate complement activation. Rather, a single targeted complement activating molecule activates complement to target an activator surface that expresses a single ligand / antigen that is targeted by the antigen binding site present in the targeted complement activating molecule.

[0098] Another advantage of the T-CAT platform is that the targeted complement-activating molecule does not require a plasma recognition complex such as the C1 complex. Both the classical and lectin pathways require the formation of immune complexes, usually bound to an activating surface within a defined distance of each other, to trigger conformational changes that initiate the conversion of serine proteases to their respective enzymatically active forms, driving a cascade of cleavage events that result in complement activation. Such activation elicits innate immune defenses that target pathogens or foreign cells, including unicellular or multicellular parasites, and host cells that have become transformed, malignant, oxygen-deprived, hypothermic, virally infected, MHC-mismatched, or otherwise damaged. Because a single targeted complement-activating molecule can initiate complement activation on a target surface, the ability of damaged, mutated, or virally infected host cells, parasitic foreign cells, or pathogenic bacteria to interfere with the highly regulated activation of the host complement system may be overcome. Examples of such strategies are molecular mimicry (cells or pathogens coating themselves with negative complement control proteins) or having evolved virulence factors that facilitate infectivity, such as glycoprotein C of herpesviruses or calreticulin on cells of Trypanosoma species.

[0099] III. Targeted Complement-Activating Molecules Provided herein is a targeted complement activating molecule, comprising a) a target binding domain and b) a complement activating serine protease effector domain. Such a molecule has the ability to deliver a targeted complement activating activity to the cell surface, thereby resulting in complement-mediated lysis of the target cell. The complement activating activity can be delivered to an individual cell expressing the target antigen, or to a tissue in which the target antigen is expressed.

[0100] A. Complement-activating serine protease effector domains In certain embodiments, the complement activation serine protease effector domain of the targeted complement activation molecule is derived from a component of the complement system. In some embodiments, the complement activation serine protease effector domain comprises MASP-1, MASP-2, MASP-3, C1r, C1s, complement factor D (CFD), C2a, or factor Bb. In some embodiments, the complement activation serine protease effector domain comprises a fragment of any of the above-mentioned proteases that has serine protease activity. For example, the serine protease domain can comprise the CCP1-CCP2-SP domain of MASP-1, MASP-2, MASP-3, C1r, or C1s. Any serine protease that activates either the classical, lectin, or alternative complement pathway can be used, as well as any fragment of such serine proteases that retains such activity. In some embodiments, the complement activation serine protease effector domain comprises a serine protease effector domain of MASP-1 (SEQ ID NO:67), MASP-2 (SEQ ID NO:57), MASP-3 (SEQ ID NO:66), C1r (SEQ ID NO:69), C1s (SEQ ID NO:76), C2a (SEQ ID NO:88), Bb (SEQ ID NO:89), mature CFD (SEQ ID NO:90), or pro-CFD (SEQ ID NO:92).

[0101] In some embodiments, the complement-activating serine protease effector domain is in an inactive zymogen form, which requires activation to form an active serine protease. Such activation can be provided by other molecules that contain the same serine protease effector domain, by molecules that contain a different serine protease effector domain, or by any other chemical or enzymatic means. In some embodiments, the complement-activating serine protease effector domain is in a catalytically active form. An example of a zymogen form of a complement-activating serine protease effector domain is the pro-CFD, which is converted to the active form, the mature CFD, by the removal of the 6 amino acid activation peptide. Many other complement-activating serine proteases, including MASP-1, MASP-2, MASP-3, C1r, and C1s, also have both active and zymogen forms.

[0102] In some embodiments, the complement-activating serine protease effector domain comprises one or more mutations compared to the wild-type serine protease. Any number of mutations may be present in the complement-activating serine protease effector domain, provided that it retains some level of serine protease activity. Thus, in some embodiments, the complement-activating serine protease effector domain comprises a sequence that has at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the wild-type sequence of the corresponding serine protease effector domain. Such mutations may confer beneficial effects to the targeted complement-activating molecule, such as increased resistance to proteolysis or increased resistance to inhibition by endogenous serpins, such as C1 inhibitor or other inhibitors of serine protease activity. In some embodiments, the complement activating serine protease effector domain is, for example, MASP-2. R444K (SEQ ID NO:58), MASP-2 K317Q,R444K(SEQ ID NO:61), MASP-2 K321Q,R444K (SEQ ID NO:62), MASP-2 K342Q,R444K (SEQ ID NO:63), MASP-2 K350Q,R444K (SEQ ID NO:64), MASP-2 K356Q,R444K (SEQ ID NO:65), MASP-1 R504Q (SEQ ID NO:68), C1r K374Q (SEQ ID NO:70), C1r R380Q (SEQ ID NO:71), C1r H484W (SEQ ID NO:72), C1r G485W (SEQ ID NO:73), C1r R486W (SEQ ID NO:74), C1s K308Q (SEQ ID NO:78), C1s K310Q (SEQ ID NO:79), C1s R314Q (SEQ ID NO:80), C1s R331Q (SEQ ID NO:81), C1s K346Q (SEQ ID NO:82), C1s K351Q (SEQ ID NO:83), C1s K353Q (SEQ ID NO:84), C1s D456W (SEQ ID NO:85), C1s N457W (SEQ ID NO:86), and C1s P458W (SEQ ID NO:87), or contains one or more mutations compared to the wild-type serine protease.

[0103] B. Target Binding Domains In certain embodiments, the target binding domain of the targeted complement activation molecule is derived from an antibody. The antibody can be a natural antibody of any class or subclass, or any type of engineered antibody. For example, the target binding domain can be derived from an antibody Fab fragment, F(ab')2 fragment, Fab' fragment, Fv fragment, single chain antibody fragment, single chain variable fragment (scFv), single domain antibody (e.g., sdAb, sdFv, or nanobody) or fragment thereof, or an intrabody, peptibody, chimeric antibody, humanized antibody, multispecific antibody, or fragment thereof. In some embodiments, the target binding domain of the targeted complement activation molecule comprises an antibody or an antigen-binding fragment thereof. In some embodiments, the target binding domain comprises an antibody VH and / or VL. In some embodiments, the target binding domain comprises one to six CDRs of an antibody.

[0104] In some embodiments, the target binding domain comprises an Fc region or a fragment thereof. In some embodiments, the Fc region comprises one or more mutations that modify (e.g., enhance or reduce) one or more functions of the Fc-containing polypeptide. Such functions include, for example, Fc receptor binding, regulation of antibody half-life, ADCC function, protein A binding, protein G binding, and complement fixation.

[0105] In certain embodiments, the target binding domain binds to an antigen present on a cell.In some embodiments, the antigen is present on a cancer cell.In some embodiments, the cancer is a solid tumor cancer or a blood cancer.For example, the cancer can be brain cancer, bladder cancer, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, gastrointestinal cancer, liver cancer, renal cancer, lymphoma, leukemia, lung cancer, melanoma, metastatic melanoma, mesothelioma, myeloma, neuroblastoma, ovarian cancer, prostate cancer, pancreatic cancer, renal cancer, skin cancer, or uterine cancer. In some embodiments, the cancer is acoustic neuroma, anal cancer (including carcinoma in situ), squamous cell carcinoma, adrenal tumors (including adenoma, hyperaldosteronism, adrenocortical carcinoma), Cushing's syndrome, benign paraganglioma, appendix cancer (including pseudomyxoma peritonei, carcinoid tumor, non-carcinoid appendix tumor), cholangiocarcinoma (including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma, distal cholangiocarcinoma), gallbladder cancer, bone cancer (chondrosarcoma, osteosarcoma, malignant fibrous histiocytoma, adenocarcinoma, fibroblast cancer ... fibrosarcoma, chordoma), brain tumors (including craniopharyngioma, dermoid cyst, epidermoid tumor, glioma, astrocytoma, low-grade astrocytoma, anaplastic astrocytoma, ependymoma, glioblastoma, oligodendroglioma, hemangioblastoma, pineal tumor, pituitary tumor, sarcoma, chordoma), breast cancer (including lobular carcinoma, triple-negative breast cancer, recurrent breast cancer, brain metastasis), bladder cancer (including transitional cell bladder cancer, squamous cell carcinoma, adenocarcinoma), carcinoma of unknown primary site (CUP), (adenocarcinoma, poorly differentiated carcinoma) , squamous cell carcinoma, poorly differentiated malignant neoplasm, neuroendocrine carcinoma), cervical cancer (including squamous cell carcinoma, adenocarcinoma, mixed carcinoma), carcinoid tumor, childhood germ cell tumor (including yolk sac tumor, teratoma, embryonal carcinoma, polygerminoma, germinoma), childhood brain tumor (including ependymoma, craniopharyngioma, chordoma, pleomorphic xanthoastrocytoma, meningioma, primitive neuroectodermal tumor, ganglioglioma, pineoblastoma, germ cell tumor, mixed glial-neuronal tumor, astrocytoma, choroid plexus tumor), childhood leukemia childhood blood disorders (including Fanconi anemia, Diamond-Blackfan anemia, aplastic anemia, Shwachman-Diamond syndrome, Kostmann syndrome, neutropenia, thrombocytopenia, hemoglobinopathies, erythrocytosis, histiocytic disorders, iron overload, coagulation and bleeding disorders), childhood liver cancer (including hepatoblastoma, hepatocellular carcinoma), childhood lymphoma (Hodgkin's lymphoma, non-Hodgkin's lymphoma,Burkitt's lymphoma, lymphoblastic lymphoma, large cell lymphoma; childhood osteosarcoma; childhood melanoma; childhood soft tissue sarcoma; colorectal cancer (including adenocarcinoma, hereditary nonpolyposis colorectal cancer syndrome, and familial adenomatous polyposis); desmoplastic small round cell tumor (DSRCT); esophageal cancer (including adenocarcinoma and squamous cell carcinoma); Ewing's sarcoma (including Ewing's sarcoma of bone, extraskeletal Ewing's tumor, and peripheral primitive neuroectodermal tumor); eye cancer (uveal melanoma, basal cell carcinoma, squamous cell carcinoma, eyelid melanoma, conjunctival melanoma, sebaceous gland carcinoma, Merkel cell carcinoma) carcinoma), mucosa-associated lymphoid tissue lymphoma, orbital lymphoma, orbital sarcoma, orbital and optic nerve meningioma, metastatic orbital tumor, lacrimal gland lymphoma, adenoid cystic carcinoma, pleomorphic adenoma, transitional cell carcinoma, lacrimal sac lymphoma; fallopian tube carcinoma (including endometrioid adenocarcinoma, serous adenocarcinoma, leiomyosarcoma, transitional cell fallopian tube carcinoma); Hodgkin lymphoma (including classical Hodgkin lymphoma, nodular sclerosing Hodgkin lymphoma, lymphocyte-rich classical Hodgkin lymphoma) lymphoma, including mixed cellularity Hodgkin lymphoma, lymphocytopenic Hodgkin lymphoma, and lymphocyte predominant Hodgkin lymphoma; implant-associated anaplastic large cell lymphoma (ALCL); inflammatory breast cancer (IBC); kidney cancer (including renal cell carcinoma and urothelial carcinoma of the kidney, pelvis, and ureter); leukemia, (including acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphoblastic leukemia, and chronic myeloid leukemia), liver cancer (including hepatocellular carcinoma, fibrolamellar hepatocellular carcinoma, angiosarcoma, hepatoblastoma, angiosarcoma), lung cancer (including non-small cell lung cancer, adenocarcinoma, squamous cell carcinoma, large cell carcinoma, small cell lung cancer, carcinoid tumor, salivary gland carcinoma, pulmonary metastasis, sarcoma); medulloblastoma; melanoma (including cutaneous melanoma, superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, acral lentigo melanoma, ocular melanoma, mucosal melanoma); mesothelioma (including sarcomatoid mesothelioma, biphasic mesothelioma), multiple endocrine neoplasia (MEN), ( multiple endocrine neoplasia type 1, multiple endocrine neoplasia type 2); multiple myeloma; myelodysplastic syndromes (MDS) (including refractory anemia, refractory cytopenia with polycythemia vera, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory cytopenia with polycythemia vera and ringed sideroblasts); myeloproliferative disorders (MPD) (polycythemia vera, primary myelofibrosis, essential thrombocythemia, systemic mastocytosis,including hypereosinophilic syndrome;neuroblastoma;neurofibromatosis (including neurofibromatosis type 1, neurofibromatosis type 2, schwannoma);non-Hodgkin's lymphoma (including B-cell lymphoma, T-cell lymphoma, NK-cell lymphoma, mucosa-associated lymphoid tissue lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse large cell lymphoma, primary mediastinal large cell lymphoma, anaplastic large cell lymphoma, Burkitt lymphoma, lymphoblastic lymphoma, marginal zone lymphoma);oral cancer (including squamous cell carcinoma);ovarian cancer (including ovarian epithelial carcinoma, germ cell ovarian carcinoma, stromal ovarian carcinoma, primary abdominal pancreatic cancer (including islet cell carcinoma, sarcoma, lymphoma, pseudopapillary neoplasm, ampullary carcinoma, pancreatoblastoma, adenocarcinoma); parathyroid disease (including hyperparathyroidism, hypoparathyroidism, parathyroid carcinoma); penile cancer (including squamous cell carcinoma, Kaposi's sarcoma, adenocarcinoma, melanoma, basal cell carcinoma); pituitary tumors (including nonfunctioning tumors, functioning tumors, pituitary carcinoma); prostate cancer (including adenocarcinoma, prostatic intraepithelial neoplasm); rectal cancer (including adenocarcinoma); retinoblastoma (including unilateral retinoblastoma, bilateral retinoblastoma, PNET retinoblastoma); skin cancer (basal cell carcinoma, squamous cell carcinoma, Skull base tumors (including meningioma, pituitary adenoma, acoustic neuroma, glomus tumor, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma, adenocarcinoma, chondrosarcoma, rhabdomyosarcoma, osteosarcoma, esthesioblastoma, neuroendocrine carcinoma, mucosal melanoma), soft tissue sarcomas; spinal tumors (including intramedullary spinal tumor, intradural extramedullary spinal tumor, extradural spinal tumor, osteoblastoma, enchondroma, aneurysmal bone cyst, giant cell tumor, hangioma, eosinophilic granuloma, osteosarcoma, chordoma, chondrosarcoma, plasmacytoma); gastric cancer (lymphoma) , gastrointestinal stromal tumors, and carcinoid tumors); testicular cancer (including germ cell tumors, non-seminomas, seminoma, embryonal carcinoma, yolk sac tumors, teratomas, Sertoli cell tumors, choriocarcinomas, stromal tumors, and Leydig cell tumors); pharyngeal cancer (including squamous cell carcinoma); thyroid cancer (including papillary thyroid carcinoma, follicular thyroid carcinoma, Hurthle cell carcinoma, medullary thyroid carcinoma, and anaplastic thyroid carcinoma); uterine cancer (including endometrioid adenocarcinoma, uterine carcinosarcoma, and uterine sarcoma); vaginal cancer (including squamous cell carcinoma, adenocarcinoma, melanoma, and sarcoma); vulvar cancer (including squamous cell carcinoma, adenocarcinoma, melanoma, and sarcoma);sarcoma); von Hippel-Lindau disease; Waldenstrom's macroglobulinemia; and Wilms' tumor. In some embodiments, the antigen is a cancer-associated antigen. For example, the antigen is CD20, CD38, or CD52. Other cancer-associated antigens are known in the art and may also be targeted by the target binding domain.

[0106] In some embodiments, the target binding domain binds to cell surface antigens on immune cells that cause autoimmune disease.In some embodiments, the immune cells are B cells or T cells.Some cancer-related antigens, such as CD20, CD38 and CD52, are also target antigens of autoimmune disease.Examples of autoimmune disease include rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, autoimmune diabetes, autoimmune encephalitis, pemphigus vulgaris, vasculitis, Sjogren's syndrome and myasthenia gravis.Additional autoimmune diseases are known in the art.

[0107] In some embodiments, the target binding domain binds to an antigen present on a microbial pathogen. The pathogen can be a bacterial pathogen, a viral pathogen, a fungal pathogen, or a parasitic pathogen. Bacterial pathogens include Neisseria meningitidis, Staphylococcus aureus, Borrelia burgdorferi, Escherichia coli, Klebsiella pneumoniae, Streptococcus pneumoniae, Serratia marcenscens, Haemophilus influenzae, Mycobacterium tuberculosis, Treponema pallidum, Neisseria gonorrhea, Clostridium difficile, Salmonella spp., Helicobacter spp., Shigella spp., Campylobacter spp., and Listeria spp. Examples of viral pathogens include Epstein-Barr virus, human immunodeficiency virus 1 (HIV-1), herpes viruses, influenza viruses, West Nile virus, cytomegalovirus, and coronaviruses, including SARS-CoV-2. Examples of fungal pathogens include Candida albicans and Aspergillus species. Examples of parasitic pathogens include Schistosoma mansoni, Plasmodium falciparum, and Trypanosoma cruzei. In some embodiments, the antigen is expressed on the surface of a microbial pathogen or on the surface of a cell infected with a microbial pathogen.For example, the antigen can be meningococcal factor H binding protein (fHbP), Streptococcus pneumoniae pneumococcal surface protein A (PspA), Staphylococcus aureus protein A, Staphylococcus aureus fibronectin binding protein, HIV-1 surface glycoprotein 120, SARS-CoV-2 S or M proteins, Plasmodium falciparum reticulocyte binding protein homolog 5, or a mannan epitope on the surface of a fungal organism such as Candida albicans.

[0108] In some embodiments, the target binding domain comprises an anti-CD20 antibody or antigen-binding fragment thereof, or an anti-CD38 antibody or antigen-binding fragment thereof, or an anti-CD52 antibody or antigen-binding fragment thereof, or an anti-fHbP antibody or antigen-binding fragment thereof, or an anti-PspA antibody or antigen-binding fragment thereof, or an anti-Fnbp antibody or antigen-binding fragment thereof, or an anti-PfRH5 antibody or antigen-binding fragment thereof, or an anti-HIV-1 GP120 or antigen-binding fragment thereof, or an anti-SARS-CoV-2 S protein or antigen-binding fragment thereof, or an anti-SARS-CoV-2 M protein or antigen-binding fragment thereof, or an anti-Candida albicans fungal mannan epitope antibody or antigen-binding fragment thereof. In some embodiments, the target binding domain comprises rituximab or an antigen-binding fragment thereof, alemtuzumab or an antigen-binding fragment thereof, daratumumab or an antigen-binding fragment thereof, or the anti-fHbP antibody clone 19 or an antigen-binding fragment thereof, or the anti-PspA antibody RX1MI005 or an antigen-binding fragment thereof, or the anti-Fnbp antibody clone G or an antigen-binding fragment thereof, or the anti-PfRH5 antibody R5.004 or an antigen-binding fragment thereof, or the anti-PfRH5 antibody R5.016 or an antigen-binding fragment thereof, or the anti-GP120 antibody PGT121 or an antigen-binding fragment thereof, or bebuterobimab or an antigen-binding fragment thereof, or the anti-fungal mannan antibody 1A2 or an antigen-binding fragment thereof.In some embodiments, the target binding domain is selected from the group consisting of rituximab heavy chain (SEQ ID NO:1) and / or rituximab light chain (SEQ ID NO:2); alemtuzumab heavy chain (SEQ ID NO:93) and / or alemtuzumab light chain (SEQ ID NO:94); daratumumab heavy chain (SEQ ID NO:95) and / or daratumumab light chain (SEQ ID NO:96); anti-fHbP clone 19 heavy chain (SEQ ID NO:103) and / or anti-fHbP clone 19 light chain (SEQ ID NO:104); RX1MI005 heavy chain (SEQ ID NO:120) and / or RX1MI005 light chain (SEQ ID NO:121); clone G heavy chain (SEQ ID NO:124) and / or clone G light chain (SEQ ID NO:125); R5.004 heavy chain (SEQ ID NO:126); NO:136) and / or R5.004 light chain (SEQ ID NO:137); R5.016 heavy chain (SEQ ID NO:140) and / or R5.016 light chain (SEQ ID NO:141); PGT121 heavy chain (SEQ ID NO:144) and / or PGT light chain (SEQ ID NO:145); bebuterovimab heavy chain (SEQ ID NO:148) and / or bebuterovimab light chain (SEQ ID NO:149), 1A2 heavy chain (SEQ ID NO:128) and / or 1A2 light chain (SEQ ID NO:129); or hJF5 heavy chain (SEQ ID NO:132) and / or hJF5 light chain (SEQ ID NO:133). In some embodiments, the target binding domain comprises one or more mutations compared to the wild-type sequence of the corresponding antibody domain. For example, the target binding domain may contain mutations that inhibit proteolysis, inhibit glycosylation, enhance or reduce binding affinity or avidity, or increase the in vivo half-life of the targeted complement activating molecule.Thus, in some embodiments, the target binding domain comprises a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to the wild-type sequence of the corresponding antibody domain.

[0109] C. Fusion Proteins and Multichain Molecules In certain embodiments, the targeted complement activating molecule comprises a fusion protein, which comprises a complement activating serine protease effector domain fused to a target binding domain. The fusion protein can have any of several configurations: a) the N-terminus of a complement-activating serine protease effector domain fused to the C-terminus of an antibody heavy chain or fragment thereof, b) the C-terminus of a complement-activating serine protease effector domain fused to the N-terminus of an antibody heavy chain or fragment thereof, c) the N-terminus of a complement-activating serine protease effector domain fused to the C-terminus of an antibody light chain or fragment thereof, d) the C-terminus of a complement-activating serine protease effector domain fused to the N-terminus of an antibody light chain or fragment thereof, e) the N-terminus of a complement-activating serine protease effector domain fused to the C-terminus of a single chain or single domain antibody or fragment thereof, or f) the C-terminus of a complement-activating serine protease effector domain fused to the N-terminus of a single chain or single domain antibody or fragment thereof.

[0110] In some embodiments, the target binding domain and the serine protease effector domain in the fusion protein are connected by a linker. Any suitable linker may be used. One example of such a linker is the pentamer Gly-Gly-Gly-Gly-Ser (SEQ ID NO:99), which may be repeated once, or 1-5 or more times, and may begin or end in the middle of a repeat. See, e.g., SEQ ID NO:100.

[0111] In some embodiments, the fusion protein comprises a target binding domain derived from rituximab and a serine protease effector domain derived from MASP-2. In some embodiments, the fusion protein comprises a target binding domain comprising any one of SEQ ID NOs: 1, 2, 3, 20, and 54-56, and a serine protease effector domain comprising any one of SEQ ID NOs: 57, 58, and 61-65. In some embodiments, the fusion protein comprises a sequence set forth as SEQ ID NOs: 4, 5, 6, 7, 8, 9, 10, 33, 34, 35, 36, 37, or 38. In some embodiments, the fusion protein comprises a target binding domain derived from rituximab and a serine protease effector domain derived from MASP-3. In some embodiments, the fusion protein comprises a target binding domain comprising any one of SEQ ID NOs: 1, 2, 3, 20, and 54-56, and a serine protease effector domain comprising SEQ ID NO: 66. In some embodiments, the fusion protein comprises a sequence set forth as SEQ ID NOs: 12, 13, 14, or 15. In some embodiments, the fusion protein comprises a target binding domain derived from rituximab and a serine protease effector domain derived from MASP-1. In some embodiments, the fusion protein comprises a target binding domain comprising any one of SEQ ID NOs: 1, 2, 3, 20, and 54-56, and a serine protease effector domain comprising any one of SEQ ID NOs: 67 and 68. In some embodiments, the fusion protein comprises a sequence set forth as SEQ ID NOs: 16 or 17. In some embodiments, the fusion protein comprises a target binding domain derived from rituximab and a serine protease effector domain derived from C1r. In some embodiments, the fusion protein comprises a target binding domain comprising any one of SEQ ID NOs:1, 2, 3, 20, and 54-56, and a serine protease effector domain comprising any one of SEQ ID NOs:69-74.In some embodiments, the fusion protein comprises a sequence set forth as SEQ ID NO: 18, 21, 39, 40, 48, 49, or 50. In some embodiments, the fusion protein comprises a target binding domain from rituximab and a serine protease effector domain from C1s. In some embodiments, the fusion protein comprises a target binding domain comprising any one of SEQ ID NO: 1, 2, 3, 20, and 54-56, and a serine protease effector domain comprising any one of SEQ ID NO: 76 and 78-87. In some embodiments, the fusion protein comprises a sequence set forth as SEQ ID NO: 19, 23, 41, 42, 43, 44, 45, 46, 47, 51, 52, or 53. In some embodiments, the fusion protein comprises a target binding domain from rituximab and a serine protease effector domain from CFD. In some embodiments, the fusion protein comprises a target binding domain comprising any one of SEQ ID NOs: 1, 2, 3, 20, and 54-56, and a serine protease effector domain comprising SEQ ID NO: 90 or 92. In some embodiments, the fusion protein comprises a sequence set forth as SEQ ID NOs: 27, 28, 29, 30, or 32. In some embodiments, the fusion protein comprises a target binding domain derived from rituximab and a serine protease effector domain derived from C2a. In some embodiments, the fusion protein comprises a target binding domain comprising any one of SEQ ID NOs: 1, 2, 3, 20, and 54-56, and a serine protease effector domain comprising SEQ ID NO: 88. In some embodiments, the fusion protein comprises a sequence set forth as SEQ ID NO: 25. In some embodiments, the fusion protein comprises a target binding domain derived from rituximab and a serine protease effector domain derived from Bb. In some embodiments, the fusion protein comprises a target binding domain comprising any one of SEQ ID NOs:1, 2, 3, 20, and 54-56, and a serine protease effector domain comprising SEQ ID NO:89.In some embodiments, the fusion protein comprises the sequence shown as SEQ ID NO:26.

[0112] In some embodiments, the fusion protein comprises a target binding domain derived from alemtuzumab and a serine protease effector domain derived from MASP-2. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:93 or 94 and a serine protease effector domain comprising any one of SEQ ID NO:57, 58, and 61-65. In some embodiments, the fusion protein comprises a target binding domain derived from alemtuzumab and a serine protease effector domain derived from MASP-3. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:93 or 94 and a serine protease effector domain comprising SEQ ID NO:66. In some embodiments, the fusion protein comprises a target binding domain derived from alemtuzumab and a serine protease effector domain derived from MASP-1. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:93 or 94 and a serine protease effector domain comprising SEQ ID NO:67 or 68. In some embodiments, the fusion protein comprises a target binding domain derived from alemtuzumab and a serine protease effector domain derived from C1r. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:93 or 94 and a serine protease effector domain comprising any one of SEQ ID NO:69-74. In some embodiments, the fusion protein comprises a target binding domain derived from alemtuzumab and a serine protease effector domain derived from C1s. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:93 or 94 and a serine protease effector domain comprising any one of SEQ ID NO:77-87. In some embodiments, the fusion protein comprises a target binding domain derived from alemtuzumab and a serine protease effector domain derived from CFD.In some embodiments, the fusion protein comprises a target binding domain comprising any one of SEQ ID NO:93 and 94, and a serine protease effector domain comprising SEQ ID NO:90 or 92. In some embodiments, the fusion protein comprises the sequence shown as SEQ ID NO:97. In some embodiments, the fusion protein comprises a target binding domain derived from alemtuzumab and a serine protease effector domain derived from C2a. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:93 or 94, and a serine protease effector domain comprising SEQ ID NO:88. In some embodiments, the fusion protein comprises a target binding domain derived from alemtuzumab and a serine protease effector domain derived from Bb. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:93 or 94, and a serine protease effector domain comprising SEQ ID NO:89.

[0113] In some embodiments, the fusion protein comprises a target binding domain from daratumumab and a serine protease effector domain from MASP-2. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:95 or 96 and a serine protease effector domain comprising any one of SEQ ID NO:57, 58, and 61-65. In some embodiments, the fusion protein comprises a target binding domain from daratumumab and a serine protease effector domain from MASP-3. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:95 or 96 and a serine protease effector domain comprising SEQ ID NO:66. In some embodiments, the fusion protein comprises a target binding domain from daratumumab and a serine protease effector domain from MASP-1. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:95 or 96 and a serine protease effector domain comprising SEQ ID NO:67 or 68. In some embodiments, the fusion protein comprises a target binding domain from daratumumab and a serine protease effector domain from C1r. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:95 or 96 and a serine protease effector domain comprising any one of SEQ ID NO:69-74. In some embodiments, the fusion protein comprises a target binding domain from daratumumab and a serine protease effector domain from C1s. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:95 or 96 and a serine protease effector domain comprising any one of SEQ ID NO:77-87. In some embodiments, the fusion protein comprises a target binding domain from daratumumab and a serine protease effector domain from CFD.In some embodiments, the fusion protein comprises a target binding domain comprising any one of SEQ ID NO:95 and 96 and a serine protease effector domain comprising SEQ ID NO:90 or 92. In some embodiments, the fusion protein comprises the sequence shown as SEQ ID NO:98. In some embodiments, the fusion protein comprises a target binding domain derived from daratumumab and a serine protease effector domain derived from C2a. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:95 or 96 and a serine protease effector domain comprising SEQ ID NO:88. In some embodiments, the fusion protein comprises a target binding domain derived from daratumumab and a serine protease effector domain derived from Bb. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:95 or 96 and a serine protease effector domain comprising SEQ ID NO:89.

[0114] In some embodiments, the fusion protein comprises a target binding domain from anti-fHbP clone 19 and a serine protease effector domain from MASP-3. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:103, 104, or 114, and a serine protease effector domain comprising SEQ ID NO:66. In some embodiments, the fusion protein comprises the sequence shown as SEQ ID NO:117. In some embodiments, the fusion protein comprises a target binding domain from anti-fHbP clone 19 and a serine protease effector domain from MASP-2. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:103, 104, or 114, and a serine protease effector domain comprising any one of SEQ ID NOs:57-65. In some embodiments, the fusion protein comprises the sequence shown as SEQ ID NO:116. In some embodiments, the fusion protein comprises a target binding domain from anti-fHbP clone 19 and a serine protease effector domain from MASP-1. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO: 103, 104, or 114, and a serine protease effector domain comprising SEQ ID NO: 67 or 68. In some embodiments, the fusion protein comprises a target binding domain from anti-fHbP clone 19 and a serine protease effector domain from C1r. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO: 103, 104, or 114, and a serine protease effector domain comprising any one of SEQ ID NO: 69-74. In some embodiments, the fusion protein comprises the sequence shown as SEQ ID NO: 108. In some embodiments, the fusion protein comprises the target binding domain from anti-fHbP clone 19 and the serine protease effector domain from C1s.In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO: 103, 104, or 114, and a serine protease effector domain comprising any one of SEQ ID NO: 76-87. In some embodiments, the fusion protein comprises the sequence set forth as SEQ ID NO: 111. In some embodiments, the fusion protein comprises a target binding domain from anti-fHbP clone 19, and a serine protease effector domain from CFD. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO: 103, 104, or 114, and a serine protease effector domain comprising SEQ ID NO: 90 or 92. In some embodiments, the fusion protein comprises the sequence set forth as SEQ ID NO: 118 or 119. In some embodiments, the fusion protein comprises a target binding domain from anti-fHbP clone 19, and a serine protease effector domain from C2a. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:103, 104, or 114, and a serine protease effector domain comprising SEQ ID NO:88. In some embodiments, the fusion protein comprises a target binding domain derived from anti-fHbP clone 19, and a serine protease effector domain derived from Bb. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:103, 104, or 114, and a serine protease effector domain comprising SEQ ID NO:89.

[0115] In some embodiments, the fusion protein comprises a target binding domain from anti-PspA RX1MI005 and a serine protease effector domain from MASP-3. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO: 120 or 121 and a serine protease effector domain comprising SEQ ID NO: 66. In some embodiments, the fusion protein comprises a target binding domain from anti-PspA RX1MI005 and a serine protease effector domain from MASP-2. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO: 120 or 121 and a serine protease effector domain comprising any one of SEQ ID NO: 57-65. In some embodiments, the fusion protein comprises a target binding domain from anti-PspA RX1MI005 and a serine protease effector domain from MASP-1. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:120 or 121 and a serine protease effector domain comprising SEQ ID NO:67 or 68. In some embodiments, the fusion protein comprises a target binding domain from anti-PspA RX1MI005 and a serine protease effector domain from C1r. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:120 or 121 and a serine protease effector domain comprising any one of SEQ ID NO:69-74. In some embodiments, the fusion protein comprises the sequence shown as SEQ ID NO:122. In some embodiments, the fusion protein comprises a target binding domain from anti-PspA RX1MI005 and a serine protease effector domain from C1s. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:120 or 121 and a serine protease effector domain comprising any one of SEQ ID NOs:76-87. In some embodiments, the fusion protein comprises the sequence shown as SEQ ID NO:123.In some embodiments, the fusion protein comprises a target binding domain from anti-PspA and a serine protease effector domain from CFD. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:120 or 121 and a serine protease effector domain comprising SEQ ID NO:90 or 92. In some embodiments, the fusion protein comprises a target binding domain from anti-PspA and a serine protease effector domain from C2a. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:120 or 121 and a serine protease effector domain comprising SEQ ID NO:88. In some embodiments, the fusion protein comprises a target binding domain from anti-PspA and a serine protease effector domain from Bb. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:120 or 121 and a serine protease effector domain comprising SEQ ID NO:89.

[0116] In some embodiments, the fusion protein comprises a target binding domain from anti-Fnbp clone G and a serine protease effector domain from MASP-3. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:124 or 125 and a serine protease effector domain comprising SEQ ID NO:66. In some embodiments, the fusion protein comprises a target binding domain from anti-Fnbp clone G and a serine protease effector domain from MASP-2. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:124 or 125 and a serine protease effector domain comprising any one of SEQ ID NO:57-65. In some embodiments, the fusion protein comprises a target binding domain from anti-Fnbp clone G and a serine protease effector domain from MASP-1. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO: 124 or 125 and a serine protease effector domain comprising SEQ ID NO: 67 or 68. In some embodiments, the fusion protein comprises a target binding domain from anti-Fnbp clone G and a serine protease effector domain from C1r. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO: 124 or 125 and a serine protease effector domain comprising any one of SEQ ID NO: 69-74. In some embodiments, the fusion protein comprises the sequence shown as SEQ ID NO: 126. In some embodiments, the fusion protein comprises a target binding domain from anti-Fnbp clone G and a serine protease effector domain from C1s. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO: 124 or 125 and a serine protease effector domain comprising any one of SEQ ID NO: 76-87. In some embodiments, the fusion protein comprises the sequence shown as SEQ ID NO:127.In some embodiments, the fusion protein comprises a target binding domain from anti-Fnbp clone G and a serine protease effector domain from CFD. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO: 124 or 125 and a serine protease effector domain comprising SEQ ID NO: 90 or 92. In some embodiments, the fusion protein comprises a target binding domain from anti-Fnbp clone G and a serine protease effector domain from C2a. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO: 124 or 125 and a serine protease effector domain comprising SEQ ID NO: 88. In some embodiments, the fusion protein comprises a target binding domain from anti-Fnbp clone G and a serine protease effector domain from Bb. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:124 or 125 and a serine protease effector domain comprising SEQ ID NO:89.

[0117] In some embodiments, the fusion protein comprises a target binding domain from the anti-Candida albicans antibody 1A2 and a serine protease effector domain from MASP-3. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:128 or 129 and a serine protease effector domain comprising SEQ ID NO:66. In some embodiments, the fusion protein comprises a target binding domain from the anti-Candida albicans antibody 1A2 and a serine protease effector domain from MASP-2. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:128 or 129 and a serine protease effector domain comprising any one of SEQ ID NO:57-65. In some embodiments, the fusion protein comprises a target binding domain from the anti-Candida albicans antibody 1A2 and a serine protease effector domain from MASP-1. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:128 or 129 and a serine protease effector domain comprising SEQ ID NO:67 or 68. In some embodiments, the fusion protein comprises a target binding domain derived from the anti-Candida albicans antibody 1A2 and a serine protease effector domain derived from C1r. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:128 or 129 and a serine protease effector domain comprising any one of SEQ ID NOs:69-74. In some embodiments, the fusion protein comprises the sequence shown as SEQ ID NO:130. In some embodiments, the fusion protein comprises a target binding domain derived from the anti-Candida albicans antibody 1A2 and a serine protease effector domain derived from C1s. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:128 or 129 and a serine protease effector domain comprising any one of SEQ ID NOs:76-87. In some embodiments, the fusion protein comprises the sequence shown as SEQ ID NO:131.In some embodiments, the fusion protein comprises a target binding domain from anti-Candida albicans antibody 1A2 and a serine protease effector domain from CFD. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO: 128 or 129 and a serine protease effector domain comprising SEQ ID NO: 90 92. In some embodiments, the fusion protein comprises a target binding domain from anti-Candida albicans antibody 1A2 and a serine protease effector domain from C2a. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO: 128 or 129 and a serine protease effector domain comprising SEQ ID NO: 88. In some embodiments, the fusion protein comprises a target binding domain from an anti-Candida albicans antibody and a serine protease effector domain from Bb. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:128 and 129 and a serine protease effector domain comprising SEQ ID NO:89.

[0118] In some embodiments, the fusion protein comprises a target binding domain from anti-PfRH5 antibody R5.004 and a serine protease effector domain from MASP-3. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:136 or 137 and a serine protease effector domain comprising SEQ ID NO:66. In some embodiments, the fusion protein comprises a target binding domain from anti-PfRH5 antibody R5.004 and a serine protease effector domain from MASP-2. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:136 or 137 and a serine protease effector domain comprising any one of SEQ ID NO:57-65. In some embodiments, the fusion protein comprises a target binding domain from anti-PfRH5 antibody R5.004 and a serine protease effector domain from MASP-1. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:136 or 137 and a serine protease effector domain comprising SEQ ID NO:67 or 68. In some embodiments, the fusion protein comprises a target binding domain from anti-PfRH5 antibody R5.004 and a serine protease effector domain from C1r. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:136 or 137 and a serine protease effector domain comprising any one of SEQ ID NOs:69-74. In some embodiments, the fusion protein comprises the sequence shown as SEQ ID NO:138. In some embodiments, the fusion protein comprises a target binding domain from anti-PfRH5 antibody R5.004 and a serine protease effector domain from C1s. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:136 or 137 and a serine protease effector domain comprising any one of SEQ ID NOs:76-87. In some embodiments, the fusion protein comprises the sequence shown as SEQ ID NO:139.In some embodiments, the fusion protein comprises a target binding domain from anti-PfRH5 antibody R5.004 and a serine protease effector domain from CFD. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:136 or 137 and a serine protease effector domain comprising SEQ ID NO:90 or 92. In some embodiments, the fusion protein comprises a target binding domain from anti-PfHR5 antibody R5.004 and a serine protease effector domain from C2a. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:136 or 137 and a serine protease effector domain comprising SEQ ID NO:88. In some embodiments, the fusion protein comprises a target binding domain from anti-PfHR5 antibody R5.004 and a serine protease effector domain from Bb. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:136 or 137 and a serine protease effector domain comprising SEQ ID NO:89.

[0119] In some embodiments, the fusion protein comprises a target binding domain from anti-PfHR5 antibody R5.016 and a serine protease effector domain from MASP-3. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:140 or 141 and a serine protease effector domain comprising SEQ ID NO:66. In some embodiments, the fusion protein comprises a target binding domain from anti-PfHR5 antibody R5.016 and a serine protease effector domain from MASP-2. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:140 or 141 and a serine protease effector domain comprising any one of SEQ ID NO:57-65. In some embodiments, the fusion protein comprises a target binding domain from anti-PfHR5 antibody R5.016 and a serine protease effector domain from MASP-1. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:140 or 141 and a serine protease effector domain comprising SEQ ID NO:67 or 68. In some embodiments, the fusion protein comprises a target binding domain from anti-PfRH5 antibody R5.016 and a serine protease effector domain from C1r. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:140 or 141 and a serine protease effector domain comprising any one of SEQ ID NOs:69-74. In some embodiments, the fusion protein comprises the sequence shown as SEQ ID NO:142. In some embodiments, the fusion protein comprises a target binding domain from anti-PfRH5 antibody R5.016 and a serine protease effector domain from C1s. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:140 or 141 and a serine protease effector domain comprising any one of SEQ ID NOs:76-87. In some embodiments, the fusion protein comprises the sequence shown as SEQ ID NO:143.In some embodiments, the fusion protein comprises a target binding domain from anti-PfRH5 antibody R5.016 and a serine protease effector domain from CFD. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:140 or 141 and a serine protease effector domain comprising SEQ ID NO:90 or 92. In some embodiments, the fusion protein comprises a target binding domain from anti-PfRH5 antibody R5.016 and a serine protease effector domain from C2a. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:140 or 141 and a serine protease effector domain comprising SEQ ID NO:88. In some embodiments, the fusion protein comprises a target binding domain from anti-PfRH5 antibody R5.016 and a serine protease effector domain from Bb. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:140 or 141 and a serine protease effector domain comprising SEQ ID NO:89.

[0120] In some embodiments, the fusion protein comprises a target binding domain from the anti-GP120 antibody PGT121 and a serine protease effector domain from MASP-3. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:144 or 145 and a serine protease effector domain comprising SEQ ID NO:66. In some embodiments, the fusion protein comprises a target binding domain from the anti-GP120 antibody PGT121 and a serine protease effector domain from MASP-2. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:144 or 145 and a serine protease effector domain comprising any one of SEQ ID NO:57-65. In some embodiments, the fusion protein comprises a target binding domain from the anti-GP120 antibody PGT121 and a serine protease effector domain from MASP-1. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:144 or 145 and a serine protease effector domain comprising SEQ ID NO:67 or 68. In some embodiments, the fusion protein comprises a target binding domain derived from the anti-GP120 antibody PGT121 and a serine protease effector domain derived from C1r. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:144 or 145 and a serine protease effector domain comprising any one of SEQ ID NOs:69-74. In some embodiments, the fusion protein comprises the sequence shown as SEQ ID NO:147. In some embodiments, the fusion protein comprises a target binding domain derived from the anti-GP120 antibody PGT121 and a serine protease effector domain derived from C1s. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:144 or 145 and a serine protease effector domain comprising any one of SEQ ID NOs:76-87. In some embodiments, the fusion protein comprises the sequence shown as SEQ ID NO:146.In some embodiments, the fusion protein comprises a target binding domain from the anti-GP120 antibody PGT121 and a serine protease effector domain from CFD. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO: 144 or 145 and a serine protease effector domain comprising SEQ ID NO: 90 or 92. In some embodiments, the fusion protein comprises a target binding domain from the anti-GP120 antibody PGT121 and a serine protease effector domain from C2a. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO: 144 or 145 and a serine protease effector domain comprising SEQ ID NO: 88. In some embodiments, the fusion protein comprises a target binding domain from the anti-GP120 antibody PGT121 and a serine protease effector domain from Bb. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:144 or 145 and a serine protease effector domain comprising SEQ ID NO:89.

[0121] In some embodiments, the fusion protein comprises a target binding domain derived from bebuterobimab and a serine protease effector domain derived from MASP-3. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO: 148 or 149 and a serine protease effector domain comprising SEQ ID NO: 66. In some embodiments, the fusion protein comprises a target binding domain derived from bebuterobimab and a serine protease effector domain derived from MASP-2. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO: 148 or 149 and a serine protease effector domain comprising any one of SEQ ID NO: 57-65. In some embodiments, the fusion protein comprises a target binding domain derived from bebuterobimab and a serine protease effector domain derived from MASP-1. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO: 148 or 149 and a serine protease effector domain comprising SEQ ID NO: 67 or 68. In some embodiments, the fusion protein comprises a target binding domain derived from bebuterobimab and a serine protease effector domain derived from C1r. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO: 148 or 149 and a serine protease effector domain comprising any one of SEQ ID NO: 69-74. In some embodiments, the fusion protein comprises the sequence shown as SEQ ID NO: 150. In some embodiments, the fusion protein comprises a target binding domain derived from bebuterobimab and a serine protease effector domain derived from C1s. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO: 148 or 149 and a serine protease effector domain comprising any one of SEQ ID NO: 76-87. In some embodiments, the fusion protein comprises the sequence shown as SEQ ID NO:151.In some embodiments, the fusion protein comprises a target binding domain from bebuterobimab and a serine protease effector domain from CFD. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO: 148 or 149 and a serine protease effector domain comprising SEQ ID NO: 90 or 92. In some embodiments, the fusion protein comprises a target binding domain from bebuterobimab and a serine protease effector domain from C2a. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO: 148 or 149 and a serine protease effector domain comprising SEQ ID NO: 88. In some embodiments, the fusion protein comprises a target binding domain from bebuterobimab and a serine protease effector domain from Bb. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:148 or 149 and a serine protease effector domain comprising SEQ ID NO:89.

[0122] In some embodiments, the fusion protein comprises a target binding domain from the anti-Aspergillus antibody hJF5 and a serine protease effector domain from MASP-3. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:132 or 133 and a serine protease effector domain comprising SEQ ID NO:66. In some embodiments, the fusion protein comprises a target binding domain from the anti-Aspergillus antibody hJF5 and a serine protease effector domain from MASP-2. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:1132 or 133 and a serine protease effector domain comprising any one of SEQ ID NOs:57-65. In some embodiments, the fusion protein comprises a target binding domain from the anti-Aspergillus antibody hJF5 and a serine protease effector domain from MASP-1. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:132 or 133 and a serine protease effector domain comprising SEQ ID NO:67 or 68. In some embodiments, the fusion protein comprises a target binding domain from the anti-Aspergillus antibody hJF5 and a serine protease effector domain from C1r. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:132 or 133 and a serine protease effector domain comprising any one of SEQ ID NOs:69-74. In some embodiments, the fusion protein comprises the sequence shown as SEQ ID NO:134. In some embodiments, the fusion protein comprises a target binding domain from the anti-Aspergillus antibody hJF5 and a serine protease effector domain from C1s. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:132 or 133 and a serine protease effector domain comprising any one of SEQ ID NOs:76-87. In some embodiments, the fusion protein comprises the sequence shown as SEQ ID NO:135.In some embodiments, the fusion protein comprises a target binding domain from anti-Aspergillus antibody hJF5 and a serine protease effector domain from CFD. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:132 or 133 and a serine protease effector domain comprising SEQ ID NO:90 or 92. In some embodiments, the fusion protein comprises a target binding domain from anti-Aspergillus antibody hJF5 and a serine protease effector domain from C2a. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:132 or 133 and a serine protease effector domain comprising SEQ ID NO:88. In some embodiments, the fusion protein comprises a target binding domain from anti-Aspergillus antibody hJF5 and a serine protease effector domain from Bb. In some embodiments, the fusion protein comprises a target binding domain comprising SEQ ID NO:132 or 133 and a serine protease effector domain comprising SEQ ID NO:89.

[0123] The above-listed fusion proteins are provided as examples of fusion proteins of antibody binding domains and serine protease effector domains, but it is envisioned that other antibody binding domains can be used instead of the listed ones. Alternative antibody binding domains include those derived from other antibodies against the listed antigens, those derived from antibodies that bind to other antigens present on the above-listed targets (e.g., cancer cells, immune cells, bacteria, fungi, viruses, and parasites), and those derived from antibodies that bind to antigens present on other suitable targets, such as other types of cancer cells, immune cells, bacteria, fungi, viruses, and parasites. The present disclosure envisions targeted complement activation molecules that include target binding domains derived from such antibodies and the serine protease effector domains described hereinabove.

[0124] In certain embodiments, the fusion protein comprises a target binding domain derived from an antibody heavy chain or an antibody light chain. In such cases, the targeted complement activating molecule may comprise additional polypeptides that enhance the antigen binding, effector function, stability, etc. of the molecule. In some embodiments, the targeted complement activating molecule comprises a) a fusion protein comprising a target binding domain derived from an antibody heavy chain, and b) an antibody light chain or a fragment thereof. In some embodiments, the targeted complement activating molecule comprises a) a fusion protein comprising a target binding domain derived from an antibody light chain, and b) an antibody heavy chain or a fragment thereof. In some embodiments, the antibody heavy chain and the antibody light chain are derived from the same antibody. In some embodiments, the targeted complement activating molecule may comprise a) a fusion protein comprising a target binding domain derived from an antibody heavy chain, and b) a fusion protein comprising a target binding domain derived from an antibody light chain.

[0125] In some embodiments, the targeted complement activating molecule comprises a) a fusion protein comprising a target binding domain derived from a rituximab heavy chain, and b) a rituximab light chain or a fragment thereof. In some embodiments, the targeted complement activating molecule comprises a fusion protein comprising a sequence set forth as any one of SEQ ID NOs:4-6, 9, 12, 13, 16, 18, 19, 21, 23, 25-28, 32-47, and 48-53, and an antibody light chain comprising a sequence set forth as SEQ ID NO:2. In some embodiments, the targeted complement activating molecule comprises a) a fusion protein comprising a target binding domain derived from a rituximab light chain, and b) a rituximab heavy chain or a fragment thereof. In some embodiments, the targeted complement activating molecule comprises a fusion protein comprising a sequence set forth as any one of SEQ ID NOs:7, 8, 14, 15, 17, 29, and 30, and an antibody heavy chain comprising a sequence set forth as any one of SEQ ID NOs:1, 3, 20, and 54-56.

[0126] In some embodiments, the targeted complement activating molecule comprises a) a fusion protein comprising a target binding domain derived from an alemtuzumab heavy chain, and b) an alemtuzumab light chain, or a fragment thereof. In some embodiments, the targeted complement activating molecule comprises a fusion protein comprising the sequence set forth as SEQ ID NO:97, and an antibody light chain comprising the sequence set forth as SEQ ID NO:94. In some embodiments, the targeted complement activating molecule comprises a) a fusion protein comprising a target binding domain derived from an alemtuzumab light chain, and b) an alemtuzumab heavy chain, or a fragment thereof.

[0127] In some embodiments, the targeted complement activating molecule comprises a) a fusion protein comprising a target binding domain derived from a daratumumab heavy chain, and b) a daratumumab light chain, or a fragment thereof. In some embodiments, the targeted complement activating molecule comprises a fusion protein comprising the sequence set forth as SEQ ID NO:98, and an antibody light chain comprising the sequence set forth as SEQ ID NO:96. In some embodiments, the targeted complement activating molecule comprises a) a fusion protein comprising a target binding domain derived from a daratumumab light chain, and b) a daratumumab heavy chain, or a fragment thereof.

[0128] In some embodiments, the targeted complement activating molecule comprises a) a fusion protein comprising a target binding domain from an anti-fHbP clone 19 heavy chain, and b) an anti-fHbP clone light chain or a fragment thereof. In some embodiments, the targeted complement activating molecule comprises a fusion protein comprising a sequence set forth as SEQ ID NO: 108, 111, 116, 117, 118, or 119, and an antibody light chain comprising a sequence set forth as SEQ ID NO: 104. In some embodiments, the targeted complement activating molecule comprises a) a fusion protein comprising a target binding domain from an anti-fHbP clone light chain, and b) an anti-fHbP clone heavy chain or a fragment thereof.

[0129] In some embodiments, the targeted complement activating molecule comprises a) a fusion protein comprising a target binding domain derived from the RX1MI005 heavy chain, and b) an RX1MI005 light chain or a fragment thereof. In some embodiments, the targeted complement activating molecule comprises a fusion protein comprising a sequence set forth as SEQ ID NO: 122 or 123, and an antibody light chain comprising a sequence set forth as SEQ ID NO: 121. In some embodiments, the targeted complement activating molecule comprises a) a fusion protein comprising a target binding domain derived from the RX1MI005 light chain, and b) an RX1MI005 heavy chain or a fragment thereof.

[0130] In some embodiments, the targeted complement activating molecule comprises a) a fusion protein comprising a target binding domain from clone G heavy chain and b) a clone G light chain or a fragment thereof. In some embodiments, the targeted complement activating molecule comprises a fusion protein comprising the sequence set forth as SEQ ID NO: 126 or 127 and an antibody light chain comprising the sequence set forth as SEQ ID NO: 125. In some embodiments, the targeted complement activating molecule comprises a) a fusion protein comprising a target binding domain from clone G light chain and b) a clone G heavy chain or a fragment thereof.

[0131] In some embodiments, the targeted complement activating molecule comprises a) a fusion protein comprising a target binding domain from a 1A2 heavy chain and b) a 1A2 light chain or a fragment thereof. In some embodiments, the targeted complement activating molecule comprises a fusion protein comprising the sequence set forth as SEQ ID NO:130 or 131 and an antibody light chain comprising the sequence set forth as SEQ ID NO:129. In some embodiments, the targeted complement activating molecule comprises a) a fusion protein comprising a target binding domain from a 1A2 light chain and b) a 1A2 heavy chain or a fragment thereof.

[0132] In some embodiments, the targeted complement activating molecule comprises a) a fusion protein comprising a target binding domain from the R5.004 heavy chain and b) an R5.004 light chain or a fragment thereof. In some embodiments, the targeted complement activating molecule comprises a fusion protein comprising the sequence set forth as SEQ ID NO:138 or 139 and an antibody light chain comprising the sequence set forth as SEQ ID NO:137. In some embodiments, the targeted complement activating molecule comprises a) a fusion protein comprising a target binding domain from the R5.004 light chain and b) an R5.004 heavy chain or a fragment thereof.

[0133] In some embodiments, the targeted complement activating molecule comprises a) a fusion protein comprising a target binding domain from the R5.016 heavy chain, and b) an R5.016 light chain, or a fragment thereof. In some embodiments, the targeted complement activating molecule comprises a fusion protein comprising the sequence set forth as SEQ ID NO:142 or 143, and an antibody light chain comprising the sequence set forth as SEQ ID NO:141. In some embodiments, the targeted complement activating molecule comprises a) a fusion protein comprising a target binding domain from the R5.016 light chain, and b) an R5.016 heavy chain, or a fragment thereof.

[0134] In some embodiments, the targeted complement activating molecule comprises a) a fusion protein comprising a target binding domain derived from a PGT121 heavy chain, and b) a PGT121 light chain or a fragment thereof. In some embodiments, the targeted complement activating molecule comprises a fusion protein comprising the sequence set forth as SEQ ID NO:146 or 147, and an antibody light chain comprising the sequence set forth as SEQ ID NO:145. In some embodiments, the targeted complement activating molecule comprises a) a fusion protein comprising a target binding domain derived from a PGT121 light chain, and b) a PGT121 heavy chain or a fragment thereof.

[0135] In some embodiments, the targeted complement activating molecule comprises a) a fusion protein comprising a target binding domain derived from a bebuterovimab heavy chain, and b) a bebuterovimab light chain or a fragment thereof. In some embodiments, the targeted complement activating molecule comprises a fusion protein comprising a sequence set forth as SEQ ID NO: 150 or 151, and an antibody light chain comprising a sequence set forth as SEQ ID NO: 149. In some embodiments, the targeted complement activating molecule comprises a) a fusion protein comprising a target binding domain derived from a bebuterovimab light chain, and b) a bebuterovimab heavy chain or a fragment thereof.

[0136] In some embodiments, the targeted complement activating molecule comprises a) a fusion protein comprising a target binding domain derived from an anti-SARS-CoV-2 M protein antibody heavy chain, and b) a light chain of an anti-SARS-CoV-2 M protein antibody, or a fragment thereof. In some embodiments, the targeted complement activating molecule comprises a) a fusion protein comprising a target binding domain derived from an anti-SARS-CoV-2 M protein antibody light chain, and b) a heavy chain of an anti-SARS-CoV-2 M protein antibody, or a fragment thereof.

[0137] In some embodiments, the targeted complement activating molecule comprises a) a fusion protein comprising a target binding domain derived from the hJF5 heavy chain, and b) an hJF5 light chain or a fragment thereof. In some embodiments, the targeted complement activating molecule comprises a fusion protein comprising the sequence set forth as SEQ ID NO: 134 or 135, and an antibody light chain comprising the sequence set forth as SEQ ID NO: 133. In some embodiments, the targeted complement activating molecule comprises a) a fusion protein comprising a target binding domain derived from the hJF5 light chain, and b) an hJF5 heavy chain or a fragment thereof.

[0138] IV. Polynucleotides, Vectors, and Host Cells Further provided herein is an isolated polynucleotide encoding any of the targeted complement activating molecules or portions thereof (e.g., fusion proteins, antibody heavy chains or fragments thereof, or antibody light chains or fragments thereof) disclosed herein. In certain embodiments, the polynucleotides are codon-optimized for expression in a host cell. Once the coding sequence is known or identified, codon optimization can be performed using known techniques and tools, such as the GenScript® OptimumGene™ tool or ThermoFisher Scientific® GeneArt GeneOptimizer™. Codon-optimized sequences include partially codon-optimized sequences, having one or more codons optimized for expression in a host cell, and fully codon-optimized sequences. It will also be understood that polynucleotides encoding targeted complement activating molecules and portions thereof may have different nucleotide sequences while encoding the same protein due to degeneracy of the genetic code, splicing, etc.

[0139] In certain embodiments, the polynucleotide encoding the targeted complement-activating molecule or a portion thereof may be included in a polynucleotide that includes other sequences and / or features. For example, the polynucleotide may include one or more sequences useful for controlling or expressing the encoded protein, such as a promoter sequence, a polyadenylation sequence, a sequence encoding a signal peptide, etc. The polynucleotide may include deoxyribonucleic acid (DNA) or ribonucleic acid (RNA).

[0140] Also provided is a vector that includes or contains a polynucleotide encoding any of the targeted complement activating molecules or portions thereof disclosed herein. Any suitable vector may be used, including viral vectors and plasmid vectors. In certain embodiments, the vector includes a polynucleotide encoding both the fusion protein and the corresponding antibody heavy or light chain, which together constitute the targeted complement activating molecule. The sequence encoding the fusion protein and the sequence encoding the antibody heavy or light chain may be included in a single open reading frame. In this case, they may be optionally separated by a polynucleotide encoding a protease cleavage site and / or a polynucleotide encoding a self-cleaving peptide. Alternatively, the sequence encoding the fusion protein and the sequence encoding the antibody heavy or light chain may be included in separate open reading frames on a single vector. In another embodiment, the sequence encoding the fusion protein and the sequence encoding the antibody heavy or light chain are present on two different vectors, such that the first vector encodes the fusion protein and the second vector encodes the antibody heavy or light chain.

[0141] In a further aspect, the present disclosure also provides a host cell comprising the polynucleotide or vector disclosed herein. Any suitable cell into which such polynucleotide or vector can be introduced can be used. Examples of such cells include eukaryotic cells, such as yeast cells, animal cells, insect cells, mammalian cells, and plant cells, and prokaryotic cells, such as bacterial cells, such as E. coli. In some embodiments, the host cell is a mammalian cell. In some embodiments, the host cell is an immortalized mammalian cell line. Cells suitable for use in the production and expression of polynucleotides and vectors are known in the art.

[0142] In some embodiments, cells may be transfected with the polynucleotide or vector disclosed herein. The term "transfection" includes any method known to those skilled in the art for introducing a nucleic acid molecule into a cell. Such methods include, for example, electroporation, lipofection, nanoparticle-based transfection, virus-based transfection, etc. Host cells may be stably or transiently transfected.

[0143] In some embodiments, the host cell expresses the targeted complement activating molecule or a portion thereof encoded by the polynucleotide or vector. Such expression may include post-translational modifications such as removal of signal sequences, glycosylation, and other modifications. In a related aspect, the disclosure provides a method for producing a targeted complement activating molecule or a portion thereof, comprising culturing a host cell for a sufficient time under conditions that allow expression of the molecule, and isolating the molecule. Methods useful for isolating and purifying recombinantly produced proteins include, for example, obtaining a supernatant from a suitable host cell that secretes the protein into the culture medium, concentrating the medium, and purifying the protein by passing it through a suitable purification matrix or series of matrices. Methods for purifying proteins are well known in the art.

[0144] V. Pharmaceutical Compositions Also provided herein are compositions that include a therapeutic agent selected from any one or more of the targeted complement activating molecules, polynucleotides, vectors, or host cells disclosed herein, alone or in any combination, and may also include other selected therapeutic agents. Such compositions may further include one or more pharma- ceutically acceptable carriers, excipients, or diluents.

[0145] Pharmaceutically acceptable carriers are selected so as to be non-toxic, biocompatible, and not to adversely affect the biological activity of the therapeutic agent (and any other therapeutic agents with which it is combined). Examples of pharma-ceutically acceptable carriers for peptides are described in Yamada, U.S. Patent No. 5,211,657. The therapeutic agents described herein can be formulated into solid, semi-solid, gel, liquid, or gaseous preparations, such as tablets, capsules, powders, granules, ointments, solutions, depositories, inhalants, and injections, that allow for oral, parenteral, or surgical administration. Local administration of the composition by coating a medical device is also envisioned.

[0146] Suitable carriers for parenteral delivery by injection, infusion or irrigation and topical delivery include distilled water, physiological phosphate-buffered saline, normal or lactated Ringer's solution, dextrose solution, Hank's solution, or propanediol. In addition, sterile fixed oils can be used as a solvent or suspending medium. Any biocompatible oil, including synthetic mono- or di-glycerides, can be used for this purpose. In addition, fatty acids such as oleic acid are also useful for the preparation of injectables. The carrier and agent can be formulated as a liquid, suspension, polymeric or non-polymeric gel, paste, or salve.

[0147] The carrier may also include a delivery vehicle to sustain (i.e., extend, delay, or control) the delivery of the agent or to enhance the delivery, uptake, stability, or pharmacokinetics of the therapeutic agent. Such delivery vehicles may include, by way of non-limiting example, microparticles, microspheres, nanospheres, or nanoparticles composed of proteins, liposomes, carbohydrates, synthetic organic compounds, inorganic compounds, polymer or copolymer hydrogels, and polymeric micelles. Suitable hydrogel and micelle delivery systems include PEO:PHB:PEO copolymers and copolymer / cyclodextrin complexes as disclosed in WO 2004 / 009664 A2, and PEO and PEO / cyclodextrin complexes as disclosed in US Patent Application Publication No. 2002 / 0019369 A1. Such hydrogels may be injected locally at the intended site of action or subcutaneously or intramuscularly to form a sustained release depot.

[0148] The compositions of the present invention may be formulated for delivery by any suitable method, including, but not limited to, oral, topical, transdermal, sublingual, buccal, subcutaneous, intramuscular, intravenous, intraarterial administration, or administration as an inhalant.

[0149] The compositions of the present invention may also contain biocompatible excipients such as dispersing or wetting agents, suspending agents, diluents, buffers, penetration enhancers, emulsifying agents, binders, thickening agents, flavoring agents (for oral administration).

[0150] Pharmaceutical compositions according to certain embodiments of the present invention are formulated so that the active ingredients contained therein are bioavailable when the compositions are administered to a patient. The compositions to be administered to a subject may be in the form of one or more dosage units. And the therapeutic agent containers described herein may hold multiple dosage units. The actual methods of preparing such dosage forms will be known or apparent to those skilled in the art. See, for example, "Remington: The Science and Practice of Pharmacy", 20th Edition (Philadelphia College of Pharmacy and Science, 2000). The compositions to be administered will, in any case, contain an effective amount of the therapeutic agent or composition of the present disclosure for treating the disease or condition of interest, according to the teachings of the present specification.

[0151] The composition may be in solid or liquid form.In some embodiments, the carrier is granular, and thus the composition is in the form of, for example, tablet or powder.The carrier may be liquid, and in this case the composition is, for example, oral oil, injectable liquid, or aerosol, which is useful for inhalation administration, etc.When intended for oral administration, the pharmaceutical composition is preferably in solid or liquid form, where semi-solid, semi-liquid, suspension and gel form are included in the form considered as solid or liquid in this specification.

[0152] As a solid composition for oral administration, pharmaceutical compositions can be formulated into powder, granule, compressed tablet, pill, capsule, chewing gum, wafer, etc. Such solid compositions will typically contain one or more inert fillers or diluents, such as sucrose, corn starch or cellulose. In addition, one or more of the following can be present: binders, such as carboxymethylcellulose, ethylcellulose, microcrystalline cellulose, tragacanth or gelatin; excipients, such as starch, lactose or dextrin; disintegrants, such as alginic acid, sodium alginate, Primogel, corn starch, etc.; lubricants, such as magnesium stearate or Sterotex; glidants, such as colloidal silicon dioxide; sweeteners, such as sucrose or saccharin; flavorings, such as peppermint, peppermint, methyl salicylate or orange flavoring; and colorings. When the composition is in the form of a capsule, for example, a gelatin capsule, it may contain, in addition to materials of the above type, a liquid carrier such as polyethylene glycol or oil.

[0153] Said composition can be in the form of liquid, for example elixir, syrup, solution, emulsion or suspension.Liquid can be for oral administration or for delivery by injection, to name two examples.When intended for oral administration, preferred compositions contain one or more of the following besides the compound: sweetener, preservative, dye / colorant and flavor enhancer.Compositions intended for administration by injection can contain one or more of the following: surfactant, preservative, wetting agent, dispersant, suspending agent, buffer, stabilizer and isotonicity agent.

[0154] Liquid pharmaceutical compositions, whether in solution, suspension, or other similar form, may contain one or more of the following excipients: sterile diluents, such as water for injection, saline solution, preferably saline, Ringer's solution, isotonic sodium chloride, fixed oils, such as synthetic mono- or diglycerides, polyethylene glycols, glycerin, propylene glycol, and other solvents that can serve as solvents or suspending media; antibacterial agents, such as benzyl alcohol or methylparabens; antioxidants, such as ascorbic acid or sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid; buffers, such as acetates, citrates, or phosphate solutions, and agents for adjusting tonicity, such as sodium chloride or dextrose. Parenteral preparations can be enclosed in ampoules, disposable syringes, or multiple dose vials. Saline is the preferred excipient. Injectable pharmaceutical compositions are preferably sterile.

[0155] Liquid compositions intended for either parenteral or oral administration should contain an amount of the therapeutic agent described herein so that a suitable dosage will be obtained. The term "parenteral" includes subcutaneous, intravenous, intramuscular, intrasternal, or intraarterial injection or infusion. Typically, the therapeutic agent is at least 0.01% of the composition. When intended for oral administration, this amount can vary and be between about 0.1% and about 70% by weight of the composition. Certain oral pharmaceutical compositions contain about 4% to about 75% of the therapeutic agent.

[0156] The composition may be intended for external administration, in which case the carrier may suitably comprise a solution, emulsion, ointment or gel base. The base may, for example, comprise one or more of the following: petrolatum, lanolin, polyethylene glycol, beeswax, mineral oil, diluents such as water and alcohol, and emulsifiers and stabilizers. A thickener may be present in a composition for external administration. If intended for transdermal administration, the composition may comprise a transdermal patch or an iontophoresis device. The pharmaceutical composition may be intended for rectal administration, for example, in the form of a suppository that melts in the rectum and releases the drug. The composition for rectal administration may contain an oily base as a suitable non-irritating excipient. Such bases include, but are not limited to, lanolin, cocoa butter and polyethylene glycol.

[0157] The composition may contain various materials that modify the physical form of the solid or liquid dosage unit. For example, the composition may contain a material that forms a coating shell around the active ingredient. The material that forms the coating shell is typically inert and may be selected from, for example, sugar, shellac and other enteric coating agents. Alternatively, the active ingredient may be encapsulated in a gelatin capsule. The solid or liquid composition may contain an agent that binds to the therapeutic agent of the present disclosure and thereby aids in the delivery of the compound. Suitable agents that may act in this way include one or more proteins or liposomes.

[0158] The composition may essentially consist of a dosage unit that can be administered as an aerosol. The term aerosol is used to describe a variety of systems, from colloidal to systems consisting of pressurized packages. Delivery may be by liquefied or compressed gas, or by a suitable pump system that dispenses the active ingredient. The aerosol may be delivered in a single-phase, two-phase, or three-phase system to deliver the active ingredient. Delivery of the aerosol includes the necessary containers, activators, valves, subcontainers, etc., which may collectively form a kit. Those skilled in the art may determine the preferred aerosol without undue experimentation.

[0159] It will be understood that the compositions of the present disclosure also encompass carrier molecules for polynucleotides (e.g., lipid nanoparticles, nanoscale delivery platforms, etc.) as described herein.

[0160] Pharmaceutical compositions can be prepared by methodologies well known in the pharmaceutical field. For example, compositions intended for administration by injection can be prepared by mixing a composition comprising the therapeutic agent described herein and optionally one or more of salts, buffers and / or stabilizers with sterile distilled water to form a solution. Surfactants may be added to facilitate the formation of a homogeneous solution or suspension. Surfactants are compounds that non-covalently interact with the composition to facilitate dissolution or homogeneous suspension in aqueous delivery systems.

[0161] VI. Methods and Uses Further provided herein is a method of using the targeted complement activation molecule, polynucleotide, vector, host cell, or composition of the present disclosure for activating one or more complement pathways in a mammalian subject. In some embodiments, the classical complement pathway, the lectin complement pathway, or the alternative complement pathway is activated. In some embodiments, any two or all three of the complement pathways are activated. In some embodiments, the targeted complement activation molecule, polynucleotide, vector, host cell, or composition of the present disclosure can be used to induce complement-dependent cell death (CDC), complement-dependent cell-mediated cytotoxicity (CDCC), or complement-dependent cytophagocytosis (CDCP) of a target cell. Such a method includes contacting a target cell with the targeted complement activation molecule or a composition comprising the targeted complement activation molecule, wherein the contacting causes complement deposition on the target cell, thereby causing complement-mediated cell death.

[0162] Also provided herein is a method for treating cancer, autoimmune disease, or microbial infection in a subject, comprising administering to the subject a therapeutically effective amount of a targeted complement activating molecule or a composition comprising a targeted complement activating molecule. In some embodiments, the cancer is treated with a targeted complement activating molecule comprising a targeting domain that binds to a cancer antigen. In some embodiments, the cancer is a solid tumor cancer or a blood cancer. For example, the cancer can be brain cancer, bladder cancer, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, gastrointestinal cancer, liver cancer, renal cancer, lymphoma, leukemia, lung cancer, melanoma, metastatic melanoma, mesothelioma, myeloma, neuroblastoma, ovarian cancer, prostate cancer, pancreatic cancer, renal cancer, skin cancer, or uterine cancer. In some embodiments, the autoimmune disease is treated with a targeted complement activating molecule comprising a targeting domain that binds to a cell surface antigen on immune cells that cause the autoimmune disease. In some embodiments, the immune cells are B cells or T cells. In some embodiments, the autoimmune disease is rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, autoimmune diabetes, autoimmune encephalitis, pemphigus vulgaris, vasculitis, Sjogren's syndrome, or myasthenia gravis. In some embodiments, the microbial infection is treated with a targeted complement activating molecule that includes a targeting domain that binds to an antigen present on the surface of a microbial pathogen or on a cell infected with a microbial pathogen. In some embodiments, the infection is a bacterial infection, a viral infection, a fungal infection, or a parasitic infection. In some embodiments, the bacterial pathogen is Neisseria meningitidis, Staphylococcus aureus, Borrelia burgdorferi, Escherichia coli, Klebsiella pneumoniae, Streptococcus pneumoniae, Serratia marcencens, Haemophilus influenzae, Mycobacterium tuberculosis, Treponema pallidum, Neisseria gonorrhoeae, Clostridium difficile, Salmonella spp., Helicobacter spp., Shigella spp., Campylobacter spp., or Listeria spp. In some embodiments, the viral pathogen is Epstein-Barr virus, human immunodeficiency virus 1 (HIV-1), herpes virus, influenza virus, West Nile virus, or cytomegalovirus.In some embodiments, the fungal pathogen is Candida albicans or Aspergillus species. In some embodiments, the parasitic pathogen is Schistosoma mansoni, Plasmodium falciparum, or Trypanosoma krusei.

[0163] Provided herein is the use of the targeted complement activation molecule, polynucleotide, vector, host cell, or composition of the present disclosure for treating cancer, autoimmune disease, or microbial infection.In some embodiments, the targeted complement activation molecule for use in treating cancer comprises a targeting domain that binds to a cancer antigen.In some embodiments, the cancer is a solid tumor cancer or a blood cancer.For example, the cancer can be brain cancer, bladder cancer, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, gastrointestinal cancer, liver cancer, renal cancer, lymphoma, leukemia, lung cancer, melanoma, metastatic melanoma, mesothelioma, myeloma, neuroblastoma, ovarian cancer, prostate cancer, pancreatic cancer, renal cancer, skin cancer, or uterine cancer.In some embodiments, the targeted complement activation molecule for use in treating autoimmune disease comprises a targeting domain that binds to an autoimmune-related antigen. In some embodiments, the autoimmune disease is rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, autoimmune diabetes, autoimmune encephalitis, pemphigus vulgaris, vasculitis, Sjogren's syndrome, or myasthenia gravis. In some embodiments, the targeted complement activating molecule for use in treating a microbial infection comprises a targeting domain that binds to an antigen present on the surface of a microbial pathogen or on a cell infected with a microbial pathogen. In some embodiments, the infection is a bacterial infection, a viral infection, a fungal infection, or a parasitic infection. In some embodiments, the bacterial pathogen is Neisseria meningitidis, Staphylococcus aureus, Borrelia burgdorferi, Escherichia coli, Klebsiella pneumoniae, Streptococcus pneumoniae, Serratia marcencens, Haemophilus influenzae, Mycobacterium tuberculosis, Treponema pallidum, Neisseria gonorrhoeae, Clostridium difficile, Salmonella spp., Helicobacter spp., Shigella spp., Campylobacter spp., or Listeria spp. In some embodiments, the viral pathogen is Epstein-Barr virus, human immunodeficiency virus 1 (HIV-1), herpes virus, influenza virus, West Nile virus, or cytomegalovirus. In some embodiments, the fungal pathogen is Candida albicans or Aspergillus species.In some embodiments, the parasitic pathogen is Schistosoma mansoni, Plasmodium falciparum, or Trypanosoma krusei.

[0164] Provided herein is a targeted complement activation molecule, polynucleotide, vector, host cell, or composition of the present disclosure for use in the manufacture of a medicament for treating cancer, autoimmune disease, or microbial infection.In some embodiments, the medicament for treating cancer comprises a targeted complement activation molecule that comprises a targeting domain that binds to a cancer antigen.In some embodiments, the cancer is a solid tumor cancer or a blood cancer.For example, the cancer can be brain cancer, bladder cancer, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, gastrointestinal cancer, liver cancer, renal cancer, lymphoma, leukemia, lung cancer, melanoma, metastatic melanoma, mesothelioma, myeloma, neuroblastoma, ovarian cancer, prostate cancer, pancreatic cancer, renal cancer, skin cancer, or uterine cancer.In some embodiments, the medicament for treating autoimmune disease comprises a targeted complement activation molecule that comprises a targeting domain that binds to an autoimmune-related antigen. In some embodiments, the autoimmune disease is rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, autoimmune diabetes, autoimmune encephalitis, pemphigus vulgaris, vasculitis, Sjogren's syndrome, or myasthenia gravis. In some embodiments, the medicament for treating a microbial infection comprises a targeted complement activation molecule comprising a targeting domain that binds to an antigen present on the surface of a microbial pathogen or on a cell infected with a microbial pathogen. In some embodiments, the microbial infection is a bacterial infection, a viral infection, a fungal infection, or a parasitic infection. In some embodiments, the bacterial pathogen is Neisseria meningitidis, Staphylococcus aureus, Borrelia burgdorferi, Escherichia coli, Klebsiella pneumoniae, Streptococcus pneumoniae, Serratia marcencens, Haemophilus influenzae, Mycobacterium tuberculosis, Treponema pallidum, Neisseria gonorrhoeae, Clostridium difficile, Salmonella spp., Helicobacter spp., Shigella spp., Campylobacter spp., or Listeria spp. In some embodiments, the viral pathogen is Epstein-Barr virus, human immunodeficiency virus 1 (HIV-1), herpes virus, influenza virus, West Nile virus, or cytomegalovirus. In some embodiments, the fungal pathogen is Candida albicans or Aspergillus species.In some embodiments, the parasitic pathogen is Schistosoma mansoni, Plasmodium falciparum, or Trypanosoma krusei.

[0165] The targeted complement activating molecule or composition of the present disclosure can be administered by any suitable route, including oral, topical, transdermal, sublingual, buccal, subcutaneous, intramuscular, intravenous, intraarterial, or inhalant.The targeted complement activating molecule or composition of the present disclosure is administered in a therapeutically effective amount. This amount will vary depending on a variety of factors, including the specific molecule used, its metabolic stability and duration of action, the subject's age, sex, weight, general health and diet, mode and time of administration, excretion rate, any additional therapeutic agents administered to the subject in the same time frame, the severity of the specific injury or disease, and the subject's genetic or epigenetic makeup.In certain embodiments, the targeted complement activating molecule or composition is administered to the subject 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 times or more. The successive administrations can be carried out at any interval, for example, about 6, about 12, about 24, about 36, about 48, about 74, about 96, or about 108 hours or more apart.

[0166] In some embodiments, the targeted complement activating molecule, polynucleotide, vector, host cell, or composition of the present disclosure is combined with other therapeutic agents. Such combination therapy may include administration of a single pharmaceutical dosage formulation containing the targeted complement activating molecule or composition of the present disclosure together with one or more additional therapeutic agents, or the targeted complement activating molecule or composition of the present disclosure and the additional therapeutic agent may each be administered as a separate dosage formulation. When separate dosage formulations are used, the targeted complement activating molecule or composition of the present disclosure and the additional therapeutic agent may be administered essentially at the same time, i.e., simultaneously, or at separate times, i.e., sequentially in any order. In some embodiments, combination therapy may include administration of two or more different targeted complement activating molecules of the present disclosure, or two or more compositions, each of which includes a different targeted complement activating molecule of the present disclosure.

[0167] VII. Sequence The sequences referred to within this specification are summarized in Table 3.

[0168] [Table 3] TIFF2024540844000003.tif230156TIFF2024540844000004.tif230156TIFF2024540844000005.tif230156TIFF2024540844000006.tif230156TIFF2024540844000007.tif230156TIFF2024540844000008.tif230156TIFF2024540844000009.tif230156TIFF2024540844000010.tif232156TIFF2024540844000011.tif232156TIFF2024540844000012.tif230156TIFF2024540844000013.tif224156TIFF2024540844000014.tif230156TIFF2024540844000015.tif230156TIFF2024540844000016.tif230156TIFF2024540844000017.tif224156TIFF2024540844000018.tif230156TIFF2024540844000019.tif229156TIFF2024540844000020.tif219156TIFF2024540844000021.tif219156TIFF2024540844000022.tif224156TIFF2024540844000023.tif224156TIFF2024540844000024.tif229156TIFF2024540844000025.tif219156TIFF2024540844000026.tif224156TIFF2024540844000027.tif214156TIFF2024540844000028.tif230156TIFF2024540844000029.tif230156TIFF2024540844000030.tif225156TIFF2024540844000031.tif230156TIFF2024540844000032.tif230156TIFF2024540844000033.tif231156TIFF2024540844000034.tif230156TIFF2024540844000035.tif230156TIFF2024540844000036.tif225156TIFF2024540844000037.tif231156TIFF202 4540844000038.tif230156TIFF2024540844000039.tif230156TIFF2024540844000040.ti f230156TIFF2024540844000041.tif230156TIFF2024540844000042.tif232156TIFF20245 40844000043.tif230156TIFF2024540844000044.tif230156TIFF2024540844000045.tif2 30156TIFF2024540844000046.tif230156TIFF2024540844000047.tif230156TIFF2024540 844000048.tif230156TIFF2024540844000049.tif230156TIFF2024540844000050.tif230 156TIFF2024540844000051.tif230156TIFF2024540844000052.tif230156TIFF202454084 4000053.tif230156TIFF2024540844000054.tif230156TIFF2024540844000055.tif79156. EXAMPLES

[0169] VIII. Working Examples Example 1 Preparation of Rituximab-derived targeted complement-activating molecules MASP fusion The C-terminal catalytic segments of MASP-1, MASP-2 and MASP-3, CCP1-CCP2-SP domains, were fused to the anti-CD20 antibody rituximab (RTX; IgG1 isotype) in various configurations and the fusion proteins were expressed using the expression vector pCAG, a modified version of pD2610-v1 (ATUM; originally from (Miyazaki et al., 1989)), which contains the characteristic CMV and chicken beta-actin hybrid promoters and a kanamycin resistance marker.

[0170] The fusion sites were either at the C-terminus or N-terminus of the antibody heavy chain (HC-CCP1 / 2SP or CCP1 / 2SP-HC, respectively) or at the C-terminus or N-terminus of the antibody light chain (LC-CCP1 / 2SP or CCP1 / 2SP-LC, respectively), resulting in the following different constructs: M3-RTX(H) (SEQ ID NO:13), RTX(L)-M3 (SEQ ID NO:14), M3-RTX(L) (SEQ ID NO:15), RTX(H)-M2 (SEQ ID NO:4), M2-RTX(H) (SEQ ID NO:6), RTX(L)-M2 (SEQ ID NO:7), and M2-RTX(L) (SEQ ID NO:8). The MASP-1 fusions include fusions with single substitutions in the serine protease domain intended to improve stability compared to the wild-type serine protease sequence. Additionally, one MASP-1 fusion incorporates a rituximab heavy chain with a deleted lysine (K) from its C-terminus: RTX(H). ΔK -M1 R504Q (SEQ ID NO:16) and M1 R504Q -RTX(L) (SEQ ID NO:17). Additionally, mutant versions of constructs RTX(H)-M2 and RTX(H)-M3 were generated that were modified by deleting a single amino acid lysine (K) from the C-terminus of the heavy chain of rituximab to produce constructs RTX(H) ΔK -M2 (SEQ ID NO: 5) and RTX (H) ΔK-M3 (SEQ ID NO: 12). A catalytically inactive version of the MASP-2 fusion was generated by introducing a single substitution in the serine protease domain: RTX(H). ΔK -M2 S633A (SEQ ID NO:11). A constitutive zymogen form of the MASP-2 fusion was also generated: RTX(H). ΔK -M2 R444Q (SEQ ID NO:10). We also generated a MASP-2 fusion that has slower activation kinetics than the wild type: RTX(H). ΔK -M2 R444K (SEQ ID NO:9).

[0171] As part of an effort to identify molecules with increased stability / reduced degradation, we also produced additional molecules with one or two single amino acid substitutions in the MASP-2 serine protease domain: RTX(H). ΔK -M2 R444K (SEQ ID NO:9), RTX(H) ΔK,K121Q -M2 R444K (SEQ ID NO:33), RTX(H) ΔK -M2 K317Q,R444K (SEQ ID NO:34), RTX(H) ΔK -M2 K321Q,R444K (SEQ ID NO:35), RTX(H) ΔK -M2 K342Q,R444K (SEQ ID NO:36), RTX(H) ΔK -M2 K350Q,R444K (SEQ ID NO:37), and RTX(H) ΔK -M2 R356Q,R444K (SEQ ID NO:38).

[0172] C1r and C1s fusions Similar to the MASP fusions, the C1r and C1s serine protease effector domains were fused to RTX and expressed. The C-terminal catalytic fragments of C1r and C1s (CCP1-CCP2-SP) were fused to RTX at the C-terminus of the antibody heavy chain (HC).

[0173] For each complement component, three constructs were generated including a "wild type" form, an aglycosylated form with a single substitution in the Fc region of the antibody, and a catalytically inactive fusion with a single substitution in the serine protease domain: RTX(H). ΔK -C1r (SEQ ID NO: 18), RTX (H) N297G,ΔK -C1r (SEQ ID NO: 21), RTX (H) N297G,ΔK -C1r S654A (SEQ ID NO:22), RTX(H) ΔK -C1s (SEQ ID NO: 19), RTX (H) N297G,ΔK -C1s (SEQ ID NO: 23), and RTX (H) N297,ΔK -C1s S632A (SEQ ID NO:24).

[0174] As part of an effort to identify molecules with increased stability / reduced degradation, additional molecules were also produced with one of several single amino acid substitutions in the serine protease domain: RTX(H). N297G,ΔK -C1r K374Q (SEQ ID NO:39), RTX(H) N297G,ΔK -C1r R380Q (SEQ ID NO:40), RTX(H) N297G,ΔK -C1s K308Q (SEQ ID NO:41), RTX(H) N297G,ΔK -C1s K310Q (SEQ ID NO:42), RTX(H) N297G,ΔK -C1s R314Q (SEQ ID NO:43), RTX(H) N297G,ΔK -C1s R331Q (SEQ ID NO:44), RTX(H) N297G,ΔK -C1s K346Q (SEQ ID NO:45), RTX(H) N297G,ΔK -C1s K351Q (SEQ ID NO:46), RTX(H) N297G,ΔK -C1s K353Q (SEQ ID NO:47), RTX(H) N297G,ΔK -C1r H484W(SEQ ID NO:48), RTX(H) N297G,ΔK -C1r G485W (SEQ ID NO:49), RTX(H) N297G,ΔK -C1r R486W (SEQ ID NO:50), RTX(H) N297G,ΔK -C1s D456W (SEQ ID NO:51), RTX(H) N297G,ΔK -C1s N457W (SEQ ID NO:52), and RTX(H) N297G,ΔK -C1s P458W (SEQ ID NO:53).

[0175] Fusions with other complement components The catalytic segments of complement factors C2 (C2a), B (Bb) and D were fused to RTX and expressed by using the expression vector pCAG.

[0176] Pro and mature CFD fusions of various configurations were generated. The CFD was fused to either the C-terminus or the N-terminus of the antibody heavy or light chain, resulting in the following constructs: RTX(H) ΔK - MatCFD (SEQ ID NO: 27), MatCFD-RTX(H) (SEQ ID NO: 28), RTX(L)-MatCFD (SEQ ID NO: 29), MatCFD-RTX(L) (SEQ ID NO: 30) and ProCFD-RTX(H) (SEQ ID NO: 32). A catalytically inactive version with a single point mutation in the serine protease domain was also generated: MatCFD S208A -RTX(H) (SEQ ID NO:31).

[0177] For the C2a and Bb fusions, one configuration was generated in which the catalytic segment was fused to the C-terminus of the antibody heavy chain: RTX(H). ΔK -C2a (SEQ ID NO:25) and RTX(H) ΔK -Bb (SEQ ID NO:26).

[0178] The configurations of the various rituximab fusions are detailed in Table 1.

[0179] [Table 1] TIFF2024540844000057.tif236156TIFF2024540844000058.tif236156

[0180] Plasmid preparation and cloning To generate the recombinant fusion protein construct, the following steps were performed: (i) digestion of the plasmid vector, (ii) cloning of the insert, and (iii) transformation into E. coli competent cells.

[0181] For cloning, the vector pCAG was linearized by digestion with the restriction enzyme SapI (NEB). For digestion in a 50 μL reaction, 3 μg of vector, 2 μL of endonuclease and 5 μL of CutSmart buffer (NEB) were used. Restriction digestion was carried out at 37° C. for approximately 2 hours.

[0182] The following constructs were made to produce MASP-3, MASP-2, MASP-1, C1r, C1s, CFD, C2a, and Bb fusions: (i) HC of rituximab; (ii) LC of rituximab, and (iii) a) the C-terminus of RTX HC; b) the N-terminus of RTX HC; c) the C-terminus of the RTX LC; d) N-terminus of RTX LC The catalytic segment of a complement protein is fused to either

[0183] PCR of the insert was performed with specific primers, 5x Phusion HF buffer (NEB), dNTPs, and Phusion DNA polymerase using the following thermocycling conditions: Initial denaturation: 98℃ for 30 seconds, Denaturation: 98°C for 10 seconds, Annealing: 60°C for 30 seconds, Extension: 72°C for 40 seconds, Further extension: 72°C for 5 min.

[0184] PCR was performed for 30 cycles. After insert amplification, the PCR reaction was monitored by gel electrophoresis and the product was purified using a NucleoSpin purification kit (Macherey-Nagel). A 5 μL cloning reaction with linearized vector, purified insert, and 5× In-Fusion HD enzyme premix (Takara Bio) was then performed at 50°C for 15 min.

[0185] Expression constructs used for the production of recombinant fusion proteins were transformed into competent E. coli cells (One Shot Mach1 T1 Phage-Resistant Chemically Competent E. coli, Invitrogen) and selected on kanamycin LB agar plates. 10 ng of plasmid was added to a vial of competent cells and the cells were incubated on ice for 30 min. The mixture was then heat shocked at 42°C for 30 s and then incubated on ice for 2 min. 250 μL of SOC medium was added to the vial and the cells were incubated at 37°C for 1 h in a shaking incubator at 225 rpm. 100 μL of this culture was plated on kanamycin-containing plates and grown overnight at 37°C. From the plates, single transformed colonies were selected and grown in their resistant antibiotic (25 μg / mL) and 2.5 mL LB in a 37°C shaker. The next day, plasmid DNA was extracted from a portion of the culture using a Qiagen Plasmid Miniprep Kit, and the remaining portion of the 1 mL culture was stored at 4°C for future use. Plasmid DNA was sequenced to ensure successful cloning, and selected clones were grown for 1 hour in a 37°C shaker and incubated in 120 mL broth containing kanamycin (Teknova). After overnight growth at 37°C, plasmid DNA was extracted using a Qiagen Plasmid Maxiprep Kit.

[0186] Protein expression and purification Expi293 cells were cultured in Expi293 medium (Gibco) and 2.9 × 10 6 The cells were prepared at a cell density of 1000 cells / mL. The concentration of purified plasmid DNA was measured and DNA was prepared at a 1:2 HC:LC ratio for transfection. A total of 500 μg of DNA was used for 500 mL of transfection. DNA was suspended in OptiMEM (Gibco) and mixed with Lipofectamine (Invitrogen). After 20 min of incubation at room temperature, the DNA and Lipofectamine mixture was added to the cells. Transfected cells were cultured at 125 rpm in a 37°C shaker for 4–5 days. Approximately 18 h after transfection, enhancer (ExpiFectamine 293 Transfection Kit, Gibco) was added to enhance cell viability and protein expression. 2.5 mL of Enhancer-1 and 25 mL of Enhancer-2 were used for a total culture volume of 500 mL.

[0187] For most recombinant fusion proteins, transfected cells were cultured at 37° C. For the fusion proteins Rituximab-MASP-3 (LC-CCP12SP) and MASP-3-Rituximab (CCP12SP-LC), a lower temperature (32.5° C.) was tested during culture to see if lowering the temperature would reduce protein aggregation.

[0188] After 4–5 days of incubation at 37°C, transfected cells were removed and culture supernatants were filtered using a Sartoclear Dynamics lab kit (Sartorius). All fusion proteins were purified with protein A sepharose. After filtration of the supernatant, protein A sepharose was added and the mixture was incubated for 2 h at room temperature on a rotary incubator to maximize protein binding. The mixture was then loaded onto a chromatography column (Bio-Rad). After 2.5 washes with 19 mL of 1× PBS (Gibco), proteins were eluted with 15 mL of pH 3 glycine buffer (Teknova) and neutralized with 3 mL of pH 9 Tris-HCl buffer (Teknova). Purification was completed by concentration using centrifugal filter units (MilliporeSigma Amicon ultracentrifugation units) and buffer exchange into PBS or histidine buffer (20 mM histidine, 150 mM NaCl) (storage buffer).

[0189] The expression yield (mg / mL) of each protein is shown in Table 2.

[0190] [Table 2] TIFF2024540844000060.tif230150TIFF2024540844000061.tif50150

[0191] Example 2 Analysis of Rituximab-derived expressed proteins Protein Integrity SDS-PAGE was performed to assess protein integrity. Subunits of each protein were separated using 4–12% gradient polyacrylamide gels (NuPAGE Bis-Tris gels, Invitrogen), and molecular weight markers (SeeBlue Plus 2, Invitrogen) were used to estimate polypeptide size. SDS-PAGE was performed under both reducing and non-reducing conditions. Gels were run in running buffer (MOPS SDS running buffer, NuPage) at 120 V for 40 min, then stained with staining solution (SimplyBlue SafeStain, Invitrogen) for 1 h on a shaking rotator and then destained overnight.

[0192] Ab-MASP-2 fusions express RTX(H) in its inactive or zymogen form due to mutations. ΔK -M2 S633A and RTX(H) ΔK -M2 R444Q All except for MASP-2 were observed to be degraded to some extent in their active forms. In contrast to MASP-2, the MASP-3 fusion was produced in its zymogen form, and no degradation products were detected (see Figure 4). Furthermore, SDS-PAGE analysis was performed on Ab-MASP-3 fusion proteins incubated at reduced temperatures during expression. For comparison, Ab-MASP-3 proteins incubated at 37°C were included. Incubation at reduced temperatures was performed to reduce aggregates formed during expression. SDS-PAGE analysis under reducing and non-reducing conditions did not reveal any degradation of the MASP-3 fusion protein, nor any differences between the proteins incubated under different conditions (data not shown).

[0193] The Ab-C1r and Ab-C1s fusions were also found to have trace amounts of degradation products, but not the Ab-C2a, Ab-Bb or Ab-CFD fusions, which showed intact protein bands upon SDS-PAGE analysis (see Figure 5).

[0194] Activation of MASP-3 serine protease activity SDS-PAGE analysis of the Ab-MASP-3 fusion showed that the protein was in the zymogen form with no detectable degradation products, see FIG.

[0195] Activation of RTX-M3 protein was performed with truncated MASP-2 (CCP1 / 2SP) and subsequent SDS-PAGE analysis was performed under reducing conditions to confirm the conversion of MASP-3 fusion protein from zymogen form to active truncated form. Activation of MASP-3 fusion was performed based on the report by Oroszlan et al., 2017. Zymogen RTX-M3 (2 μM) was diluted in 140 mM NaCl, 10 mM HEPES, pH 7.4, 0.1 mM EDTA buffer and incubated at 37 °C alone (negative control) or with the addition of MASP-2 (CCP1 / 2SP) (91 nM) at various time points (0, 10, 20, 40, 60, 90, 120, 150 and 190 min). Samples were removed at each time point and placed at -20 °C to stop the reaction. Samples were analyzed by SDS-PAGE under reducing conditions.

[0196] Assays demonstrated that the recombinant MASP-3 fusion can be activated by another serine protease and become functional. The zymogen RTX-M3 fusion polypeptide migrates at approximately 92 kDa, while the active form gives two bands, RTX-M3 (CCP1 / 2) and the cleaved SP domain. See Figure 6.

[0197] agglomeration Size exclusion chromatography was performed to assess the aggregation of recombinant MASP-3 fusion proteins using an AKTA (GE Healthcare). To separate proteins by size, 200 μg of sample diluted in His buffer (20 mM histidine, 150 mM NaCl) was injected and passed through the column (Superdex 200 Increase 5 / 150 GL column). The proteins analyzed were the rituximab heavy chain fusion rituximab-MASP-3 (RTX(H) ΔKThe rituximab light chain fusions rituximab-MASP-3 (RTX(L)-M3) and MASP-3-rituximab (M3-RTX(H)), as well as the rituximab light chain fusions rituximab-MASP-3 (RTX(L)-M3) and MASP-3-rituximab (M3-RTX(L)). The latter two proteins were expressed at two different temperatures (37°C and 32.5°C).

[0198] This analysis showed that RTX(H) incubated at 37°C ΔK -M3 and M3-RTX(H) showed greater than 10% aggregation. Analysis of RTX(L)-M3 and M3-RTX(L) grown at 37°C or 32.5°C showed approximately two-fold higher aggregation levels and approximately one-third reduction in expression yield at the lower growth temperature (data not shown).

[0199] Example 3 Binding of Rituximab-derived targeted complement-activating molecules to targets Flow cytometry The binding of certain targeted complement activation molecules to CD20 expressed on the cell surface was evaluated using flow cytometry. First, the expression levels of CD20 were examined in three cell lines, human Burkitt lymphoma line Ramos (ATCC), large cell lymphoma line SU-DHL-8 (ATCC), and acute lymphoblastic leukemia line Kasumi-2 (DSMZ). All cell lines were maintained at 37°C in RPMI 1640 medium [-]L-glutamine supplemented with 10% heat-inactivated FBS and GlutaMax (Gibco). Approximately 500,000 cells were harvested and resuspended in FACS buffer (PBS containing 2% FBS and 0.05% sodium azide). To prevent nonspecific binding, 5 μL of blocking solution (FcR binding inhibitor, eBioscience) was added to 100 μL of cell suspension and then incubated at room temperature for 15 min. A primary antibody targeting CD20 (rituximab) was added to the cell suspension. After 20 min incubation on ice, the cells were washed twice and resuspended in FACS buffer containing the secondary antibody, anti-human IgG Fc Ab conjugated with Alexa Fluor 647 (clone HP6017, Biolegend). The cells were incubated for 20 min on ice, then washed three times and resuspended in FACS buffer. Finally, a sample of the stained cells was analyzed on a FACSCalibur. The results are shown in the left column of Figure 2.

[0200] For the assay of CD20 binding by targeted complement activation molecules containing the rituximab binding domain, the human Burkitt's lymphoma line Ramos (ATCC) was selected. Cells were maintained at 37°C in RPMI 1640 medium [-]L-glutamine supplemented with 10% heat-inactivated FBS and GlutaMax (Gibco). Approximately 500,000 cells were harvested and resuspended in FACS buffer (PBS containing 2% FBS and 0.05% sodium azide). To prevent non-specific binding, 5 μL of blocking solution (Fc binding inhibitor, eBioscience) was added to 100 μL of cell suspension, followed by incubation for 15 min at room temperature. Primary antibodies targeting CD20 were added to the cell suspension. These antibodies included rituximab (anti-CD20 mAb) and recombinant targeted complement activation molecules M2-RTX(H), RTX(L)-M2, M2-RTX(L), RTX(H) ΔK -M3, M3-RTX(H), RTX(L)-M3, M3-RTX(L), RTX(H) ΔK -MatCFD, MatCFD-RTX(H), RTX(L)-MatCFD, and MatCFD-RTX(L), as well as the catalytically inactive construct RTX(H) ΔK -M2 S633A After 20 min incubation on ice, cells were washed twice and resuspended in FACS buffer containing the secondary antibody, anti-human IgG Fc Ab conjugated with Alexa Fluor 647 (clone HP6017, Biolegend). Cells were incubated for 20 min on ice, then washed three times and resuspended in FACS buffer. Finally, samples of stained cells were analyzed on a FACSCalibur.

[0201] FACS analysis showed that all C-terminal protein fusions bound to CD20 on the cell surface, whereas among the N-terminal configurations, only M2-RTX(H) and MatCFD-RTX(H) bound to CD20 on the cell surface. See Figure 9.

[0202] Biolayer Interferometry To analyze the binding kinetics of recombinant targeted complement activating molecules to the target CD20 (Acro Biosystems), biolayer interferometry was performed using the Octet RED96 system (ForteBio Inc.) with recombinant targeted complement activating molecule RTX(H) diluted to a concentration of 69 nM in kinetic buffer (PBS, 0.02% Tween 20, 0.1% BSA, 0.05% DDM, 0.01% CHS) using anti-hIgG Fc(AHC) (ForteBio Inc.). ΔK -C1r, RTX(H) ΔK -C1s, ProCFD-RTX(H), RTX(H) ΔK -M2 R444K , or RTX(H) ΔK -M3 was loaded and added to one column of the assay plate. Various concentrations of CD20 were tested. Antigen was diluted in kinetic buffer in two-fold serial dilutions starting at 200 nM and added to one column. A regeneration step is required to dissociate the protein from the biosensor in order to load the next test sample. For this, regeneration buffer (10 mM glycine pH 1.6) was added to one column of the assay plate and kinetic buffer was added to another column for neutralization. Protein binding kinetics were analyzed using Octet CFR software (ForteBio Inc.).

[0203] All of the targeted complement-activating molecules tested were shown to bind to the antigen CD20 in a dose-dependent manner. The calculated equilibrium constants (K D ) are: RTX<1.00E-12M, OBZ 5.03E-09M, RTX(H) ΔK -M3 8.03E-10M, RTX ΔK -M2 R444K 2.89E-10M, RTX(H) ΔK -C1r 6.30E-11M, RTX(H) ΔK -C1s 7.31E-10M, and ProCFD-RTX(H) 3.20E-10M. See Figure 10 and Table 4.

[0204] [Table 4]

[0205] Example 4 Activity of Rituximab-derived Targeted Complement-activating Molecules Serine protease activity Substrate cleavage activation assays of various targeted complement activation molecules were performed using complement components C4 and C3 as substrates. Substrates were diluted in PBS (1x), pH 7.4, and incubated alone or with RTX (H). ΔK -C1r, RTX(H) ΔK -C1s, RTX(H) ΔK -M3, proCFD-RTX(H), RTX(H) ΔK -M2 R444K , RTX(H) ΔK -C2a or RTX(H) ΔK One of the -Bbs was added at an enzyme / substrate ratio of 1:20 and incubated at 37° C. Samples were removed after 3 hours and analyzed by SDS-PAGE under reducing conditions to detect either C4 or C3 cleavage. The results are shown in FIG. 11A (C4 substrate) and FIG. 11B (C3 substrate).

[0206] The enzymatic activity of Ab-protease fusions was measured in microtiter plates based on the cleavage of fluorogenic or chromogenic synthetic peptide substrates. Recombinant fusion proteins were incubated with the appropriate synthetic peptide substrate (5-200 μM depending on the enzyme) in assay buffer (20 mM HEPES pH 7.4, 140 mM NaCl, 0.1% Tween 20 for fluorometric assays, 50 mM Tris pH 7.5, 1 M NaCl for colorimetric assays) at room temperature. The change in fluorescence or absorbance was monitored for 20 min and the enzyme activity was calculated from the initial rate of change and expressed as RU / min / μmol enzyme catalytic sites to allow comparison with purified enzyme controls. The results are shown in Table 5.

[0207] [Table 5]

[0208] C4 deposition assay In the lectin pathway of the complement system, the serine protease MASP-2 activates the complement cascade by cleaving the proteins C4 and C2. Activation of C4 leads to C4b deposition on the surface of target cells. This cleavage activity is shared with the C1 complex of the classical pathway. Therefore, the functional activity of MASP-2, C1r and C1s proteins was examined by C4 deposition assay. In the absence of MASP-2, the lectin pathway does not function, as shown in plasma from MASP-2-depleted human serum (Moller-Kristensen et al., 2007) and plasma from MASP-2 knockout mice (Schwaeble et al., 2011). Therefore, to prevent deposition from serine proteases in the plasma itself, the plasma used was collected from MASP-2 knockout mice. Activity in normal human serum was also tested. Those tested included a serum only control, a non-glycosylated antibody domain (to prevent C1q binding to the Fc region and initiation of classical pathway activity), and a negative control with a catalytically inactive molecule.

[0209] For mouse plasma assays, Nunc Maxisorp microtiter ELISA plates were coated with 100 μL of coating buffer (15 mM Na2CO3, 35 mM NaHCO3) containing mannan (50 μg / mL, Sigma-Aldrich, M7504) and / or recombinant targeted complement activating molecules (215 nM) and incubated overnight at 4°C. The next day, 250 μL of PBS buffer containing 1% BSA (Sigma-Aldrich, A3294) was added to each well and incubated for 2 h at room temperature to block remaining protein binding surfaces. The plates were washed three times with PBS containing 0.05% Tween 20 (wash buffer). Hirudin mouse plasma was diluted in PBS (calcium-free, magnesium-free) and added to the wells. The plates were incubated for 15 min at 4°C and washed three times.

[0210] To evaluate the deposition of C4 on the mannan surface, C4b was detected with a rat anti-C4 monoclonal antibody (16D2, Santa Cruz Biotechnology). 100 μL / well diluted in wash buffer to a final concentration of 0.2 μg / mL was added and the plate was agitated at 200 rpm at 37°C for 30 min. The plate was washed three times and 100 μL of secondary antibody was added. The secondary antibody used was goat anti-rat IgG (H+L) conjugated with alkaline phosphatase (AP) (cat. no. 3051-05, Southern Biotech), which was diluted in wash buffer to a final concentration of 0.043 μg / mL. The plate was incubated at room temperature for 30 min. Finally, 100 μL of the colorimetric substrate TMB (1-step Ultra TMB-ELIS, Thermo-Scientific, 34029) was added to the plate. The reaction was stopped by adding 100 μL of 0.1 N sulfuric acid (BDH7230-1), and the absorbance was measured at 450 nm using a plate reader.

[0211] For human serum assays, Nunc Maxisorp microtiter ELISA plates were coated with 100 μL of coating buffer (15 mM Na2CO3, 35 mM NaHCO3) containing recombinant fusion protein (69 nM) and incubated overnight at 4°C. The next day, 250 μL of PBS buffer containing 1% BSA (Sigma-Aldrich, A3294) was added to each well and incubated for 2 h at room temperature to block remaining protein binding surfaces. The plates were washed three times with PBS containing 0.05% Tween 20 (wash buffer). Normal human serum (NHS) was diluted in PBS (calcium-free, magnesium-free) and added to the wells. The plates were incubated for 10 min at 4°C and washed three times.

[0212] To evaluate the deposition of C4 on the mannan surface, C4b was detected with C4c polyclonal rabbit anti-human (Q0369, Dako). 100 μL / well diluted in wash buffer to a final concentration of 0.88 μg / mL was added and the plate was agitated at 200 rpm at 37°C for 30 min. The plate was washed three times and 100 μL of secondary antibody was added. The secondary antibody used was goat anti-heron IgG (H+L) conjugated with alkaline phosphatase (AP) (Lot No. G0710-V488D, Southern Biotech), which was diluted in wash buffer to a final concentration of 0.043 μg / mL. The plate was incubated at room temperature for 30 min. Finally, 100 μL of the colorimetric substrate TMB (1-step Ultra TMB-ELIS, Thermo-Scientific, 34029) was added to the plate. The reaction was stopped by adding 100 μL of 0.1 N sulfuric acid (BDH7230-1), and the absorbance was measured at 450 nm using a plate reader.

[0213] The results are shown in Figures 12A and 12B.

[0214] C3 deposition assay The role of MASP-3 in the alternative pathway of the complement system has recently been elucidated, showing that active MASP-3 converts pro-CFD to mature CFD (Dobo et al., 2016). Activated complement factor D (CFD) is a serine protease that cleaves factor B (FB) in the alternative pathway pro-convertase C3bB, resulting in the formation of the C3 convertase C3bBb. The C3 convertase cleaves C3 to generate C3b molecules, which are covalently attached to the cell surface. The formation of the C4bC2a convertase involves the participation of complement components of the classical and lectin pathways. Complement component C2 undergoes cleavage by MASP-1, MASP-2, C1r, and C1s, resulting in binding to C4b, leading to the C3 convertases of the classical and lectin pathways. The C3 convertase then cleaves C3 to generate C3b molecules, which are covalently attached to the surface (Figure 1). Therefore, the functional activity of all these serine proteases mentioned above can be assessed in a C3 deposition assay.To prevent C3 deposition by MASP-3 activity from plasma (Takahashi et al., 2008), plasma from MASP-1 / 3 knockout mice was used.

[0215] For mouse plasma assays, Nunc Maxisorp microtiter enzyme-linked immunosorbent assay plates were coated with 100 μL of zymosan (10 μg / mL) and / or recombinant targeted complement activating molecules (215 nM) suspended in coating buffer (15 mM Na2CO3, 35 mM NaHCO3) and then incubated overnight at 4 °C. The next day, 250 μL of 1% BSA (Sigma-Aldrich, A3294) in PBS buffer was added to each well and the plate was incubated at room temperature for 2 h before being washed with washing buffer. Hirudin mouse plasma was diluted in MgEGTA buffer (10 mM EGTA, 5 mM MgCl2, 5 mM barbital, 145 mM NaCl [pH 7.4]) and added to the wells. Plates were incubated at 37 °C for 50 min and washed three times.

[0216] For C3b detection on the surface, rabbit anti-human C3c antibody (Dako, lot number B298875) was used. This C3c antibody is capable of recognizing C3b. 100 μL / well ((2.4 μg / mL)) diluted in wash buffer was added and the plate was incubated for 30 min at 37° C. and 200 rpm. The plate was washed three times and 100 μL of secondary antibody goat anti-rabbit (Southern Biotech) conjugated with alkaline phosphatase (AP) diluted in wash buffer (0.043 μg / mL) was added to the plate. The plate was incubated for 30 min at room temperature. To determine C3 deposition, 100 μL of TMB (1-step Ultra TMB-ELIS, Thermo-Scientific, 34029) was added to the plate. The reaction was stopped by adding 100 μL of 0.1 N sulfuric acid (BDH7230-1), and the absorbance was measured at 450 nm using a plate reader.

[0217] For the human serum assay, Nunc Maxisorp microtiter enzyme-linked immunosorbent assay plates were coated with recombinant fusion protein (250 nM) suspended in coating buffer (15 mM Na2CO3, 35 mM NaHCO3) and then incubated overnight at 4 °C. The next day, 250 μL of 1% BSA (Sigma-Aldrich, A3294) in PBS buffer was added to each well and the plate was incubated at room temperature for 2 h and then washed with washing buffer. NHS was diluted in MgEGTA buffer (10 mM EGTA, 5 mM MgCl2, 5 mM barbital, 145 mM NaCl [pH 7.4]) and added to the wells. The plate was incubated at 37 °C for 25 min and washed three times. C3b detection was performed as for the mouse plasma assay.

[0218] The results are shown in Figure 13.

[0219] Complement deposition on target cells The targeted complement-activating molecules consist of two domains: a target-binding domain that binds to the target by the variable region (Fv) of the Fab fragment of the antibody, and a serine protease effector domain derived from a complement-activating serine protease. To evaluate the effect of the targeted complement-activating molecules as a whole, a complement component deposition assay was performed in CD20-positive cells. The acute lymphoblastic leukemia line Kasumi-2 (purchased from DSMZ) was used to study complement deposition on the cell surface after treatment with the targeted complement-activating molecules ProCFD-RTX(H) and MatCFD-RTX(H). Proteins at final concentrations of 12.5 nM and 1.4 nM were diluted in CDC assay buffer (RPMI 1640 medium [-] L-glutamine, 5% heat-inactivated FBS, GlutaMax and 25 mM HEPES). RTX and non-glycosylated forms were included as controls. Normal human serum (NHS) was also diluted in assay buffer to a final concentration of 15%. Cells were resuspended in assay buffer to a final concentration of 300,000 cells / mL and transferred to a 6-well assay plate, followed by the addition of diluted protein and human serum. The assay plate was incubated for 2 hours at 37°C in a humidified incubator. After treatment, cells were resuspended in FACS buffer (PBS containing 2% FBS and 0.05% sodium azide), blocked with blocking solution (Human TruStain FcX, Biolegend) (5 μL / 100 μL) to prevent non-specific binding, and stained with primary antibodies against complement components C3 or C5b-9 (MAC). Primary antibodies used (5 μg / mL) were rabbit anti-human C3c (A0062, Dako) and monoclonal mouse anti-human C5b-9 (M0777, Dako). After 20 min incubation on ice, cells were washed twice and resuspended in FACS buffer containing secondary antibodies (5 μL / 100 μL) APC anti-rabbit IgG (F0111, R&D Systems) and PE anti-mouse IgG (405307, BioLegend) that recognize C3 and C5b-9 antibodies, respectively. Cells were incubated for 20 min on ice, then washed three times and resuspended in FACS buffer.Finally, samples of stained cells were analyzed on a FACSCalibur.

[0220] CFD fusions, especially MatCFD fusions, induced significantly higher C3 and MAC deposition in target cells compared to serum alone or RTX treatment. The results are shown in Figure 14A (C3 deposition) and Figure 14B (MAC deposition).

[0221] Example 5 Cytotoxicity of targeted complement-activating molecules derived from rituximab CDC assay The Ramos B cell line expresses high levels of CD20, to which the antibody rituximab binds. Increased antigen density is involved in the initiation of the complement cascade, with antibody binding initiating the classical pathway. Similarly, active C1r and C1s serine proteases are activators of the classical pathway. The catalytic domains of MASP-1 and MASP-2 activate the lectin pathway, while the catalytic domains of MASP-3 and CFD activate the alternative pathway. C2 is an activator of the classical and lectin pathways, while factor B activates the alternative pathway.

[0222] All three pathways of the complement system lead to the formation of MAC on the surface of target cells, followed by cell lysis. It is predicted that activation of more than one complement pathway will lead to enhanced complement-dependent cytotoxicity (CDC). Therefore, targeted complement-activating molecules were tested for their ability to increase the levels of CDC that can result from activation of any two or more of the classical, lectin and alternative complement pathways.

[0223] Complement-dependent cytotoxicity (CDC) assays were performed using the CytoTox-Glo Cytotoxicity Assay Kit (Promega). Serial dilutions (highest concentration: 12.5 nM) of rituximab and targeted complement-activating molecules were prepared in assay buffer (RPMI1640, 5% heat-inactivated FBS, GlutaMax, 25 mM HEPES). Normal human serum (NHS) was also diluted in assay buffer to a final concentration of 15%. CD20+ cells were resuspended in assay buffer to a final concentration of 10,000 cells / well and transferred to a 96-well assay plate, followed by the addition of diluted proteins and human serum. The assay plate was incubated for 2 h at 37°C in a humidified incubator. After cooling at room temperature for 15 min, CytoTox-Glo reagent (Promega) was added and incubated for an additional 10 min. Finally, luminescence was measured using a microplate luminometer (Luminoskan Labsystems).

[0224] In some cases, CDC assays were performed using propidium iodide. Serial dilutions of rituximab and targeted complement-activating molecules were prepared in assay buffer (Opti-MEM cell culture medium, Gibco). Normal human serum (NHS) was also diluted in assay buffer to a final concentration of 10%. CD20+ cells were washed with PBS, resuspended in assay buffer to a final concentration of 150,000 cells / well, transferred to a 96-well assay plate, and then diluted proteins and human serum were added. The assay plate was incubated for 2 hours at 37°C in a humidified incubator. After incubation, 5 μL of propidium iodide (Invitrogen, Cat. No. 00-6990-50) was added and stained cells were immediately analyzed by flow cytometry using a FACSCalibur.

[0225] The results of the CytoTox-Glo assay are shown in Figures 16 to 18. The results of the propidium iodide assay are shown in Figure 19.

[0226] Inhibition of CD55 and CD59 To determine the possible influence of complement regulatory proteins (CRPs) on the CDC assay, additional assays were performed using CRP inhibitors: antibodies against CRP CD55 (clone BRIC 216, Sigma-Aldrich), antibodies against CRP CD59 (clone BRIX 229, IBGRL), or both were used to inhibit CD55 and / or CD59 activity in the assay.

[0227] Rituximab (RTX), Modified Rituximab (RTX N297G ), the targeted complement activation molecule MatCFD-RTX, and the targeted complement activation molecule MatCFD-RTX N297G Dilutions of the antibodies were prepared in assay buffer to a final concentration of 337.5 nM. Anti-CD55 antibodies were prepared in assay buffer to a final concentration of 10 μg / mL and anti-CD59 to a final concentration of 2 μg / mL. Normal human serum (NHS) was also diluted in assay buffer to a final concentration of 15%. Ramos cells were resuspended in assay buffer to a final concentration of 300,000 cells / well and transferred to a 96-well assay plate, followed by addition of anti-CRP, diluted RTX and targeted complement activating molecules, and human serum. The assay plate was incubated for 2 hours at 37°C in a humidified incubator. After incubation, 5 μL of propidium iodide (Invitrogen, Cat. No. 00-6990-50) was added and cells were immediately analyzed by flow cytometry using a FACSCalibur. Samples without anti-CRP antibodies were also processed as controls (no inhibitors).

[0228] When one or both CRPs were inhibited, MatCFD-RTX N297G was used to treat Ramos cells with RTX N297G Glycosylated RTX induced significantly higher CDC compared to MatCFD-RTX(H). Because glycosylated RTX already had high CDC, no further enhancement with MatCFD-RTX(H) was observed. The results are shown in Figure 20.

[0229] Example 6 Production of alemtuzumab and daratumumab fusion proteins Mature complement factor D (MatCFD) was fused to the anti-CD52 antibody alemtuzumab (ALM) or the anti-CD38 antibody daratumumab (DARA), and the fusion proteins were expressed using the expression vector pCAG, a modified version of pD2610-v1 (ATUM; originally from (Miyazaki et al., 1989)), which contains the unique CMV and chicken beta-actin hybrid promoters and a kanamycin resistance marker.

[0230] The MatCFD domain was fused to the N-terminus of the antibody heavy chain resulting in the following constructs: MatCFD-ALM(H) (SEQ ID NO:97) and MatCFD-DARA(H) (SEQ ID NO:98).

[0231] Plasmid preparation, cloning, protein expression and purification were carried out as described in Example 1.

[0232] Example 7 Binding of Alemtuzumab- and Daratumumab-Derived Targeted Complement-Activating Molecules to Targets Flow cytometry Flow cytometry was used to evaluate the binding of targeted complement activation molecules with the binding domain derived from alemtuzumab to CD52 expressed on the cell surface, and the binding of targeted complement activation molecules with the binding domain derived from daratumumab to CD38 expressed on the cell surface. Approximately 500,000 cells of the human B-cell lymphoma line HT (ATCC) were harvested and resuspended in FACS buffer. To prevent non-specific binding, 5 μl of blocking solution was added to 100 μl of the cell suspension, which was then incubated for 15 min at room temperature. The antibodies alemtuzumab (targeting CD52) and daratumumab (targeting CD38) or one of the targeted complement activation molecules MatCFD-ALM(H) or MatCFD-DARA(H) were added to the cell suspension and incubated on ice for 20 min. Cells were then washed twice and resuspended in FACS buffer containing secondary antibody (mouse anti-human IgG1 conjugated with Alexa Fluor 647). Cells were incubated on ice for 20 minutes, then washed three times and resuspended in FACS buffer. Samples of stained cells were analyzed by FACS (FACSCalibur).

[0233] FACS analysis showed that both ALM and the targeted complement activation molecule MatCFD-ALM(H) bind to CD52 on the surface of HT cells, and that both DARA and MatCFD-DARA(H) bind to CD38 on the surface of HT cells, see columns headed "CD52" and "CD38" in Figure 15.

[0234] Example 8 Activity of targeted complement-activating molecules derived from alemtuzumab and daratumumab C3 deposition Complement activation by the targeted complement activating molecules MatCFD-ALM(H) and MatCFD-DARA(H) was assessed by measuring C3b deposition on HT target cells. Normal human serum (NHS) was diluted in assay buffer to a final concentration of 15%. HT cells were resuspended in assay buffer to a final concentration of 300,000 cells / ml and transferred to a 6-well assay plate. Diluted protein and NHS were added to the wells. Plates were incubated for 2 hours at 37°C in a humidified incubator. Cells were then resuspended in FACS buffer, blocked to prevent non-specific binding, and stained with primary antibody (rabbit anti-human C3c). After 20 minutes of incubation on ice, cells were washed twice and resuspended in FACS buffer containing secondary antibody (APC anti-rabbit IgG). Cells were incubated for an additional 20 minutes on ice before being washed three times and resuspended in FACS buffer. Samples of stained cells were analyzed by FACS (FACSCalibur).

[0235] FACS analysis showed that treatment with MatCFD-ALM(H) or MatCFD-DARA(H) led to C3b deposition, see Figure 15, column headed "C3b".

[0236] Example 9 Preparation of targeted complement-activating molecules derived from anti-fHbP Using hybridoma technology, monoclonal antibodies against the meningococcal factor H binding protein (fHbP) were produced in mice and isolated. Three different mouse monoclonal antibodies were identified: anti-fHbP clone 5 (aN5), anti-fHbP clone 7 (aN7), and anti-fHbP clone 19 (aN19). The binding of each of these three antibodies to fHbP on the surface of an ELISA plate was tested. All three antibodies showed binding to fHbP under these conditions. See Figure 21, left panel. The binding of each of the three antibodies to Neisseria meningitidis was then tested on the surface of an ELISA plate. Clone 19 showed binding to Neisseria meningitidis under these conditions. See Figure 21, right panel.

[0237] Each of clones 5, 7 and 19 was sequenced and expressed as a recombinant mouse-human chimera. The binding of these chimeric versions to N. meningitidis was tested on the surface of an ELISA plate. Clone 19 showed binding to N. meningitidis under these conditions. See Figure 22.

[0238] The C1r and C1s serine protease effector domains were fused to one of three monoclonal antibodies that bind to the meningococcal factor H binding protein (fHbP). These fusion proteins were expressed using the expression vector pCAG similar to the proteins described in Example 1. The C1r and C1s C-terminal catalytic fragments (CCP1-CCP2-SP) were fused to anti-fHbP clone 5 (aN5), clone 7 (aN7) or clone 19 (aN19) at the C-terminus of an antibody heavy chain (HC) that was modified by deleting a single amino acid lysine (K) from the C-terminus. This process yielded the following constructs: aN7(H) ΔK -C1r (SEQ ID NO: 107), aN19 (H) ΔK -C1r (SEQ ID NO: 108), aN5 (H) ΔK -C1r (SEQ ID NO: 109), aN7 (H) ΔK -C1s (SEQ ID NO: 110), aN19 (H) ΔK -C1s (SEQ ID NO: 111), aN5 (H) ΔK -C1s (SEQ ID NO:112).

[0239] The following additional clone 19-derived targeted complement-activating molecules were also produced: aN19(H) ΔK -M2 R444K (SEQ ID NO:116), aN19(H) ΔK -M3(SEQ ID NO:117), MatCFD-aN19(H)(SEQ ID NO:118), ProCFD-aN19(H)(SEQ ID NO:119).

[0240] Plasmid preparation, cloning, protein expression and purification were carried out as described in Example 1.

[0241] Example 10 Binding of targeted complement-activating molecules derived from anti-fHbP to Neisseria meningitidis. Binding to Neisseria meningitidis was tested for each of the targeted complement activating molecules containing the clone 19 binding domain. Targeted complement activating molecule aN19(H) ΔK -C1r (also called clone 19-C1r) and aN19(H) ΔK -C1s (also referred to as clone 19-C1s) was tested together with monoclonal antibody clone 19. All three molecules showed binding to N. meningitidis. See FIG. 23.

[0242] Example 11 Activity of targeted complement-activating molecules derived from anti-fHbP Complement deposition activity Serum samples from 12 individuals were evaluated for fHbP antibody titers. The results are shown in Figure 24. Deposition of C5b-9 (MAC) by targeted complement activation molecules clone 19-C1s and clone 19-C1r was assayed using serum from individual "6" who showed the lowest fHbP antibody titers. Maxisorp polystyrene microtiter plates were coated with 100 μL of 10 μg / mL mannan or immune complex in carbonate buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6). Residual binding sites on the ELISA plate were blocked for 2 hours with 1 percent BSA (w / v) in TBS buffer (10 mM Tris-HCl, 140 mM NaCl, pH 7.4). The ELISA plate was then washed with TBS containing 0.05% (v / v) Tween 20 and 5 mM CaCl2. Human serum from individual "NL" was diluted in BBS and added to the plate, which was then incubated at 37°C for 1 hour. C5b-9 deposition was detected using anti-C5b-9 (Abcam) followed by peroxidase-conjugated goat anti-rabbit IgG. After 1 hour, the wells were washed and 100uL of 1-Step Ultra TMB solution (Thermo fisher scientific) was added to each well and incubated at room temperature for 5 minutes. The reaction was stopped by adding 2M H2SO4 and the optical density at 450nm was immediately measured. C5b-9 deposition by monoclonal antibody clone 19 and by serum alone were also measured as controls. Both clone 19-C1s and clone 19-C1r targeted complement activating molecules showed enhanced C5b-9 deposition compared to the control. See Figure 25.

[0243] Sera from individuals "1", "2", "5" and "Y" were used to assess deposition of C3b, C4b and C5b by the targeted complement activation molecule clone 19-C1r. Complement component deposition was assayed as described above for C5b using various serum concentrations. C3b and C4b deposition was assayed similarly using rabbit anti-C3c (Dako) or rabbit anti-C4c (Dako) as detection antibodies, respectively. Results are shown in Figure 27A (C3b deposition), Figure 27B (C4b deposition) and Figure 27C (C5b deposition).

[0244] Additional targeted complement-activating molecules were prepared that contained the clone 19 binding domain and domains derived from MASP-2, MASP-3, or factor D. These targeted complement-activating molecules were designated aN19(H), ΔK -M2 R444K (also called anti-fHbp-MASP-2), aN19(H) ΔK These targeted complement activating molecules, named MatCFD-aN19(H) (also called anti-fHbp-MASP-3) and MatCFD-aN19(H) (also called anti-fHbp-fD), were assayed for C3b deposition on the bacterial surface of N. meningiditis along with the clone 19-C1r (also called anti-fHbp-C1r) and clone 19-C1s (also called anti-fHbp-C1s) targeted complement activating molecules.

[0245] Maxisorp polystyrene microtiter ELISA plates were incubated with formalin-fixed meningococcal cells (OD ) in carbonate buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6). 600 =0.6). The next day, the wells were blocked with 5% nonfat milk in TBS buffer (10 mM Tris-HCl, 140 mM NaCl, pH 7.4) for 2 h and then washed with TBS buffer containing 0.05% (v / v) Tween 20 and 5 mM CaCl2. ++1% NHS or 5% mouse serum containing 150 nM of monospecific antibodies diluted in buffer (4 mM barbital, 145 mM NaCl, 2 mM CaCl2, 1 mM MgCl2, pH 7.4) were added to the plates and incubated for 5, 10, 15, 20 and 25 minutes at room temperature, then washed. C3b deposition was detected using rabbit anti-C3c (Dako) followed by peroxidase-conjugated goat anti-rabbit IgG. After 1 hour, the wells were washed, then 100 μL of 1-Step Ultra TMB solution (Thermo Fisher Scientific) was added to each well and incubated for 5 minutes at room temperature. The reaction was stopped by the addition of 2M H2SO4, and the optical density at 450 nm was immediately measured. The results are shown in Figure 28. The difference in C3b deposition between clone 19 (i.e., anti-fHbp) and anti-fHbp-C1r was found to be significant.

[0246] Serum bactericidal activity The targeted complement activating molecules clone 19-C1s and clone 19-C1r were evaluated for serum bactericidal activity. Meningococcus serogroup B (MC58) were grown on blood agar plates at 37°C and 5% CO2. The next day, cells were scraped and suspended in BBS (4mM barbital, 145mM NaCl, 2mM CaCl2, 1mM MgCl2, pH 7.4). 1500 cells were incubated with 25% normal human serum from individual "1" (Figure 26A, top row), individual "2" (Figure 26A, bottom row), individual "5" (Figure 26B, top row), or individual "Y" (Figure 26B, bottom row) with or without 10ug of anti-fHbp clone 19, clone 19-C1s, or clone 19-C1r. At pre-determined time points (30 min and 60 min), samples were taken and plated on blood agar plates at 37°C and 5% CO2 overnight. Serum bactericidal activity was calculated by measuring the reduction in viable bacterial counts recovered after incubation with NHS, compared to the original bacterial counts at zero time point and heat-inactivated serum. Targeted complement activation molecule clone 19-C1r showed a significant reduction in viable bacterial counts compared to control or clone 19 monoclonal antibody in serum 1 assay at 30 min and serum 2 assay at 60 min. See Figures 26A and 26B.

[0247] Example 12 In vivo studies of targeted complement-activating molecules derived from anti-fHbP in a mouse model of meningococcal infection. We investigated the effect of anti-fHbP-derived targeted complement-activating molecules in a mouse model of meningococcal infection. Twelve-week-old female C57BL / 6 wild-type mice (Charles River Laboratory) were used in this study. Twelve hours prior to infection, mice were injected intraperitoneally (ip) with iron dextran (400 mg / kg, Sigma-Aldrich). The following day, mice were injected with 5 × 10 6100 μL of subcultured N. meningitidis B-MC58 suspension containing cfu and iron dextran (400 mg / kg) were injected ip. Monoclonal antibodies or targeted complement activating molecules were injected ip 18 h before infection. Mice treated with isotype control antibodies served as controls. Each group consisted of 12 mice. The inoculum dose was confirmed by viable counts after plating on 5% (vol / vol) blood agar. Mice were monitored for the development of clinical signs and euthanized when they became lethargic. Blood samples were obtained at predetermined time points, serially diluted in PBS, and viable counts were calculated after spreading on blood agar plates.

[0248] Mice were treated with monoclonal antibody clone 19 or targeted complement activation molecules clone 19-C1r or clone 19-C1s. Bacterial load in blood samples collected 8 and 24 hours after infection is shown in Figure 43. Bacterial load was significantly lower at both time points in mice treated with clone 19-C1r compared to mice treated with antibody clone 19. Survival of mice after infection is shown in Figure 44. The number of mice that survived, i.e., did not require euthanasia, was significantly improved in mice treated with clone 19-C1r compared to mice treated with antibody clone 19. For both Figures 43 and 44, *p<0.05 and **p<0.01 using the Mantel-Cox log-rank test.

[0249] Example 13 Preparation of anti-PspA-derived targeted complement-activating molecules Monoclonal antibodies against the pneumococcal surface protein A (PspA) of Streptococcus pneumoniae were produced using mouse hybridomas kindly provided by Dr. David Briles and Dr. W. Edward Swords at the University of Alabama at Birmingham. The anti-PspA antibodies 5C6.1 and RX1MI005 are described in Vaccine (2013);32(1):39-47 and mSphere (2019)4:e00589-19, respectively. The binding of each of these antibodies to Streptococcus pneumoniae was tested. Streptococcus pneumoniae strain D39 was incubated with either 5C6.1 or RX1MI005 at a concentration of 10 μg / mL for 30 minutes at room temperature, then washed and incubated with Alexa Fluor goat anti-human IgG for 30 minutes. Binding was measured by FACS analysis. The results are shown in Figure 29. Antibody RX1MI005 was observed to bind better than 5C6.1 and was therefore selected for further use.

[0250] The antibody RX1MI005 was sequenced and the sequence was used to generate targeted complement activation molecules containing the RX1MI005 binding domain and a fragment of either C1r or C1s. The C-terminal catalytic fragment of C1r or C1s was fused to the anti-PspA antibody RX1MI005 at the C-terminus of an antibody heavy chain (HC) that was modified by deleting a single amino acid lysine (K) from the C-terminus. This process yielded the following constructs: RX1MI005(H) ΔK -C1r_HC(SEQ ID NO:122) and RX1MI005(H) ΔK -C1s_HC (SEQ ID NO: 123).

[0251] Plasmid preparation, cloning, protein expression and purification were carried out as described in Example 1.

[0252] Example 14 Binding of targeted complement-activating molecules derived from anti-PspA to Streptococcus pneumoniae Binding to Streptococcus pneumoniae was tested for each of the targeted complement activating molecules that contain the RX1MI005 binding domain. Targeted complement activating molecule RX1MI005(H) ΔK -C1r (also called anti-PspA-C1r or MI005-C1r) and RX1MI005(H) ΔK -C1s (also called anti-PspA-C1s or MI005-C1s) was tested together with monoclonal antibody RX1MI005. ELISA plates were coated with S. pneumoniae strain D39 in coating buffer and blocked with 5% nonfat milk. Serial dilutions of antibodies or targeted complement activation molecules were added to the plates and incubated for 30 minutes at room temperature before washing. Bound antibodies and targeted complement activation molecules were detected using HRP-conjugated anti-human IgG. An irrelevant isotype antibody was included as a control. All three molecules showed binding to S. pneumoniae. See Figure 30.

[0253] Example 15 Activity of anti-PspA-derived targeted complement-activating molecules Complement deposition activity The deposition of C3b on the surface of Streptococcus pneumoniae by the anti-PspA antibody RX1MI005 and the targeted complement activation molecules derived from RX1MI005 was evaluated. Streptococcus pneumoniae cells were washed twice with TBS buffer and incubated for 10 min at 4°C for 1 h. 6 Add BBS to a final concentration of cfu / mL. ++Bacteria were resuspended in buffer (4 mM barbital, 145 mM NaCl, 2 mM CaCl2, 1 mM MgCl2, pH 7.4). Bacterial suspensions (100 μL) were opsonized with antibodies or targeted complement-activating molecules using 1% (vol / vol) NHS or 5% (vol / vol) wild-type mouse serum for 15 min at room temperature. Nonopsonized bacteria served as negative controls. After opsonization, bacterial samples were washed twice with TBS buffer and bound C3b was detected using FITC-conjugated rabbit anti-human C3c (Dako). Fluorescence intensity was measured on a FACSCalibur cell analyzer (BD Biosciences). The results are shown in Figure 31. In the presence of MI005-Cr and MI005-C1s targeted complement activation molecules, complement C3b deposition on the surface of S. pneumoniae was found to be enhanced compared to the RX1MI005 antibody or isotype control antibody.

[0254] Example 16 Preparation of Targeted Complement-activating Molecules Derived from Antibodies Against Candida albicans Monoclonal antibody 1A2 binds to a fungal mannan epitope on the surface of Candida albicans. This antibody is described in PCT Patent Application Publication WO 2014 / 174293. The sequence of antibody 1A2 was used to create targeted complement activating molecules that contain the 1A2 binding domain and a fragment of either C1r or C1s. The C-terminal catalytic fragment of C1r or C1s was fused to antibody 1A2 at the C-terminus of an antibody heavy chain (HC) that was modified by deleting a single amino acid lysine (K) from the C-terminus. This process yielded the following constructs: 1A2(H) ΔK -C1r_HC (SEQ ID NO: 130) and 1A2(H) ΔK -C1s_HC (SEQ ID NO: 131).

[0255] Plasmid preparation, cloning, protein expression and purification were carried out as described in Example 1.

[0256] Example 17 Binding of targeted complement-activating molecules derived from antibodies against Candida albicans to Candida albicans Targeted complement-activating molecule 1A2(H) ΔK -C1r (also called 1A2-C1r) and monoclonal antibody 1A2 were tested for binding to Candida albicans. ELISA plates were coated with Candida albicans in coating buffer and blocked with 5% nonfat milk. Serial dilutions of antibody 1A2 and targeted complement activating molecule were added to the plate and incubated for 30 minutes at room temperature and then washed. Bound antibody was detected using HRP-conjugated anti-human IgG. Both antibody 1A2 and targeted complement activating molecule 1A2-C1r showed binding to Candida albicans. An irrelevant isotype antibody was used as a control. See Figure 32.

[0257] Binding to Candida albicans was also tested in an alternative assay. Fungal cells were incubated with antibody 1A2 or the targeted complement activating molecule 1A2-C1r for 30 minutes at room temperature, then washed and incubated with Alexa Fluor goat anti-human IgG for 30 minutes. Binding was measured by FACS analysis. An irrelevant isotype antibody was used as a control. Both antibody 1A2 and the targeted complement activating molecule 1A2-C1r showed binding to Candida albicans. See Figure 33.

[0258] Example 18 Activity of targeted complement-activating molecules derived from antibodies against Candida albicans Complement deposition activity The deposition of C3b by antibody 1A2 and the targeted complement activation molecule 1A2-C1r on the surface of Candida albicans was evaluated. First, human sera with the lowest natural antibodies to Candida albicans were identified by screening sera from five different individuals. ELISA plates were coated with Candida albicans and incubated with sera from each individual. Antibodies to Candida albicans were detected using horseradish peroxidase (HRP)-conjugated anti-human IgG antibodies. The serum with the lowest titer of Candida albicans antibodies measured (indicated as "GC") was used for the C3b deposition assay. The results are shown in the left panel of Figure 34.

[0259] For the C3b deposition assay, Maxisorp polystyrene microtiter ELISA plates were coated with formalin-fixed Candida albicans in carbonate buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6). The next day, wells were blocked with 5% nonfat milk in TBS buffer (10 mM Tris-HCl, 140 mM NaCl, pH 7.4) for 2 h and then washed with TBS buffer containing 0.05% (v / v) Tween 20 and 5 mM CaCl2. ++1% NHS serum "GC" containing 150 nM of antibody or targeted complement activating molecule diluted in buffer (4 mM barbital, 145 mM NaCl, 2 mM CaCl2, 1 mM MgCl2, pH 7.4) was added to the plate and incubated for 5, 10, 15, 20 and 25 minutes at room temperature, then washed. C3b deposition was detected using rabbit anti-C3c (Dako) followed by peroxidase-conjugated goat anti-rabbit IgG. After 1 hour, the wells were washed, then 100 μL of 1-Step Ultra TMB solution (Thermo Fisher Scientific) was added to each well and incubated for 5 minutes at room temperature. The reaction was stopped by the addition of 2M H2SO4, and the optical density at 450 nm was immediately measured. The results are shown in the right panel of Figure 34. When the targeted complement activating molecule 1A2-C1r was used, the levels of C3b deposition were significantly enhanced compared to antibody 1A2 or the isotype control.

[0260] Example 19 Preparation of targeted complement-activating molecules derived from anti-Fnbp Monoclonal antibodies against the fibronectin-binding protein (Fnbp) of Staphylococcus aureus were produced and isolated in mice using hybridoma technology. Mouse spleen cells were mixed with NS0 myeloma cells in a 1:4 ratio in RPMI SFM (Sigma) and pelleted at 1200×g for 5 min. After centrifugation, the supernatant was completely removed. The spleen cells and NS0 cells were then fused together by adding 0.8 mL of polyethylene glycol 1500 (Roche) for 1 min with gentle agitation. Then, 10 mL of RPMI-SFM was added stepwise for 5 min with gentle agitation. The fused cells were then pelleted and resuspended in 50 mL of RPMI medium supplemented with 15% FCS (Sigma), 200 u / mL penicillin / streptomycin (Sigma), 1 mM pyruvate (Sigma), 0.05 μM β-mercaptoethanol (Sigma), 0.5 μg / mL hydrocortisone (Sigma) and 0.4 mM L-glutamine (Sigma). Finally, the hybridoma cells were plated in 96-well plates and incubated at 37°C and 5% CO2. As a negative control, NS0 myeloma cells were added to the last two rows of each plate. The next day, hypoxanthine and azaserine (Sigma) were added to each well at a final concentration of 100 μM hypoxanthine and 5.7 μM azaserine. The hybridomas were fed every 3 days by removing 100 μL of the old medium and replacing it with fresh RPMI medium containing 15% FCS. When hybridomas reached 30-50% confluence, supernatant samples were taken for screening using ELISA. Positive clones were selected and transferred to 24-well plates and finally to 25cm 2 Transferred to a flask.

[0261] Eleven candidate antibodies were identified and screened for binding to S. aureus. Maxisorp polystyrene microtiter ELISA plates were coated with formalin-fixed S. aureus (OD600=0.6) in carbonate buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6). The next day, wells were blocked with 5% nonfat milk in TBS buffer (10 mM Tris-HCl, 140 mM NaCl, pH 7.4) for 2 h and then washed with TBS buffer containing 0.05% (v / v) Tween 20 and 5 mM CaCl2. Candidate antibodies were serially diluted in TBS buffer, added to the plates, incubated at room temperature for 1 h, and then washed. Antibody binding was detected using peroxidase-conjugated rabbit anti-human IgG. After 1 h, wells were washed, then 100 μL of 1-Step Ultra TMB solution (Thermo Fisher Scientific) was added to each well and incubated at room temperature for 5 min. The reaction was stopped by the addition of 2M H2SO4 and the optical density at 450 nm was immediately measured. Antibody clone G was identified as showing the best binding to S. aureus. See Figure 35.

[0262] Antibody clone G was tested for binding to S. aureus MSSA strains. S. aureus MSSA cells were washed twice with TBS buffer and diluted with 10 6 Add BBS to a final concentration of cfu / mL. ++ Bacteria were resuspended in buffer (4 mM barbital, 145 mM NaCl, 2 mM CaCl2, 1 mM MgCl2, pH 7.4). Bacterial suspension (100 μL) was incubated with 150 nM of antibody clone G for 30 min at room temperature. Bacteria opsonized with isotype control antibody were used as negative control. After incubation, bacterial samples were washed twice with TBS buffer and bound antibodies were detected using FITC-conjugated rabbit anti-human IgG. Fluorescence intensity was measured with a FACSCalibur cell analyzer (BD Biosciences). The results are shown in Figure 36. Clone G was found to bind to S. aureus MSSA strains.

[0263] Antibody clone G was also tested for binding to several different isolates of S. aureus MRSA strains. S. aureus MRSA bacteria from two clinical and one of the laboratory isolates were washed twice with TBS buffer and resuspended in BBS++ buffer (4 mM barbital, 145 mM NaCl, 2 mM CaCl2, 1 mM MgCl2, pH 7.4) to a final concentration of 106 cfu / mL. Bacterial suspensions (100 μL) were incubated with 150 nM of antibody clone G at room temperature for 30 min. Bacteria opsonized with an isotype control antibody were used as a negative control. After incubation, bacterial samples were washed twice with TBS buffer and bound antibodies were detected using FITC-conjugated rabbit anti-human IgG. Fluorescence intensity was measured on a FACSCalibur cell analyzer (BD Biosciences). The results are shown in Figure 37. Clone G was found to bind to all three isolates of S. aureus MRSA strains.

[0264] Antibody clone G was sequenced and the sequence was used to generate targeted complement activating molecules containing the clone G binding domain and a fragment of either C1r or C1s. The C-terminal catalytic fragment of C1r or C1s was fused to the anti-Fnbp antibody clone G at the C-terminus of an antibody heavy chain (HC) that was modified by deleting a single amino acid lysine (K) from the C-terminus. This process yielded the following constructs: Cl.G(H) ΔK - C1r_HC (SEQ ID NO: 126) and Cl.G(H) ΔK -C1s_HC (SEQ ID NO: 127).

[0265] Plasmid preparation, cloning, protein expression and purification were carried out as described in Example 1.

[0266] Example 20 Binding of targeted complement-activating molecules derived from anti-Fnbp Binding to Fnbp was tested for each of the targeted complement activating molecules containing the Clone G binding domain. Targeted complement activating molecule Cl.G(H) ΔK -C1r (also called clone G-C1r) and Cl.G(H) ΔK -C1s (also called clone G-C1s) was tested together with monoclonal antibody clone G. Maxisorp polystyrene microtiter ELISA plates were coated with 2 μg / mL of recombinant S. aureus FnbpB in coating buffer. The next day, wells were blocked with 5% nonfat milk in PBS for 2 h and then washed with PBS buffer containing 0.05% (v / v) Tween 20. Two-fold serial dilutions of antibodies and targeted complement activation molecules were prepared in PBS buffer starting at 15 μg / mL. 100 μL of samples were transferred to the ELISA plate and incubated at room temperature. After 1 h, the plate was washed and 100 μL of HRP-conjugated goat anti-human IgG detection antibody was added to the plate followed by incubation at room temperature for 30 min. The plate was washed and 100 μL of 1-Step Ultra TMB solution (Thermo Fisher Scientific) was added to each well and incubated at room temperature for 2 min. The reaction was stopped by the addition of 2M H2SO4 and the optical density at 450 nm was immediately measured. See Figure 38A.

[0267] Binding to S. aureus was tested for each of the targeted complement activating molecules that contain the clone G binding domain. The targeted complement activating molecules clone G-C1r and clone G-C1s were tested along with the monoclonal antibody clone G. ELISA plates were coated with S. aureus in coating buffer and blocked with 5% nonfat milk. Serial dilutions of antibodies or targeted complement activating molecules were added to the plates and incubated at room temperature for 30 minutes before washing. Bound antibodies and targeted complement activating molecules were detected using HRP-conjugated anti-human IgG. An irrelevant isotype antibody was included as a control. All three molecules showed binding to S. aureus. See Figure 38B.

[0268] Example 21 Activation of targeted complement-activating molecules derived from anti-Fnbp Complement deposition activity Deposition of C3b by antibody Cone G and targeted complement activating molecules clone G-C1r and clone G-C1s on Fnbp-coated surfaces was evaluated. Maxisorp polystyrene microtiter ELISA plates were coated with recombinant FnbpB at 2 μg / mL in coating buffer. The next day, wells were blocked with 5% nonfat milk in PBS for 2 h and then washed with PBS buffer containing 0.05% (v / v) Tween 20. NHS containing 7.5 μg of antibody or targeted complement activating molecule was added to PBS buffer to a concentration of 2.5%. ++Dilutions in buffer (4 mM barbital, 145 mM NaCl, 2 mM CaCl2, 1 mM MgCl2, pH 7.4) were added to the plate and incubated at room temperature for 5, 10, 15, 20 and 25 minutes, then washed three times. C3b deposition was detected by using rabbit anti-human C3c (Dako) followed by peroxidase-conjugated goat anti-rabbit IgG (Southern Biotech). After 1 hour, the plate was washed three times and 100 μL of 1-Step Ultra TMB solution (Thermo Fisher Scientific) was added to each well at room temperature. The reaction was stopped by the addition of 2M H2SO4 and the optical density at 450 nm was immediately measured. The results are shown in Figure 46.

[0269] Example 22 Preparation of targeted complement-activating molecules derived from anti-PfRH5 Antibodies against the Plasmodium falciparum antigen reticulocyte-binding protein homolog 5 (PfRH5) were described by Alanine et al. (Cell (2019) 178:216-228). The sequences of the anti-PfRH5 antibodies R5.004 and R5.016 were used to generate targeted complement activating molecules containing the antibody binding domain and either a fragment of C1r or C1s. The C-terminal catalytic fragment of C1r or C1s was fused to the antibody at the C-terminus of an antibody heavy chain (HC) that was modified by deleting a single amino acid lysine (K) from the C-terminus. This process yielded the following constructs: R5.004(H) ΔK -C1r_HC(SEQ ID NO:138), R5.004(H) ΔK -C1s_HC(SEQ ID NO:139), R5.016(H) ΔK -C1r_HC (SEQ ID NO: 142) and R5.016(H) ΔK -C1s_HC (SEQ ID NO: 143).

[0270] Plasmid preparation, cloning, protein expression and purification were carried out as described in Example 1.

[0271] Example 23 Binding of Anti-PfRH5-derived Targeted Complement-Activating Molecules to PfRH5 Binding to P. falciparum was tested for each of the targeted complement activating molecules containing the anti-PfRH5 binding domain. Maxisorp polystyrene microtiter ELISA plates were coated with 50 μL per well of cell supernatant from cells transfected with PfRH5. The next day, wells were blocked with 1% BSA in PBS (1×) for 2 h and then washed with PBS buffer containing 0.05% (v / v) Tween 20. Two-fold serial dilutions of antibodies and targeted complement activating molecules were prepared in buffer containing 0.1% BSA in PBS (1×) with a top concentration of 13.9 nM. 100 μL of each sample was transferred to the ELISA plate and incubated at room temperature. After 1 h, the plate was washed and 100 μL of HRP-conjugated goat anti-human IgG detection antibody was added to the plate, followed by incubation at room temperature for 30 min. Plates were washed and 100 μL of 1-step Ultra TMB solution (Thermo Fisher Scientific) was added to each well and incubated for 2 min at room temperature. The reaction was stopped by the addition of 2M H2SO4 and the optical density at 450 nm was immediately measured. An irrelevant antibody (RTX) was used as a control. The results are shown in Figure 41. Both antibodies and all targeted complement activation molecules tested showed binding to PfRH5.

[0272] Example 24 Activity of targeted complement-activating molecules derived from anti-PfRH5 Complement deposition activity Antibodies R5.004, R5.016 and the targeted complement activating molecule R5.004(H) on PfRH5 coated surfaces ΔK -C1r (also called R5.004-C1r), R5.004(H) ΔK -C1s (also called R5.004-C1s), R5.016(H) ΔK -C1r (also called R5.016-C1r) and R5.016(H)ΔK C3b deposition by PfRH5-C1s (also called R5.016-C1s) was evaluated. Maxisorp polystyrene microtiter ELISA plates were coated with 50 μL of cell supernatant from PfRH5-transfected cells per well. The next day, wells were blocked with 1% BSA in PBS (1×) for 2 h and then washed with PBS buffer containing 0.05% (v / v) Tween 20. Normal human serum (NHS) containing 13.9 nM of antibody or targeted complement activating molecule was added to the wells at a concentration of 3% in BBS. ++ The antibodies were diluted in buffer (4 mM barbital, 145 mM CaCl, 2 mM CaCl2, 1 mM MgCl2, pH 7.4) and added to the wells. The plates were incubated at room temperature for either 5, 10, 15, 20 or 25 min and then washed three times. C3b deposition was detected using rabbit anti-human C3c (Dako) followed by peroxidase-conjugated goat anti-rabbit IgG (Southern Biotech). After 1 h, the plates were washed three times and 100 μL of 1-Step Ultra TMB solution (Thermo Fisher Scientific) was added to each well and incubated for 2 min at room temperature. The reaction was stopped by the addition of 2M H2SO4 and the optical density at 450 nm was immediately measured. An irrelevant antibody (RTX) was used as a control. The results are shown in Figure 42.

[0273] Example 25 Preparation of targeted complement-activating molecules derived from anti-GP120 An antibody against the HIV-1 envelope glycoprotein GP120 was described by Julien et al. (PLoS Pathog (2013) 9: e1003342). The sequence of the anti-GP120 antibody PGT121 was used to generate targeted complement activating molecules containing the antibody binding domain and either a fragment of C1r or C1s. The C-terminal catalytic fragment of C1r or C1s was fused to the antibody at the C-terminus of an antibody heavy chain (HC) that was modified by deleting a single amino acid lysine (K) from the C-terminus. This process yielded the following construct: PGT121(H) ΔK -C1r_HC (SEQ ID NO: 146) and PGT121(H) ΔK -C1s_HC (SEQ ID NO: 147).

[0274] Plasmid preparation, cloning, protein expression and purification were carried out as described in Example 1.

[0275] Example 26 Binding of Anti-GP120-derived Targeted Complement-activating Molecules to GP120 Targeted complement-activating molecule PGT121(H) with monoclonal antibody PGT121 ΔK -C1r (also called PGT121-C1r) and PGT121(H) ΔKEach of the GP120-C1s (also called PGT121-C1s) was tested for binding to GP120. An irrelevant isotype antibody was used as a control. Maxisorp polystyrene microtiter ELISA plates were coated with 2 μg / mL of recombinant GP120 in coating buffer. The next day, wells were blocked with 5% nonfat milk in PBS for 2 h and then washed with PBS buffer containing 0.05% (v / v) Tween 20. Two-fold serial dilutions of antibodies and targeted complement activation molecules were prepared in PBS buffer starting at 15 μg / mL. 100 μL of samples were transferred to the ELISA plate and incubated at room temperature. After 1 h, the plate was washed and 100 μL of HRP-conjugated goat anti-human IgG detection antibody was added to the plate and incubated at room temperature for 30 min. The plate was washed and 100 μL of 1-Step Ultra TMB solution (Thermo Fisher Scientific) was added to each well and incubated at room temperature for 2 min. The reaction was stopped by the addition of 2M H2SO4 and the optical density at 450 nm was immediately measured. The results are shown in Figure 45. Antibody PGT121 and both targeted complement activating molecules tested showed binding to GP120.

[0276] Example 27 Activity of targeted complement-activating molecules derived from anti-GP120 Complement deposition activity Deposition of C3b by antibody PGT121 and targeted complement activating molecules PGT121-C1r and PGT121-C1s on GP120-coated surfaces was assayed. Maxisorp polystyrene microtiter ELISA plates were coated with recombinant GP120 at 2 μg / mL in coating buffer. The next day, wells were blocked with 5% nonfat milk in PBS for 2 h and then washed with PBS buffer containing 0.05% (v / v) Tween 20. 7.5 μg of antibody or targeted complement activating molecule containing NHS was added to a concentration of 2.5% in BBS. ++Diluted in buffer (4 mM barbital, 145 mM NaCl, 2 ...

Claims

1. (a) a target binding domain; (b) complement-activating serine protease effector domains and A targeted complement activating molecule comprising:

2. The molecule of claim 1, wherein the complement activating serine protease effector domain comprises MASP-1 or a fragment thereof, MASP-2 or a fragment thereof, MASP-3 or a fragment thereof, C1r or a fragment thereof, C1s or a fragment thereof, factor D or a fragment thereof, C2a or a fragment thereof, or factor Bb or a fragment thereof.

3. The molecule of claim 1 , wherein the target binding domain binds to an antigen present on a cell.

4. The molecule of claim 3, wherein the target binding domain binds to CD20, CD38, or CD52.

5. The molecule of claim 1 , wherein the target binding domain binds to an antigen present on a microbial pathogen.

6. The molecule of claim 5, wherein the target binding domain binds to an antigen present on a bacterial, viral, fungal, or parasitic pathogen.

7. The pathogen may be Neisseria meningitidis, Staphylococcus aureus, Borrelia burgdorferi, Escherichia coli, Klebsiella pneumoniae, Streptococcus pneumoniae, Serratia marcenscens, Haemophilus influenzae, Mycobacterium tuberculosis, Treponema pallidum, Neisseria gonorrhea, Clostridium difficile, dificile), Salmonella spp., Helicobacter spp., Shigella spp., Campylobacter spp., Listeria spp., Epstein-Barr virus, human immunodeficiency virus 1 (HIV-1), herpes virus, influenza virus, West Nile virus, cytomegalovirus, coronavirus, Schistosoma mansoni, Plasmodium falciparum, or Trypanosoma cruzei.

8. The molecule of claim 1 , wherein the target binding domain comprises an antibody or an antigen-binding fragment thereof.

9. The molecule of claim 8 , wherein the target binding domain comprises an antibody heavy chain or a fragment thereof and an antibody light chain or a fragment thereof.

10. a) i) the N-terminus of said complement activating serine protease effector domain fused to the C-terminus of said antibody heavy chain or fragment thereof; or ii) the C-terminus of the complement activating serine protease effector domain fused to the N-terminus of the antibody heavy chain or fragment thereof; and Antibody light chain or fragment thereof or b) i) the N-terminus of said complement activating serine protease effector domain fused to the C-terminus of said antibody light chain or fragment thereof; or ii) the C-terminus of the complement activating serine protease effector domain fused to the N-terminus of the antibody light chain or fragment thereof; and Antibody heavy chain or fragment thereof A fusion protein comprising 10. The molecule of claim 9, comprising:

11. a) the N-terminus of said complement-activating serine protease effector domain fused to the C-terminus of a single chain antibody or fragment thereof or a single domain antibody or fragment thereof; or b) the C-terminus of said complement-activating serine protease effector domain fused to the N-terminus of a single chain antibody or fragment thereof or a single domain antibody or fragment thereof The molecule of claim 8, comprising a fusion protein comprising:

12. The molecule of claim 1 , wherein the target binding domain and the serine protease effector domain are connected by a linker.

13. 9. The molecule of claim 8, wherein the target binding domain comprises rituximab, alemtuzumab, daratumumab, anti-fHbP antibody clone 19, anti-PspA antibody RX1MI005, anti-Fnbp antibody clone G, anti-Candida antibody 1A2, anti-PfRH5 antibody R5.004, anti-PfRH5 antibody R5.016, anti-GP120 antibody PGT121, bebuterobimab, anti-SARS-CoV-2 M protein antibody RB572, anti-SARS-CoV-2 M protein antibody RB574, anti-Aspergillus antibody hJF5, or an antigen-binding fragment of any of the foregoing.

14. The molecule of claim 2, wherein the serine protease effector domain comprises Factor D, C1r, C1s, MASP-2, MASP-3, MASP-1, C2a, or Bb, or a fragment of any of the above.

15. 10. The molecule of claim 9, wherein the target binding domain comprises a heavy chain as set forth in any one of SEQ ID NOs: 1, 3, 20, 54-56, 93, 95, 97, 98, 103, 105, 113-115, 120, 124, 128, 132, 136, 140, 144, and 148.

16. 10. The molecule of claim 9, wherein the target binding domain comprises a light chain as set forth in any one of SEQ ID NOs:2, 94, 96, 102, 104, 106, 121, 125, 129, 133, 137, 141, 145, and 149.

17. a) the target binding domain comprises a heavy chain as set forth in any one of SEQ ID NOs:1, 3, 20, and 54-56, and a light chain as set forth in SEQ ID NO:2; b) the target binding domain comprises a heavy chain as set forth in SEQ ID NO:93 or 97 and a light chain as set forth in SEQ ID NO:94; c) the target binding domain comprises a heavy chain as set forth in SEQ ID NO:95 or 98 and a light chain as set forth in SEQ ID NO:96; d) the target binding domain comprises a heavy chain as set forth in any one of SEQ ID NOs: 103, 114, 116, 117, 118, and 119, and a light chain as set forth in SEQ ID NO: 104; e) the target binding domain comprises a heavy chain as set forth in SEQ ID NO:122 or 123 and a light chain as set forth in SEQ ID NO:121; f) the target binding domain comprises a heavy chain as set forth in SEQ ID NO:126 or 127 and a light chain as set forth in SEQ ID NO:125; g) the target binding domain comprises a heavy chain as set forth in SEQ ID NO:130 or 131 and a light chain as set forth in SEQ ID NO:129; h) the target binding domain comprises a heavy chain as set forth in SEQ ID NO:138 or 139 and a light chain as set forth in SEQ ID NO:137; i) the target binding domain comprises a heavy chain as set forth in SEQ ID NO:142 or 143 and a light chain as set forth in SEQ ID NO:141; j) the target binding domain comprises a heavy chain as set forth in SEQ ID NO:146 or 147 and a light chain as set forth in SEQ ID NO:145; k) the target binding domain comprises a heavy chain as set forth in SEQ ID NO:150 or 151 and a light chain as set forth in SEQ ID NO:149; or l) the target binding domain comprises a heavy chain as shown in SEQ ID NO: 134 or 135 and a light chain as shown in SEQ ID NO: 133; 10. The molecule of claim 9.

18. 15. The molecule of claim 14, wherein the serine protease effector domain comprises an amino acid sequence set forth in any one of SEQ ID NOs:57-92.

19. 11. The molecule of claim 10, wherein the fusion protein comprises an amino acid sequence set forth in any one of SEQ ID NOs:4-9, 12-19, 21, 23, 25-53, 97, 98, 108, 111, 116, 117, 119, 122, 123, 126, 127, 130, 131, 134, 135, 138, 139, 142, 143, 146, 147, 150, and 151.

20. 20. The molecule of claim 19, wherein the fusion protein comprises an amino acid sequence as set forth in any one of SEQ ID NOs:4-6, 9, 12, 13, 16, 18, 19, 21, 23, 25-28, and 31-53, and a light chain as set forth in SEQ ID NO:

2.

21. 20. The molecule of claim 19, wherein the fusion protein comprises an amino acid sequence as set forth in any one of SEQ ID NOs:7, 8, 14, 15, 17, 29, and 30, and a heavy chain as set forth in any one of SEQ ID NOs:1, 3, 20, and 54-56.

22. 11. The molecule of claim 10, wherein the fusion protein comprises an amino acid sequence set forth in any one of SEQ ID NOs:97, 98, 108, 111, 116, 117, 119, 122, 123, 126, 127, 130, 131, 134, 135, 138, 139, 142, 143, 146, 147, 150, and 151.

23. a) a fusion protein as shown in SEQ ID NO:97 and a light chain as shown in SEQ ID NO:94; b) a fusion protein as shown in SEQ ID NO:98 and a light chain as shown in SEQ ID NO:96; c) a fusion protein as set forth in any one of SEQ ID NOs:108, 111, 116, 117, and 119, and a light chain as set forth in SEQ ID NO:104; d) a fusion protein as shown in SEQ ID NO:122 or 123 and a light chain as shown in SEQ ID NO:121; e) a fusion protein as set forth in SEQ ID NO:126 or 127 and a light chain as set forth in SEQ ID NO:125; f) a fusion protein as set forth in SEQ ID NO:130 or 131 and a light chain as set forth in SEQ ID NO:129; g) a fusion protein as shown in SEQ ID NO:138 or 139 and a light chain as shown in SEQ ID NO:137; h) a fusion protein as set forth in SEQ ID NO:142 or 143 and a light chain as set forth in SEQ ID NO:141; i) a fusion protein as shown in SEQ ID NO:146 or 147 and a light chain as shown in SEQ ID NO:145; j) a fusion protein as set forth in SEQ ID NO:150 or 151 and a light chain as set forth in SEQ ID NO:149; or k) a fusion protein as shown in SEQ ID NO:134 or 135 and a light chain as shown in SEQ ID NO:133 23. The molecule of claim 22, comprising:

24. 24. The molecule of any one of claims 1 to 23, which binds to a target with an affinity of between 1 pM and 1 μM.

25. 24. The molecule of any one of claims 1 to 23, having a serine protease activity that is at least 70% of the serine protease activity of said serine protease domain alone.

26. 24. The molecule of any one of claims 1 to 23, which binds to a target on a cell surface and activates the complement pathway when administered to a mammalian subject.

27. A polynucleotide encoding the molecule of any one of claims 1 to 23.

28. A polynucleotide encoding the fusion protein of any one of claims 10, 11, and 19 to 23.

29. A cloning vector or expression cassette comprising a polynucleotide encoding a molecule according to any one of claims 1 to 23 or encoding a fusion protein according to any one of claims 10, 11, and 19 to 23.

30. 24. A cloning vector or expression cassette comprising a first polynucleotide encoding a fusion protein according to any one of claims 10, 11 and 19 to 23, and a second polynucleotide, wherein the second polynucleotide encodes an antibody heavy chain or a fragment thereof if the fusion protein comprises an antibody light chain or a fragment thereof, and wherein the second polynucleotide encodes an antibody light chain or a fragment thereof if the fusion protein comprises an antibody heavy chain or a fragment thereof.

31. A first cloning vector or expression cassette and a second cloning vector or expression cassette, 24. The first cloning vector or expression cassette and the second cloning vector or expression cassette, wherein the first cloning vector or expression cassette comprises a first polynucleotide encoding a fusion protein according to any one of claims 10, 11 and 19 to 23, and the second cloning vector or expression cassette comprises a second polynucleotide, wherein the second polynucleotide encodes an antibody heavy chain or a fragment thereof if the fusion protein comprises an antibody light chain or a fragment thereof, and wherein the second polynucleotide encodes an antibody light chain or a fragment thereof if the fusion protein comprises an antibody heavy chain or a fragment thereof.

32. A host cell expressing a molecule according to any one of claims 1 to 23.

33. (a) a target-binding domain; (b) complement-activating serine protease effector domains and 33. A method for producing a molecule comprising the steps of culturing a host cell of claim 32 under conditions allowing expression of said molecule, and isolating said molecule.

34. 24. Use of a molecule according to any one of claims 1 to 23 in the manufacture of a medicament for activating at least one complement pathway in a mammalian subject.

35. 24. Use of a molecule according to any one of claims 1 to 23 in the manufacture of a medicament for inducing complement dependent cell death (CDC), complement dependent cell-mediated cytotoxicity (CDCC) or complement dependent cyophagocytosis (CDCP) in a target cell.

36. 24. Use of a molecule according to any one of claims 1 to 23 in the manufacture of a medicament for treating cancer, an autoimmune disease or a microbial infection.

37. 37. The use according to claim 36, wherein the infection is a bacterial infection, a viral infection, a fungal infection, or a parasitic infection.

38. 24. A composition comprising a molecule according to any one of claims 1 to 23 and one or more excipients.

39. 24. A pharmaceutical composition for activating at least one complement pathway in a mammalian subject, comprising a molecule according to any one of claims 1 to 23.

40. A pharmaceutical composition for inducing complement dependent cell-mediated cytotoxicity (CDCC) or complement dependent cyophagocytosis (CDCP) against a target cell, comprising a molecule according to any one of claims 1 to 23, wherein contact with said target cell results in complement deposition on said target cell, thereby causing complement mediated cell death.

41. 24. A pharmaceutical composition for treating cancer, an autoimmune disease, or a microbial infection in a mammalian subject in need thereof, comprising a molecule according to any one of claims 1 to 23.

42. 24. The targeted complement activating molecule of any one of claims 1 to 23 for use in the manufacture of a medicament for treating cancer, an autoimmune disease, or a microbial infection.

43. 40. The composition of claim 38, for use in treating cancer, an autoimmune disease, or a microbial infection.

44. A pharmaceutical composition for activating at least one complement pathway in a mammalian subject, comprising the composition of claim 38.

45. A pharmaceutical composition for inducing complement-dependent cell-mediated cytotoxicity (CDCC) or complement-dependent cyophagocytosis (CDCP) against a target cell, comprising the composition of claim 38, wherein contact with the target cell results in complement deposition on the target cell, thereby causing complement-mediated cell death.

46. ​​A pharmaceutical composition for treating cancer, an autoimmune disease, or a microbial infection in a mammalian subject in need thereof, comprising the composition of claim 38.

47. The composition of claim 38 for use in the manufacture of a medicament for treating cancer, an autoimmune disease, or a microbial infection.